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ABSTRACT
Mild traumatic brain injury (MTBI) accounts for 80–90% of the nearly two million
traumatic brain injuries (TBI) that occur each year. The psychological consequences of MTBI
can be extensive and can persist well beyond the acute injury, profoundly impacting the lives of
the individual, their families, and society. A substantial number of MTBI patients suffer
depressive mood, fatigue, and poor sleep (i.e., behavioral symptoms) for weeks and months postinjury. These symptoms reduce quality of life and delay the return to previous cognitive and
functional status. Behavioral symptoms of depressed mood, fatigue, and poor sleep commonly
co-occur and thus may constitute a symptom cluster, defined as co-occurring symptoms which
share a common influence on an outcome. Symptoms of depression, fatigue, and poor sleep may
share a common inflammatory etiology, and may develop as a result of pro-inflammatory
cytokine elevation that occurs post-injury and which may persist beyond the acute phase of
injury. Inflammatory molecules from sites of injury or infection are known to signal the brain to
engender inflammatory-related sickness behaviors, such as depressed mood, fatigue, and poor
sleep. It is possible that these co-occurring symptoms synergize to negatively impact cognitive
and functional recovery. Yet investigation of these behavioral symptoms as a cluster and their
association with MTBI recovery is limited.
Purpose: The purpose of this project is to identify different behavioral profiles of MTBI
patients based on the intensity of depressive mood, fatigue, and sleep quality, to determine

xiii

whether there are differences in cognitive and functional outcomes at six months post-MTBI
among the identified behavioral cluster profiles, and to explore differences in the intensity of
behavioral symptoms at six months post-MTBI based on SNP genotype.
Research Design: This was a secondary data analysis of the database from the
International Traumatic Brain Injury Initiative—TRACK-TBI pilot, which previously recruited
TBI patients from two level I trauma centers. That study enrolled a total of 600 TBI patients; 340
of which suffered MTBI and who will thus be considered for potential inclusion in the current
study. Participants in the original TRACK-TBI pilot study completed a battery of psychometric
and health-related instruments and provided a blood sample for genetic analysis; these data were
available to accomplish the aims of the present study.
Sample and Setting: From the TRACK-TBI pilot database, we selected a convenience
sample (n=340) of male and females (ages >18years) who suffered external force trauma to the
head, and who had an MTBI with classification by emergency department arrival Glasgow Coma
Scale (GCS) as follows: mild (GCS 13–15). Only individuals who had completed follow-up at
three months and six months were eligible.
Statistical Analysis: Latent Class Analysis was used to identify subgroups of MTBI
patients with behavioral symptom cluster, using items derived from the psychological battery
completed by participants in the TRACK-TBI pilot study completed; the presence and intensity
of behavioral symptom cluster was analyzed with respect to cognitive and functional recovery.
An analysis of covariance was used to explore differences in the intensity of behavioral
symptoms at six months post-MTBI based on SNP genotype. The outcomes of this study will
build a foundation upon which to establish clinically based strategies to identify MTBI patients

xiv

at risk for protracted recovery and to identify those who may require earlier and more intense
intervention.

xv

CHAPTER ONE
INTRODUCTION AND BACKGROUND OF THE PROBLEM
Nature of the Problem
Traumatic brain injury (TBI) is a significantly growing public health, social, and
economic concern, as it can result in adverse outcomes that persist for an extended period of
time. Mild traumatic brain injury (MTBI) accounts for 80–90% of the nearly two million
traumatic brain injuries (TBI) that occur each year (Carroll et al., 2004; Kristman et al., 2014; R.
Ruff, 2005; R. M. Ruff, 2011). The psychological consequences of MTBI can be extensive and
can persist well beyond the acute injury, profoundly impacting the lives of the individuals, their
families, and society (Center for Disease Control and Prevention, 2003). Advances in the
diagnosis and management of TBI continue to reduce mortality for those who have incurred
traumatic injuries, resulting in an increasing number of trauma survivors (Kristman et al., 2014;
R. Ruff, 2005). Yet, surviving MTBI profoundly impacts the lives of the individual, their
families, and society (Center for Disease Control and Prevention, 2003). The consequences of
MTBIs can be extensive and wide ranging, and include physical, emotional, and financial
difficulties. These consequences may be enduring (Center for Disease Control and Prevention,
2003). Traditionally the evaluation of the impact of TBIs has focused on survival, complications,
and length of hospital stay. Few studies have evaluated the long-lasting psychological
repercussions resulting from TBIs; yet such impairment can significantly reduce quality
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of life outcomes and escalate health care costs (Center for Disease Control and Prevention,
2003).
Research suggests that only 20–25% of all patients who suffer MTBI are hospitalized,
and of these MTBI patients, 80 to 90% recover without residual psychological adverse outcomes.
The remaining 10–20% (referred to as the “miserable minority”) (R. Ruff, 2005; R. M. Ruff et
al., 2009); however, will suffer from long-term debilitating, unfavorable psychological outcomes
and persistent physical, emotional, and cognitive symptoms (R. Ruff, 2005; R. M. Ruff et al.,
2009). This could affect them for weeks or months after the injury, and possibly hinder them
from returning to previous functional status and daily activities (J. Kraus et al., 2005). Such
adverse outcomes lead to extensive economic costs for the healthcare system (Carroll et al.,
2004; Cassidy et al., 2004; Kristman et al., 2014; R. Ruff, 2005). Nationally, MTBI costs nearly
$17 billion each year (Center for Disease Control and Prevention, 2003).
Several studies have described the possible adverse behavioral outcomes following MTBI
(Ayalon, Borodkin, Dishon, Kanety, & Dagan, 2007; Bay & Donders, 2008; Bay, 2009; Beetar,
Guilmette, & Sparadeo, 1996; Levin et al., 2005; Ponsford, 2005). In particular, a substantial
number of MTBI patients suffer depressive mood, fatigue, and poor sleep (i.e., behavioral
symptoms) for weeks and months post-injury (Ayalon et al., 2007; Bay & Xie, 2009; BeaulieuBonneau & Morin, 2012; Beetar et al., 1996; Chaput, Giguere, Chauny, Denis, & Lavigne, 2009;
Levin et al., 2005; Norrie et al., 2010; Ponsford et al., 2000; Rapoport, Kiss, & Feinstein, 2006).
These symptoms not only reduce quality of life (Center for Disease Control and Prevention,
2003), but also likely delay the return to previous cognitive and functional status (J. Kraus et al.,
2005). Behavioral symptoms of depressed mood, fatigue and poor sleep commonly co-occur and
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thus may constitute a symptom cluster. Based on the oncology literature, a symptom cluster is
when co-occurring symptoms share a common influence on an outcome (Fox & Lyon, 2007).
Symptoms of depression, fatigue, and poor sleep may share a common inflammatory etiology,
and may develop as a result of proinflammatory cytokine elevation (Kossmann, Hans, Imhof,
Trentz, & Morganti-Kossmann, 1996; Shohami, Novikov, Bass, Yamin, & Gallily, 1994; S. H.
Su et al., 2014; Woodcock & Morganti-Kossmann, 2013) that occurs post-injury and which may
persist beyond the acute phase of injury. Inflammatory molecules from sites of injury or
infection are known to signal the brain to engender inflammatory-related sickness behaviors,
such as depressed mood, fatigue, and poor sleep (Dantzer, Wollman, Vitkovic, & Yirmiya, 1999;
Dantzer, 2001; Dantzer & Kelley, 2007; Dantzer, O'Connor, Freund, Johnson, & Kelley, 2008;
Dantzer, 2009; Dantzer, O'Connor, Lawson, & Kelley, 2011; Kelley et al., 2003).
Evidence confirms that MTBI patients exhibit elevations in pro-inflammatory cytokines
(Kossmann et al., 1996; Shohami et al., 1994; S. H. Su et al., 2014; Woodcock & MorgantiKossmann, 2013), which may endure beyond the acute phase of injury. However, the
pathogenesis of psychological long-term outcomes following MTBI is not fully understood.
Low-grade systemic inflammation might contribute to the development of psychological longterm outcomes in patients with MTBI. Studies that focused on the systemic inflammation
following MTBI are limited. According to findings from studies using animal models, MTBI
could activate systemic inflammatory processes. For example, research findings demonstrate that
circulating levels of IL-6 is increased in experimental rodent models of MTBI (Holmin et al.,
1997; Shohami et al., 1994; S. H. Yang et al., 2013). Yet, it still remains unknown as to whether
the systemic inflammatory process could be used to predict adverse psychological outcomes after
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MTBI. Thus, it presents a fruitful area of research, in view of the fact that it is well established
that systemic inflammatory processes activate the hypothalamic-pituitary-adrenal (HPA) axis
(Murray, Buggey, Denes, & Allan, 2013) which may result in chronic stress, anxiety, and
depression (Mustafa, 2013).
Furthermore, peripheral pro-inflammatory cytokines are capable of signaling the brain to
induce behavioral symptoms like fatigue, sleep disturbance, and depressive mood (i.e., sickness
behavior). It is possible that cytokine-to-brain signaling may contribute to behavioral symptoms
of trauma patients. For example, pro-inflammatory cytokines that access the brain initiate a
cascade of brain-derived cytokines that increase in indoleamine 2,3-dioxy-genase (IDO)
expression (Yamada, Akimoto, Kagawa, Guillemin, & Takikawa, 2009). Increased IDO, in turn,
can lead to overproduction of kynurenic and quinolinic acids and to less production of serotonin.
Lower serotonin is linked to the pathogenesis of depression, which is primarily interferongamma-induced (Capuron & Miller, 2011; Haroon, Raison, & Miller, 2012; A. H. Miller,
Maletic, & Raison, 2009).
Although experiences of MTBI patients are described in literature, there is lack of
evidence to guide health care providers to identify which MTBI patients are at greater risk for
behavioral symptoms. Explication of the psychobiological mechanisms that underlie behavioral
symptom expression in MTBI survivors is a critical first step that will improve risk assessment
and ultimately lead to prevention and/or better management of trauma-associated behavioral
symptoms. It is possible that these co-occurring symptoms synergize to negatively impact
cognitive and functional recovery. Yet investigation of these behavioral symptoms as a cluster
and their association with MTBI recovery is limited. Thus, the primary aim of this proposal is to
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determine the extent to which these behavioral symptoms, independently or as a cluster, predict
worse cognitive and functional outcomes post-MTBI. Further, it is possible that genetic variants
may predispose to more persistent behavioral symptoms post-MTBI. This proposal explores the
relationship of these genetic variants to risk for depressive mood, fatigue, and poor sleep
independently and as a cluster.
Size and Importance of the Problem
Behavioral Symptoms and MTBI
MTBI patients can suffer from anxiety, fatigue, poor sleep, and depressive mood for
weeks and months after injury (Ayalon et al., 2007; Bay & Xie, 2009; Beaulieu-Bonneau &
Morin, 2012; Beetar et al., 1996; Chaput et al., 2009; Levin et al., 2005; Norrie et al., 2010;
Ponsford et al., 2000; Rapoport et al., 2006).
Ample research indicates that anxiety symptoms are prevalent in the aftermath of a mild
TBI (Hiott & Labbate, 2002; Koponen et al., 2002; Ma et al., 2014; Mooney & Speed, 2001;
Moore, Terryberry-Spohr, & Hope, 2006; Rao & Lyketsos, 2002; Rao et al., 2010; R. Ruff,
2005; R. M. Ruff, 2011; Stulemeijer et al., 2006; Woodcock & Morganti-Kossmann, 2013).
Anxiety in general has been reported at rates as high as 70% in patients with TBIs (Rao &
Lyketsos, 2002).
Likewise, fatigue is a frequent burdensome symptom post-TBI, and although the nature
of fatigue may change with time, it can persist for years after the initial injury (Mollayeva et al.,
2014). The incidence of fatigue after TBI varies from 21% to73%, depending on patient
characteristics (e.g., severity of injury, time since injury, etc.) and how fatigue is measured
(Belmont, Agar, Hugeron, Gallais, & Azouvi, 2006; Borgaro, Baker, Wethe, Prigatano, &
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Kwasnica, 2005; Lidvall, Linderoth, & Norlin, 1974; Middleboe, Andersen, Birket-Smith, &
Friis, 1992; Ponsford, Cameron, Fitzgerald, Grant, & Mikocka-Walus, 2011). Although fatigue is
linked to poor recovery post-TBI, a recent systematic review concluded that the impact of fatigue
on patient outcomes is unclear and more intensive investigation is essential (Mollayeva et al.,
2014). The prevalence and persistence of fatigue after TBI has the potential to impact activities
of daily functioning, occupational and leisure activities, and thus quality of life (Cantor et al.,
2008; Ouellet, Savard, & Morin, 2004). Previous studies highlight the importance of fatigue after
MTBI and the need for further investigation and identification of markers that could possibly
identify MTBI patients who are at risk for more severe symptoms in order to implement
interventions earlier for better quality of life in MTBI survivors.
Additionally, the increased incidence of sleep disorders after TBI relative to the general
population has been increasingly recognized (Castriotta et al., 2007; Watson, Dikmen,
Machamer, Doherty, & Temkin, 2007). Sleep disturbance is a common complaint following TBI,
and it is more common with MTBI (Beetar et al., 1996; Clinchot, Bogner, Mysiw, Fugate, &
Corrigan, 1998; Fichtenberg, Millis, Mann, Zafonte, & Millard, 2000; Mahmood, Rapport,
Hanks, & Fichtenberg, 2004). In recent reviews, 30–70% of TBI survivors reported sleep
disturbances (Orff, Ayalon, & Drummond, 2009). Sleepiness may present as a separate symptom
or along with other sleep disorders (e.g., sleep apnea, narcolepsy, post-traumatic hypersomnia,
delayed sleep phase, insomnia, fatigue, alteration of sleep-wake schedule to movement disorders)
(Castriotta et al., 2007; Orff et al., 2009; Watson et al., 2007). However, insomnia has been
found to be more prevalent in mild TBI individuals (Ouellet et al., 2004). Most of the time the
sleep disturbances are directly related to the TBI, enduring for months and/or years after the
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injury, consequently hindering the recovery process and return to pre-injury function (Orff et al.,
2009).
Lastly, evidence reveals that MTBI patients with sleep disturbance are more likely to
suffer depressive symptoms (Auxemery, 2012; Bay & Donders, 2008; Bay, 2009; BeaulieuBonneau & Morin, 2012; Chaput et al., 2009; Guskiewicz et al., 2007; Kristman et al., 2014;
Levin et al., 2005; Mooney & Speed, 2001; Ponsford et al., 2011; Rapoport, McCullagh,
Streiner, & Feinstein, 2003; Rapoport et al., 2006). Depression is commonly reported after
MTBI—with a prevalence of 15% in the first three months post-MTBI (Rapoport et al., 2003)
and a prevalence of 18% new onset depressive symptoms up to a year after MTBI (Rao et al.,
2010)—and is highly correlated with poor recovery (Guskiewicz et al., 2007; Mooney & Speed,
2001). There are only a few studies that investigated the relationship between MTBI and
depression, as well as the risk factors related to the development of depression after MTBI
(Levin et al., 2005; Rao et al., 2010).
The results of these studies suggest that there are several possible predictive factors
associated with MTBI, psychological adverse outcomes, and other biological factors that could
be identified in future research. Using predictive parameters can help emergency department
(ED) personnel to identify MTBI patients who are at higher risk before discharge from the ED;
allowing the opportunity to make appropriate referrals and prevent suffering from debilitating
symptoms. This is a clinically relevant and important area for research, as early identification
with more knowledge about risk factors for MTBI behavioral symptoms soon after the injury can
help initiate treatment early on, thus promoting optimal quality of life.
Depression, fatigue, and poor sleep have been independently associated with impeded

8
recovery from MTBI for cognitive function (Guskiewicz et al., 2007; Mooney & Speed, 2001;
Orff et al., 2009) and with the resumption of pre-injury lifestyle and responsibilities (Patterson &
Holahan, 2012; Silver, McAllister, & Arciniegas, 2009).
Although experiences of MTBI patients are described in literature, as summarized above,
understanding the psychiatric morbidity following MTBI remains limited, even though these
comorbidities are prevalent. Several studies have reported short- and long-term increased rates of
comorbidities following TBI; most studies; however, combined mild and moderate to severe TBI
in their analyses. Hence, it is difficult to draw conclusions regarding psychiatric outcomes
following MTBI, as opposed to more severe forms of TBI.
However, predictive power may be gained by evaluating clusters of symptoms that cooccur and which may portend slower recovery. To date only six studies used cluster analysis to
identify symptom profiles related to recovery (Bailie et al., 2016; Hellstrom et al., 2013; Hoffer
et al., 2016; Snell, Surgenor, Hay-Smith, Williman, & Siegert, 2015; Velikonja, Warriner, &
Brum, 2010). One study identified three clusters of psychological adaptation (high, medium, and
low) which related to injury outcomes (Snell et al., 2015). A second study used cluster analysis
to identify subgroups of MTBI patients based on a symptom intensity profile (Hellstrom et al.,
2013). Findings revealed that those with minor symptoms had a reduced risk for a positive CT or
MRI findings, whereas the high-symptom-level group experienced difficulty returning to work
and reported high levels of anxiety, depression and disability. Although both of these studies
support this proposal, neither evaluated inflammation-related behavioral symptoms as a cluster
predictive of cognitive recovery. Thus, there is a critical need to further develop prognostic
models of MTBI to identify those at greater risk for poorer cognitive and functional recovery,
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who will thus most benefit from targeted therapy (McMahon et al., 2014). Explication of the
cluster of behavioral symptoms (i.e., depressive mood, fatigue, and poor sleep) posited to
underlie cognitive and functional recovery in MTBI survivors is a critical first step to improve
risk assessment and to better manage post-MTBI outcomes (Lingsma et al., 2014).
Genetic Variants and Behavioral Symptoms Post-MTBI
Genetic variants may contribute to risk for clustering of behavioral symptoms (depressive
mood, fatigue, and poor sleep) following MTBI. Yet most studies to date have not evaluated
whether genetic variants predict a more intense and/or prolonged clustering of these behavioral
symptoms. It is known that impairment of neuropsychological and cognitive functions are
prevalent in MTBI patients with the APOE e4 allele (Isoniemi, Tenovuo, Portin, Himanen, &
Kairisto, 2006; Liberman, Stewart, Wesnes, & Troncoso, 2002; Millar, Nicoll, Thornhill,
Murray, & Teasdale, 2003; Potapov, Iusupova, Tendieva, Nikitin, & Nosikov, 2010; Sundstrom
et al., 2004; Sundstrom et al., 2007; S. T. Yang et al., 2015) and although presence of the APOE4
allele is not associated with the initial severity of brain injury post-TBI, it is correlated with
greater risk of poorer outcomes at six months post-injury (Zhou et al., 2008). The negative
influence of the e4 allele on memory, executive function, and fine motor control (Ariza et al.,
2006) has been highlighted in a meta-analysis (Zhou et al., 2008). In older (non-injured) adults,
findings demonstrated a relationship between the APOE genotype and depressive symptoms
(Rigaud et al., 2001; Yen et al., 2007) while other studies reported no such association (Cervilla,
Prince, Joels, Russ, & Lovestone, 2004; Kessing & Jorgensen, 1999). With respect to fatigue,
one study found that post-MTBI carriers of the APOE e4 allele had pronounced fatigue
(Sundstrom et al., 2007). However, no studies have evaluated the linkage of the APOEe4 allele
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to poor sleep post-MTBI or to the clustering of behavioral symptoms (depression, fatigue, and
poor sleep) following MTBI. Thus, there is a need to explore the linkage of the APOEe4 allele to
vulnerability for more intense and enduring depressive symptoms, fatigue and poor sleep—
common behavioral symptoms which may share a similar inflammatory etiology in individuals
following MTBI.
Further, genetic association analyses suggest certain common single nucleotide
polymorphisms (SNPs) may negatively influence recovery from MTBI (Feng et al., 2015;
Lanctot et al., 2010; McAllister et al., 2005; McAllister et al., 2008; Pap et al., 2012; Roetker et
al., 2012). It is possible that certain SNPs may predispose individuals to experience persistent
behavioral symptom clusters after MTBI, further impeding recovery. McAllister et al. (2005;
2008) found that rs1800497 allele status was associated with cognitive function post-mild to
moderate TBI (McAllister et al., 2005; McAllister et al., 2008). Subsequently, others examined
the influence of the (C/T) SNP rs1800497 on post-TBI outcome using data from two multicenter
studies (the Citicoline Brain Injury Treatment trial and TRACK-TBI Pilot). Findings showed that
the ANKK1 T/T genotype is related to poorer verbal learning performance at six months postTBI (Yue et al., 2015). Previous evidence also suggests that SNPs play a role in predisposing
patients to depression (Feng et al., 2015; Pap et al., 2012; Roetker et al., 2012) and also may
explain differential response to treatment (Lanctot et al., 2010). Since previous studies focused
on TBI in general, it is thus the purpose of this project to explore which alleles SNPs are
associated with more intense and/or persistent behavioral symptom cluster (depressive mood,
fatigue, and poor sleep) post-MTBI, which may negatively influence recovery.
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Justification of the Importance
In light of the primary aim of this secondary analysis study research to determine
the extent to which behavioral symptoms, independently or as a cluster, predict worse cognitive
and functional outcomes post-MTBI, three important and innovative aspects of this project may be
examined.
The first is the use of symptom clusters analysis as a predictive tool for profiling
subgroups enduring behavioral symptoms post-MTBI. As it also to a certain extent reveals
symptom interrelationships (Aktas, Walsh, & Rybicki, 2010), this aspect primarily facilitates in
exploring the influence of symptoms on each other, and aids in tailoring specific treatments
accordingly. This conceptualization of symptom clusters is visualized as a shift of the paradigm
of symptom management research, which addressed the reality of concurrent symptoms
experienced in different populations and may lead to more promising research that will
potentially generate knowledge needed for rapid improvement in symptom management. Thus,
the paradigm shift would bridge the gap between research and bedside nursing by addressing
symptoms (as a cluster), which is the most common reason that individuals seek healthcare
(Dodd et al., 2001). This paradigm shift might improve the management of symptoms, ultimately
reducing symptom burden (Aktas et al., 2010). Thus, profiling subgroups of MTBI patients will
improve clinical practice, inform clinical practice guidelines, and ultimately provide patients
with the most effective and innovative treatment modalities (Barsevick, Whitmer, Nail, Beck, &
Dudley, 2006; Dodd et al., 2001; Kim & Abraham, 2008). In addition, when symptoms are not
treated the patient can suffer from lingering long-term negative outcomes. Therefore, enhancing
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the knowledge regarding the symptom cluster experiences and cognitive and functional
outcomes is crucial and can lead to innovative treatments.
The second innovative aspect involve the chosen frameworks (the psycho-neuroimmunology (PNI) framework and the Theory of Unpleasant Symptoms (TOUS) that guide this
investigation. This integrative framework can lead to advancement in improving quality of life
and cognitive and functional recovery post-MTBI. Specifically, the investigator will apply the
field of genetics to explore a potential mechanism and to explain how genetic variants may
predispose to more persistent behavioral symptoms post-MTBI. Understanding these
physiological (genetic) factors may lead to effective symptom management approaches and/or
tailored strategies. The PNI framework will guide the understanding of these relationships, where
it is possible that these co-occurring symptoms synergize to negatively impact cognitive and
functional recovery. Furthermore, the TOUS (Lenz, Suppe, Gift, Pugh, & Milligan, 1995; Lenz,
Pugh, Milligan, Gift, & Suppe, 1997) will guide the symptom-clustering aim, since it illustrates
the importance of inclusion and consideration of the symptom experience as clusters.
Incorporating the experience of symptoms “as clusters” (adapted from TOUS) would allow
researchers to have a broader view of the symptom-related variables (e.g., genetic variants) that
contribute to the symptoms clusters, as well as the symptoms-related recovery outcomes (e.g.,
cognitive and functional recovery). Overall, it is hoped that the innovative 3-dimensionally
conceptualized frameworks will creatively illustrate the variations in MTBI patients with the
enhanced understanding regarding symptom clusters and long-term recovery outcome.
Lastly, the third innovative aspect is the objective to explore the extent to which genetic
variants (SNPs) influence behavioral symptoms at six months post-MTBI. It is possible that

13
genetic variants may predispose to more persistent behavioral symptoms post-MTBI. There is a
compelling impetus for further exploration of genetic variants linked to inflammatory-related
behavioral symptoms in individuals who suffer MTBI. Determining the extent to which genetic
variants might contribute directly or indirectly to the symptoms (depression, fatigue, and poor
sleep) and might impact cognitive impairment in MTBI patients is innovative, as results may
provide novel biomarkers to predict more intense and persistent symptoms as early as possible.
This will provide a new and potentially important avenue for investigation into the biological
basis for these behavioral symptoms. Understanding the role of these biomarkers (SNPs) in
MTBI has potential to lead to predicting at discharge which MTBI patients are at risk for
prolonged behavioral symptoms. The findings can guide the future development of personalized
genetic-based approaches to help identify and treat trauma patients, in turn to promote quality of
life and reduce symptom intensity and duration.
In summary, the long-range objective of this research is to develop novel approaches to
predict risk for behavioral symptoms in mild traumatic brain-injured (MTBI) patients at
discharge from the ED. The outcomes of the proposed study will build a foundation to establish
clinically based strategies to identify MTBI patients at risk and to target interventions to reduce
behavioral symptoms and improve quality of life in trauma survivors and their families. Thus,
there is strong rationale for this research in its potential to improve long-term outcomes for
MTBI survivors who overcome their acute injury but who remain at risk for chronic and
disabling behavioral symptom clusters.
Central Hypothesis
There will be differences in cognitive and functional outcomes in patients at six months
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post-MTBI based on inflammation-related behavioral symptoms (depressive symptoms, fatigue,
and poor sleep), independently or as a cluster; and there will be differences in behavioral
symptoms at six months post-MTBI based on SNP phenotype. The evaluation of inflammationrelated behavioral symptom clusters post MTBI with respect to outcomes and genetic variants is
an innovative approach that can result in novel predictive biomarkers for early risk assessment.
Thus, there is strong rationale for the proposed research, which can improve long-term outcomes
for MTBI survivors who overcome their acute injury but who remain at risk for chronic and
disabling behavioral symptoms.
Specific Aims and Hypotheses
The following specific aims and hypotheses will be addressed:
Aim 1: Identify different behavioral profiles of MTBI patients based on the intensity of
depressive mood, fatigue, and sleep quality.
Hypothesis 1: There will be individual differences in the profiles of MTBI patients based
on the intensity of depressive mood, fatigue, and poor sleep.
Aim 2: Determine whether there are differences in cognitive and functional outcomes at
six months post-MTBI among the identified behavioral cluster profiles.
Hypothesis 2: There will be differences in cognitive and functional outcomes at six
months post-MTBI among the identified behavioral cluster profiles.
Aim 3: Explore differences in the intensity of behavioral symptoms at six months postMTBI based on SNP genotype.
Hypothesis 3: There will be differences in behavioral symptoms at six months post-MTBI
based on SNP genotype.
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Expected Outcomes
For a sizeable subgroup of MTBI patients, recovery is protracted, and prediction of who
will experience protracted recovery is not well defined. Thus, there is a critical need to identify
those at risk for a poorer outcome. Findings from this study will increase understanding of the
role of depressive mood, fatigue, and poor sleep—as a symptom cluster—on cognitive and
functional recovery. Additionally, enhanced knowledge from this secondary analysis will
provide a foundation to guide future studies that evaluate the usefulness of these biomarkers
(genetic variants), as predictors for the risk of more intense and enduring behavioral symptoms
in MTBI patients. As well, the identified symptom clusters profiles as predictors for risk for
more cognitive and functional outcomes at six months post-MTBI. Ultimately, this knowledge
can be used to develop clinical strategies for earlier identification (i.e., at discharge) of MTBI
patients who are at risk of such behavioral symptoms. This crucial knowledge will have a
positive impact on the care of MTBI patients, as it will stimulate the development and
implementation of specific symptom profiles to be used clinically to stratify risk for poor
recovery and to identify those who may require earlier and more intense intervention to promote
better quality of life.

CHAPTER TWO
REVIEW OF THE LITERATURE
MTBI: Introduction and Definition of MTBI
Traumatic brain injury (TBI) is an acquired brain injury, which occurs when a sudden
trauma produces damage to the brain. TBI can result when the head suddenly and violently
strikes an object, or when an object penetrates the skull and enters brain tissue (National Institute
of Neurological Disorders and Stroke, 2014). In the United States, TBI is a significantly growing
public health, social, and economic concern. Of note, TBI can result in adverse outcomes, which
may persist for an extended period of time. The annual incidence of TBI is estimated to be
approximately 1.5–2 million, and of all TBIs—including mild traumatic brain injuries
(MTBIs)—account for 80–90% (Carroll et al., 2004; Kristman et al., 2014; R. Ruff, 2005; R. M.
Ruff, 2011). Research findings reveal that only 20–25% of all MTBI patients are hospitalized,
and among these MTBI patients, 80–90% recover without residual psychological adverse
outcomes. Yet, the remaining 10–20% (referred to as the “miserable minority”) will continue to
suffer from long-term debilitating, unfavorable psychological outcomes. These symptoms could
affect these individuals for weeks or months after the injury, and possibly hinder them from
returning to previous functional status and daily activities (J. Kraus et al., 2005). Such long-term
symptoms result in extensive economic costs for the healthcare system (Carroll et al., 2004;
Cassidy et al., 2004; Kristman et al., 2014; R. Ruff, 2005), with costs approaching nearly $17
billion each year (Center for Disease Control and Prevention, 2003).
16
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It is important to highlight that past incidence data for MTBIs were primarily derived
from patients evaluated in hospital emergency departments (ED). These ED-derived data
underestimate TBI incidence because the majority of persons who sustain an MTBI either
consult their primary care physician days after the injury or do not seek care at all (Langlois et
al., 2003; Mellick, Gerhart, & Whiteneck, 2003). Consequently, the 1998 National Institute of
Health (NIH) consensus statement concluded that MTBIs were under-diagnosed and the statistics
likely underestimate the real extent of the problem (Rehabilitation of persons with traumatic
brain injury.1998; Consensus conference. rehabilitation of persons with traumatic brain injury.
NIH consensus development panel on rehabilitation of persons with traumatic brain injury.1999;
Rose, 1999).
For some individuals, suffering an MTBI can lead to persistent behavioral symptoms
long after sustaining the injury. Several studies described the possible adverse behavioral
outcomes following MTBI (Bay & Donders, 2008; Bay & Xie, 2009; Bay, 2009). Those studies
report that a substantial number of MTBI patients suffer from fatigue, sleep disturbances,
cognitive impairment, and depression for weeks and months following the initial injury (Ayalon
et al., 2007; Bay & Xie, 2009; Beaulieu-Bonneau & Morin, 2012; Beetar et al., 1996; Chaput et
al., 2009; Levin et al., 2005; Norrie et al., 2010; Ponsford et al., 2000; Rapoport et al., 2006).
Yet, few studies have attempted to investigate predictive factors which can be used to identify
who is at risk for developing intense behavioral symptoms following MTBI (R. M. Ruff et al.,
2009).
Conclusions from a comprehensive review emphasized the need for future research to
develop diagnostic or predictive tools that would identify patients at risk for poor outcomes post-
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MTBI. These tools would have a powerful clinical advantage to target vulnerable MTBI patients
and would be cost-effective (R. Ruff, 2005). Although MTBI is not life-threatening, suffering
from poor outcomes interferes with the ability to return to work or the resumption of social
activities for up to six months after injury (J. Kraus et al., 2005). Thus, reliable predictive
measures are essential to identify patients at increased risk of developing poor psychological
outcomes, and to implement follow-up strategies for MTBI patients at risk early on.
Establishment of protocols in clinical practice that demand early assessment and follow-up
treatments would possibly prevent and improve the psychological burden for MTBI patients
(Lingsma et al., 2014)
Although experiences of MTBI patients have been described in literature, understanding
the psychiatric morbidity following MTBI remains limited, despite agreement that such
comorbidities are common. Several studies have reported short- and long-term increased rates of
comorbidities following TBI; most studies; however, combined mild and moderate to severe TBI
in their analyses. Hence, it is difficult to draw conclusions regarding psychiatric outcomes
following MTBI separately. Additionally, there is lack of evidence to guide health care providers
to identify which MTBI patients are at greater risk for behavioral symptoms. Explication of the
psychobiological mechanisms that underlie behavioral symptom expression in MTBI survivors is
a critical first step that will improve risk assessment and ultimately lead to prevention and/or
better management of trauma-associated behavioral symptoms.
In comparison with moderate and severe brain injuries, MTBIs are often more
challenging to diagnose. The lack of a universally agreed-upon definition of MTBI contributes to
many clinical and research challenges (R. Ruff, 2005). Therefore, it is essential to define MTBI.

19
The World Health Organization (WHO) Task Force proposed an operational definition that
differs from the definition developed by the MTBI Injury Committee of the Head Injury
Interdisciplinary Special Interest Group of the American Congress of Rehabilitation Medicine
(ACRM) (Carroll et al., 2004; Kristman et al., 2014). The definition proposed by WHO and the
one used for this study is as follows:
MTBI is an acute brain injury resulting from mechanical energy to the head from external
physical forces. Operational criteria for clinical identification include: (1) 1 or more of
the following: confusion or disorientation, LOC [Loss of Consciousness] for 30 minutes
or less, posttraumatic amnesia for less than 24 hours, and/or other transient neurologic
abnormalities such as focal signs, seizure, and intracranial lesion not requiring surgery;
(2) GCS [Glasgow Coma Score] score of 13-15 after 30 minutes post-injury or later upon
presentation for health care. (3) These manifestations of MTBI must not be due to drugs,
alcohol, medications, caused by other injuries or treatment for other injuries (e.g.,
systemic injuries, facial injuries, or intubation), caused by other problems (e.g., psychological trauma, language barrier, or coexisting medical conditions), or caused by
penetrating craniocerebral injury. (Carroll et al., 2004), p. 115)
The WHO Collaborating Centre for Neurotrauma Task Force conducted a comprehensive
critical review of the literature to determine the best evidence on the epidemiology, diagnosis,
prognosis, and treatment of MTB. That Task Force concluded that identification of prognostic
factors is a priority for research. Exploratory studies have suggested a number of potential
prognostic factors for recovery after MTBI (Carroll et al., 2004; Kristman et al., 2014). Yet, no
definitive study has yet been published that establish prognostic factors to predict outcomes postMTBI.
Theoretical Frameworks
The psychoneuroimmunology (PNI) framework will be used to guide this investigation.
In addition, the investigator will use the field of genetics to explore a potential mechanism to
explain how genetic variants may predispose to more persistent behavioral symptoms post-

20
MTBI. Understanding these physiological (genetic) factors may lead to effective symptom
management approaches and/or tailored strategies. Furthermore, the Theory of Unpleasant
Symptoms (TOUS) (Lenz et al., 1995; Lenz et al., 1997) will guide the symptom-clustering aim,
since it illustrates the importance of inclusion and consideration of the symptom experience as
clusters. Incorporating the experience of symptoms “as clusters” (adapted from TOUS) would
allow researchers to have a broader view of the symptom-related variables (e.g., genetic variants)
that contribute to the symptoms clusters, as well as the symptoms-related recovery outcomes
(e.g., cognitive and functional recovery). The PNI framework will guide the understanding of
these relationships, where it is possible that these co-occurring symptoms synergize to negatively
impact cognitive and functional recovery. Additionally, it is possible that genetic variants may
predispose to more persistent behavioral symptoms post-MTBI; this also speaks to the mind and
body connection. This suggests that this relationship is orchestrated by the unique mind and body
connection.
Psychoneuroimmunology Framework
PNI is defined as the study of the interaction between behavioral, neural, endocrine
(neuroendocrine), and immunological processes of adaptation (Ader, 1980). The interdisciplinary
science of PNI examines an individual’s emotional responses on a multidimensional level to
determine if valid relationships exist among emotions, immune function, and health (Robinson,
Mathews, & Witek-Janusek, 2000). Interdisciplinary researchers discovered the biological link
between the brain on one hand and the cells and tissues of the immune system on the other,
which built the foundation for this field of science (Kemeny & Schedlowski, 2007).The basic
principle of the PNI framework is that an individual’s adaptive response to the environment
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involves coordinated interactions among the nervous, endocrine, and immune systems. The
biological pathways that connect the brain to the cells and tissues of the immune system include
direct innervations of lymphatic tissue by the central nervous system and a shared
communication network in which cells of the nervous, endocrine, and immune systems use
common molecules and receptors to jointly modulate one’s biology and one’s emotions and
behavior. Moreover, an expanding body of evidence suggests that emotions play a role in the
development and progression of disorders that involve immune processes (Kemeny &
Schedlowski, 2007).
Of particular relevance to this investigation is the concept of sickness behavior. Sickness
behavior refers to the non-specific adaptive response of the innate immune system, which results
in behaviors associated with sickness including lethargy, lack of interest in the environment,
decreased appetite, and fatigue (Dantzer & Kelley, 2007). It is proposed that sickness behavior
represents an expression of a central motivational state mediated by release of cytokines (Aubert,
Kelley, & Dantzer, 1997; Dantzer & Kelley, 2007). In essence cytokine-induced sickness
behavior refers to a motivational state that belongs to the realm of physiology, similar to other
motivational states, such as fear or hunger (Dantzer & Kelley, 2007). Withdrawing from the
environment to seek rest and care for the body is as normal in response to infectious agents as
being able to shift to a state of increased arousal and readiness for action when confronted with a
potential external threat. In theory, cytokines released in response to infection or inflammation
alert the brain of any real or potential threats and initiate behaviors that are important for survival
(Frink et al., 2009).
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The result of a hyperactive pro-inflammatory state marked by excess production of proinflammatory cytokines may contribute to the pathogenesis of various human diseases such as
allergy, autoimmunity, obesity, depression and atherosclerosis (Sternberg, 2006). Some even
refer to the ability of the immune system to alert or communicate information about the body to
the brain as a “sixth sense” (Blalock & Smith, 2007). Sickness behavior is adaptive in that it
forces an individual to rest and withdraw from activities so that physiological processes can
effectively produce healing (Blalock & Smith, 2007; Kelley et al., 2003). However, sickness
behavior is no longer adaptive if it goes beyond the organism’s resources and/or occurs out of
proportion to the triggering factors that initiated the adaptive response. This is prevalent during a
variety of chronic inflammatory diseases (Dantzer & Kelley, 2007). Pro-inflammatory cytokines
released during infection, inflammation, injury and even psychological stress can signal the brain
to initiate behavioral changes that facilitate adaptation to these threats.
Cytokines signal the brain to induce sickness behaviors through neural, hormonal, and
cellular pathways (Capuron & Miller, 2011). The purpose of the following section is to describe
how cytokines access and signal the brain. Secondly, key evidence that supports the concept that
cytokines signal the brain to induce sickness behaviors will be described. To accomplish this,
two crucial models will be considered: Dantzer’s Motivational Model of Sickness Behavior and
the Two-Hit Model of Cytokine-Induced-Depression.
Cytokine signals access the brain. Cytokines are relatively large protein molecules, and
as a result are prohibited from passing through the blood-brain barrier; however, the blood-brain
barrier may be disrupted following TBI (Kumar & Loane, 2012). In view of the fact that
cytokines signal the brain in a manner to influence behavior and the expression of emotion
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(Capuron & Miller, 2011), there are specific mechanisms that differentially mediate cytokine
effects on the central nervous system. The entry of peripheral cytokines into the brain initiates a
cascade of signals, which become amplified within the context of the brain cytokine network.
This network consists of cells within the brain (e.g., microglia and astrocytes) that are
themselves capable of further cytokine secretion. The neural pathway of immune-to-brain
signaling underlies the potent effects of peripheral proinflammatory cytokines on pathways
involved in the pathophysiology of neuropsychiatric disorders, including the activation of the
HPA axis and the alteration of the metabolism of key neurotransmitters, such as serotonin
(Dantzer et al., 1999).
Cytokines access and signal the brain through hormonal, neural and cellular pathways.
Hormonal pathways refer to the activation of monocytes and macrophages, which release the
proinflammatory cytokine and enter the brain through the choroid plexus and circumventricular
organs of the blood-brain barrier. Once inside the brain, the activation of endothelial cells is
responsible for the subsequent release of second messengers that act on specific brain targets
(Capuron & Miller, 2011). Cytokines also signal the brain via neural pathways in which
activated monocytes and macrophages stimulate primary afferent nerve fibers in the vagus nerve;
this, in turn, results in the release of proinflammatory cytokines. This information reaches the
brain by sensory afferents of the vagus nerve, which connect with specific brain regions through
the activation of the nucleus of the tractus solitarius and postrema area (Capuron & Miller,
2011). Lastly, D’Mello & Swain (2009) identified another new immune-to-central nervous
system communication pathway in the setting of organ-centered peripheral inflammation.
According to D’Mello & Swain (2009), evidence shows that there is a significant infiltration of
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activated monocytes into the brain in mice with hepatic inflammation (D'Mello et al., 2009). This
cellular pathway refers to the stimulation of microglia by pro-inflammatory cytokines to produce
monocyte chemoattractant protein-1, which in turn is responsible for the recruitment of
monocytes into the brain (D'Mello et al., 2009).
Dantzer’s motivational model of sickness behavior. Dantzer’s theory of sickness as a
motivational state is built upon Bolles’ definition of motivations as central states that reorganize
perception and action (Bolles & Fanselow, 1980). Bolles (1974) emphasized that a motivational
state enables the individual to detach perception from action, which results in a selective
appropriate strategy depending on the encountered state. In order for the body to efficiently deal
with an invading infectious organism, sickness takes precedence over other behavioral activities
when the infected organism is at the death stage (Dantzer & Kelley, 2007). Bolles and Fanselow
(1980) presented a fear motivation system, which by assumption activates a unique class of
defensive behavior, such as freezing and flight from a frightening situation. This activation aims
to defend the animal against predation of natural danger while reorganizing the perception of
environmental events to facilitate the perception of danger and safety (Bolles & Fanselow,
1980). The following examples illustrate the expression of sickness behavior as a motivational
state.
First, Neal Miller (1964) conducted the first series of experimental investigation that
demonstrated a differential effect of bacterial endotoxin on behavior. Endotoxin administration
decreased bar-pressing when the bar-pressing resulted in an appetitive stimulus like food or
water, but endotoxin did not decrease bar-pressing when it resulted in the termination of an
aversive event. Rats given an endotoxin injection increased bar-pressing to stop the rotation of a
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drum, an aversive stimulus (N. E. Miller, 1964). Interestingly, these results revealed that the
consequence of the behavior, which does not necessarily decrease following exposure to
sickness-inducing agents, influences the effect of the sickness-inducing agent.
Second, Aubert, Goodall, and Dantzer (1995) compared the effects of cold and cytokines
on spontaneous dietary self-selection of rats. First, they habituated rats to free access to
carbohydrate, protein, and fat diets for 4 hours a day for 10 days. Then they randomly received
physiological saline, IL-1 beta injection or lipopolysaccharide (LPS), or were exposed to cold (5
degrees C). Results revealed that LPS- and IL-1 beta-treated rats ate less, but ingested relatively
more carbohydrates and less protein, whereas relative fat intake remained unchanged. The rats
exposed to cold slightly increased their food intake, but in a non-significant manner. They also
increased their relative intake of fat but did not change their relative intake of carbohydrate and
protein. These results reveal interesting pyrogenic and metabolic effects of cytokines, which
provides a clear-cut example of behavioral reorganization in response to sickness (Aubert et al.,
1995).
In a subsequent study, Aubert, Goodall, Dantzer, & Gheusi (1997) investigated the
sensitivity to LPS injection in lactating mice. They found that nest-building significantly
decreased in LPS-treated mothers compared with saline-treated animals at an ambient
temperature of 22 degrees C. Furthermore, they found that LPS-treated mice exposed to cold
temperature (6 degrees C) expressed not only pup-retrieving but also nest-building activity.
Therefore, these activities are a result of a motivational state due to the cooler environment.
These differential results indicate that the maternal behavioral expressions of LPS-induced
sickness are dependent on the comparative priority of the behavior under consideration (different
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components of maternal care under consideration). Apparently, sickness prevents mice from
displaying motor activities (pup-retrieving or nest-building) and from evaluating the situation
under consideration efficiently (Aubert et al., 1997).
Finally, Aubert Kelley, & Dantzer (1997) compared the effects of LPS on food intake and
food hoarding. Rats underwent tests under different motivational levels for food hoarding
(receiving food supplement to maintain stable body weight or not receiving such a supplement).
Interestingly, they found that LPS-injection significantly decreased total food intake in rats in
general, whereas food-hoarding was less in LPS-treated rats compared to those who did not
receive a supplement. The expression of a still salient secondary motivation in LPS-treated rats,
which did not receive any food supplement, suggested the expression of an anticipatory feeding
behavior along with a reduced immediate appetite. Their results demonstrated that LPS treatment
disrupted food-hoarding in a minor way when rats received all of their food from hoarding,
compared to rats that had supplemental food in their home cages (Aubert et al., 1997). LPStreated animals still appear able to adjust their defensive behavioral strategies with regard to their
needs and capacities. These findings support the adaptive value of the behavioral changes
displayed by LPS-treated animals (Aubert et al., 1997).
In summary, the evidence described above confirms the hypothesis that sickness
behaviors reflect the expression of motivational changes and reorganizations of behavioral
priorities (Dantzer & Kelley, 2007). Additionally, Aubert, Kelley, & Dantzer (1997) confirmed
that environmental conditions can be determinants of the behavioral change induced by illness or
cytokines. In other words, when there are possible adverse effects of behavioral depression,
behavior is less likely to suffer disruptions by infections and cytokines.
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Motivational aspect of sickness behavior. From the previous discussion of the historical
origin of the motivational model, it was clear that sickness has motivational properties that
reorganize the function of the organism at subjective, behavioral, and visceral levels in order to
cope with the threat encountered (Dantzer, 2009). The motivational aspect of sickness behavior
is a vital perspective in pathophysiology; it entails that the neural pathways underlie the
expression of sickness behavior, activated by immune stimuli but could possibly receive
activations from non-immune stimuli (Dantzer et al., 1999).
Therefore, cytokines signal the brain by inducing sickness behavior as a result of
expression of a motivational state triggered by activation of the peripheral innate immune system
(Dantzer, 2009). As mentioned earlier it is an adaptive normal response to the exposure to a
threat of a predator rather than being pathologic. In theory, cytokines released in response to
infection or inflammation alert the brain to any real or potential threats and initiate behaviors that
are important for survival (Frink et al., 2009). Some even refer to the ability of the immune
system to alert or communicate with the brain as a “sixth sense” (Blalock & Smith, 2007).
Sickness behavior is adaptive in that it forces an individual to rest and withdraw from activities
so that physiological processes can more effectively produce healing (Blalock & Smith, 2007;
Kelley et al., 2003).
Pro-inflammatory cytokines released during infection, inflammation, injury and even
psychological stress can signal the brain to initiate behavioral changes that facilitate adaptation
to these threats. However, similar to other responses, sickness behavior can become anomalous
or pathologic outside its original context and in the absence of inflammatory stimulus (Dantzer,
2009). This pathologic state derives from several factors:
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The hyperactive pro-inflammatory state marked by persistent excess production of proinflammatory cytokines like IL-1, IL-6 and TNF alpha and IFN gamma (Dantzer, 2009), which
may also contribute to the pathogenesis of various human diseases in addition to sickness
behaviors, such as allergy, autoimmunity, obesity, depression and atherosclerosis (Sternberg,
2006).
There is a predominance of pro-inflammatory cytokines over anti-inflammatory
cytokines, which normally down-regulate the activation of the pro-inflammatory cytokines of the
sickness response. This mismatch results in the exaggerated sickness response due to the
peripheral immune system or direct activation of the brain cytokine system (Dantzer, 2009).
The sensitization of the neuronal circuits is another facet. Activation of afferent nerve
fibers by peripherally released cytokines represents the fast pathway of transmission of immune
signals from the periphery to the brain. This neural pathway certainly sensitizes the brain target
areas of inflammatory mediators to the action of brain-produced cytokines that relay and amplify
the action of peripheral cytokines (Dantzer, 2001).
The motivational competition between motivational states for behavioral output.
Normally, hierarchal organization of motivational states is required for the expression of
behaviors, along with continuous evaluation of the encountered internal context and external
events occurrences (Dantzer, 2001). For example, if an individual is sick with the flu and
experiences generalized muscle weakness, which cause them to stay in bed for the whole day,
this individual is more likely to overcome this illness and will be better equipped to response to a
threat.
The effect of cytokines on maternal behavior provides a more representative example of
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the competition of motivational states, in the sense that maternal behaviors are critical for the
survival of the offspring. In the previously mentioned study by Aubert, Goodall, Dantzer, &
Gheusi (1997), LPS-treated mice exposed to ambient temperature of 22 degrees C, compared to
saline-treated mice, demonstrated pup-retrieving activity, but nest-building was significantly
decreased. However, LPS-treated mice exposed to ambient cold temperature, compared with
saline-treated mice, demonstrated both pup-retrieving and nest-building activity. Interestingly,
their results signify that the behavioral expression of LPS-induced sickness depends on the
priority of the behavior under consideration (Aubert et al., 1997). In motivational terms, maternal
behaviors compete with sickness, and maternal-motivated behavior takes superiority over
sickness behavior. This observation provides a valuable example of the motivational competition
between behaviors.
The Two-Hit Model of Cytokine-Induced Depression
Production of pro-inflammatory cytokines induces sickness behavior, which is
terminated by endogenous anti-inflammatory molecules. Sustained production of proinflammatory cytokines in the context of insufficient production of anti-inflammatory molecules
causes depression in vulnerable individuals. Factors acquired or genetic can contribute to
vulnerability. Vulnerability in the present context refers to an innate or acquired predisposition to
develop a given pathology when causal factors are present. Dysfunction in genes controlling key
proteins in cytokine production (e.g., IL-6) and serotoninergic neurotransmission (e.g., activity
of the serotonin transporter) or serotonin receptor subtype are identified as vulnerability factors
for cytokine-induced depression (M. R. Kraus et al., 2007). The association between IL-6
polymorphism and reduced risk of depressive symptoms confirms the role of the inflammatory
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response system in the pathophysiology of IFN-alpha-induced depression. In contrast, the effect
of the 5-HTT-serotonin transporter gene was reported to be small and perhaps dependent on the
status of the inflammatory response (Bull et al., 2009).
There are several features that contribute to vulnerability and are considered markers of
vulnerability. Firstly, psychological features can influence vulnerability to cytokine-induced
depression. Patients who have high scores on depression scales at the start of cytokine treatment
are more likely to develop depressive syndrome in response to immunotherapy than patients who
have a low score at baseline (Capuron & Ravaud, 1999). Another example of psychological
features is childhood adversity and maltreatment. Danese et al. (2007) conducted a cohort study
and followed 1,000 individuals from birth to age 32. They found that patients with major
depression and a documented history of childhood maltreatment showed higher levels of
peripheral blood concentrations of high-sensitivity CRP compared with depressed patients
without a history of childhood maltreatment (Danese et al., 2008)
Secondly, physiological features can also influence vulnerability. For example, patients
who respond to the first injection of IFN-α by an exaggerated pituitary-adrenal response are
more likely to become depressed in response to repeated administration of IFN-α than patients
who display a lower pituitary-adrenal response (Capuron et al., 2003; Capuron & Miller, 2011).
Aging is accompanied by several changes in the immune system and reflect immuno-senescence
and an altered susceptibility of disease. Thus, the elderly respond to stressful events with a larger
fluctuation of immune function and a greater propensity for the development or progression of
disease than young or middle-aged individuals (Irwin & Miller, 2007). Godbout et al. (2005)
investigated whether aging exacerbated neuro-inflammation and sickness behavior after
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peripheral injection of lipopolysaccharide (LPS) in aged mice. Their data revealed that activation
of the peripheral innate immune system leads to exacerbated neuro-inflammation in the aged
mice compared with adult mice. The dysregulation link between the peripheral and central innate
immune system is likely to be involved in the severe behavioral deficits that frequently occur in
older adults with systemic infections.
Another example is obesity, an inflammatory condition. O’Connor et al. (2005) tested the
hypothesis that obesity affects the IL-1beta system, with functional consequences in the brain of
obese mice. Their results indicate IL-1beta-mediated innate immunity is augmented in diabetic
obese mice at the periphery and in the brain, and the mechanism is due to diabetes-associated
loss of IL-1beta counter-regulation. Obesity and aging is correlated with chronic low-grade
inflammation that leads to priming or sensitization of brain microglial cells (Perry, 2004).
Superimposed on this low-grade inflammation status, a peripheral infectious episode leads to
exaggerated synthesis of inflammatory cytokines and other mediators in the brain that has an
impact on behavior and mood or exacerbates the progression of chronic neurodegenerative
disease.
Finally, immuno-compromised individuals, patients taking certain immune-altering
medications, or drug abusers can be more vulnerable (Irwin & Miller, 2007). These groups may
be more vulnerable as any alteration in the balance between pro-inflammatory and antiinflammatory cytokines (in the sense of a predominance of pro-inflammatory cytokines over
anti-inflammatory cytokines), results in an exaggerated sickness response to activation of the
peripheral immune system or direct activation of the brain cytokine system (Dantzer, 2009).
Patients who respond to the first injection of IFN-alpha with an exaggerated pituitary-adrenal
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response are more likely to become depressed in response to repeated administration of IFNalpha than patients who display a lower pituitary-adrenal response (Capuron et al., 2003)
The third vulnerability factor is genetic predisposition to particular diseases (e.g.,
autoimmune diseases, diabetes or cancer etc.) (Irwin & Miller, 2007). Dysfunction in genes
controlling key proteins in cytokine production and serotoninergic neurotransmission are
identified as vulnerability factors for cytokine-induced depression (Bull et al., 2009; M. R. Kraus
et al., 2007). Krauset et al. (2007) conducted a study to investigate the impact of functional gene
variants of the cerebral serotonin (5-HT) signaling pathway previously implicated in depression
risk in hepatitis C-infected outpatients treated with interferon alfa-2b. Their findings suggest an
impact of allelic variation in 5-HT1A receptor expressions on the development of interferon
alpha-induced depression during antiviral treatment of chronic hepatitis C. Prediction models of
interferon-induced depressive symptoms based on HTR1A variation offer a perspective for an
antidepressant-selective serotonin reuptake inhibitor prophylaxis in patients genetically at risk
for interferon-induced depression (M. R. Kraus et al., 2007).
In another study, Bull et al. (2009) determined if these polymorphisms were associated
with the development of depression and fatigue during IFN-alpha and ribavirin treatment.
Ninety-eight Caucasian patients who were receiving pegylated IFN-alpha and ribavirin treatment
for chronic hepatitis C virus participated in this prospective cohort study. The association
between the IL-6 polymorphism and reduced risk of depressive symptoms confirms the role of
the inflammatory response system in the pathophysiology of IFN-alpha-induced depression. In
contrast, the effect of the 5-HTT genes was small and perhaps dependent on the status of the
inflammatory response (Bull et al., 2009).
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The interaction between psychosocial factors and other psychobiological vulnerability
(e.g., depression) is characterized by alteration of immune function and increased susceptibility
to, or progression of, disease (Irwin & Miller, 2007). Collectively, the above features may help
while using markers for prediction of patients at risk for depressive symptoms and a guide in the
development of interventions to prevent the occurrence of depression thus improving the quality
of life.
Cytokines and depression. Cytokine-to-brain signaling has been implicated in mood
disorders, particularly depression that accompanies illness (Dantzer et al., 2008; Dantzer, 2009).
Because of the close similarities between symptoms of sickness and clinical signs of depression,
any of these conditions is likely a risk factor for the occurrence of major depressive disorders.
Evidence for the possibility of a shift from sickness behavior to depression is available from two
different sources: clinical research and experimental studies on animal models of depressive
disorders (Dantzer, 2009). The growing body of evidence implicates pro-inflammatory cytokines
in the etiology of depressive-like symptoms associated with chronic illness (Dantzer et al., 2008).
In the research field of PNI, accumulated evidence demonstrates reciprocal
communication pathways between nervous, endocrine, and immune systems (Schiepers,
Wichers, & Maes, 2005). Findings in the field of PNI stimulated increased interest in the
involvement of the immune system in psychiatric disorders (Capuron & Miller, 2011). Research
suggests that these reciprocal connections between nervous and immune systems are essential to
understand the underlying pathophysiology of depression. More so, pro-inflammatory cytokines,
such as IL-6, play a significant role in developing depression and can mediate its psychological,
behavioral, and neurobiological manifestations (Dantzer et al., 2011). The cytokine hypothesis of
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depression indicates that external psychological stressors and internal organic inflammatory
diseases or condition stressors induce inflammatory process (Maes et al., 1999; Maes et al.,
2009; Schiepers et al., 2005; Wichers & Maes, 2002). Additionally, it evident that psychological
stress might induce an inflammatory response with increased production of pro-inflammatory
cytokines (Maes et al., 1999; Maes et al., 2009; Schiepers et al., 2005; Steptoe, Hamer, & Chida,
2007; Wichers & Maes, 2002).
The conceptual model for the proposed investigation is grounded in the inflammatory
theory of depression. Convergent findings from several lines of evidence reveal a robust
association between depressive disorders and pro-inflammatory pathways, and some of this
evidence is causal (Dantzer et al., 2008; A. H. Miller et al., 2009; Oxenkrug, 2013). Proinflammatory cytokines access the brain through multiple mechanisms and initiate a cascade of
reactions that lower serotonin levels and increase glutamatergic effects (Dantzer et al., 2008).
Depression is characterized by deficient serotonergic neurotransmission and enhanced glutamate
receptor N-methyl-d-aspartate activation. Pro-inflammatory cytokines activate indoleamine 2,3dioxygenase (IDO), which degrades tryptophan, a precursor to serotonin. In a pro-inflammatory
environment, tryptophan is shunted toward production of kynurenine, via IDO, competing with
the serotonin pathway. These pro-inflammatory cytokine-induced modifications promote the
development of depressive symptoms. Within the microglia, kynurenine is metabolized to
quinolinic acid, an agonist of glutamatergic NMDA receptors. This results in a serotonergic
deficiency and glutamatergic overdrive in pro-inflammatory states that promotes the
development of depressive symptoms (Heizmann, Koeller, Muhr, Oertli, & Schinkel, 2008;
Oxenkrug, 2013)
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The Theory of Unpleasant Symptoms
The Theory of Unpleasant Symptoms (TOUS) (Lenz et al., 1995; Lenz et al., 1997) is
one of the guiding frameworks for this research. The original theory provides a model for the
experience of, and relationships between, concurrent symptoms (Lenz et al., 1995). The theory
was developed through collaboration among three researchers who initially were working with
two concepts, dyspnea and fatigue. The investigators acknowledged shared characteristics
between the dyspnea and fatigue that led to the ideas of developing an inclusive theory that
addresses multiple unpleasant symptoms across clinical populations. The original theory
included influencing factors—physiologic, psychological, and situational factors. The
investigators emphasized that symptoms vary in several components—duration, intensity,
quality, and distress. The experience of the symptoms ultimately produced an effect on a
patient’s level of performance across the three domains of functional status, cognitive
functioning, and physical performance (Lenz et al., 1995). After the development of the original
theory, the authors recognized that further refinements in the theory were necessary in order to
address the possibility of experiencing several symptoms at the same time. Furthermore, they
acknowledged the need to include the possibility for the experience of several symptoms to have
multiple effects (Lenz et al., 1995). A revision of the TOUS was published in 1997 (Lenz et al.,
1997). The revision reemphasized the three major concepts of the theory: the symptoms, the
influencing factors which affect the symptom experience, and the performance of outcomes. The
revised theory is useful in describing the possibility of interactions between the influencing
factors. Lenz et al. (1997) stated that the symptom experience might have an effect on influential
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factors and that there is a reciprocal relationship between the influencing factor and symptoms.
The TOUS has been applied in research and practice.
The TOUS has three major concepts: the symptoms, influencing factors, and performance
of outcomes. First, symptoms in the updated version are conceptualized as a multidimensional
experience, which can be conceptualized and measured separately or in combination with other
symptoms (Lenz et al., 1997). The dimensions of the symptom experience are the following: (a)
intensity which refers to strength or severity, (b) timing which refers to duration and frequency
of occurrence, (c) level of distress perceived which refers to degree of discomfort, and (d) quality
which refers to the patient’s description of what the symptom feels like. Lenz et al. (1997) stated
that the dimensions are separable but related. Using these dimensions, each symptom can be
conceptualized and measured separately or related to other symptoms. Quality is frequently the
most difficult to discern because of individuals’ varying levels of ability to describe a symptom
or their ability to pinpoint or differentiate one symptom from another (Lenz et al., 1997). The
second concept is influencing factors. Three categories are identified that influence the
symptoms: physiological, psychological, and situational factors. In the updated version of the
theory, the authors acknowledged the need to consider several interrelated aspects within each
factor, in addition to the relations between these factors and interactions that could influence the
symptom experience in return (Lenz et al., 1997). The third concept is performance of outcomes
or effects of the symptom experience. The authors conceptualized performance to include
functional and cognitive activities. Functional performance was conceptualized generally to
include physical activities, activities of daily living, social activities, and role performance such
as work-related roles (Lenz et al., 1997).
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The main difference between the original and the revised model is that the original model
represents a unidirectional influence moving from the influencing factors to the symptom
experience to the performance or consequences. The revised model is more detailed and
represents a bidirectional influence among all three of the major concepts of the model:
symptoms, influencing factors, and performance of outcomes. Additionally, the revised model
emphasizes the importance of the experience of multiple symptoms at the same time. It also
advocates that one or more symptoms may aggravate effects on performance and provide a
reciprocal influence on the influencing factors. Interaction occurs among symptoms, allowing for
the multiplicity or additive nature of the symptom experience when more than one symptom is
involved (Lenz et al., 1997).
It was emphasized by the authors that the experience of unpleasant symptoms could
change the physiological, psychological, and situational status of a person. Therefore, the major
theoretical statements of the updated version of the theory are as follows: (1) the performance of
outcomes has a reciprocal relation to the symptom experience; (2) the decreased levels of
performance can have a feedback loop of the influential factors, with a negative impact on
physiological and psychological states and situational conditions; (3) the influential factors can
display an interaction effect in their relation to the symptom experience; and (4) the symptom
experience can have a moderating or mediating influence in the relationship between
physiological or psychological status and performance (Lenz et al., 1997).
The two main assumptions, as Lenz says, are the following: (1) There are commonalities
across different symptoms experienced by persons in varied situations; and (2) symptoms are
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individual subjective phenomena occurring in family and community contexts (Lenz et al.,
1997).
The elements of the theory provide perspective for research in both the basic and the
clinical science of nursing. The Theory of Unpleasant Symptoms was examined in published
research in different populations, such as cancer patients (Chen & Tseng, 2005), pregnancy
(Milligan, Flenniken, & Pugh, 1996), childbirth (Pugh & Milligan, 1993), dyspnea in patients
with chronic obstructive pulmonary disease (Gift, 1990), and cardiac patients (Jurgens et al.,
2009). The theory has clearly demonstrated its usefulness in research to date. As the model
continues to develop, it will serve as a framework quantitative research (Motl & McAuley, 2009;
Rychnovsky, 2007; S. J. Woods, Kozachik, & Hall, 2010). The usefulness of the TOUS in
practice has been demonstrated in a variety of clinical settings and various populations (Chen &
Tseng, 2005; Gift, 1990; Gift, Jablonski, Stommel, & Given, 2004; Milligan et al., 1996; Pugh &
Milligan, 1993).
The TOUS presents a holistic, comprehensive and dynamic view of the unpleasant
symptoms experience. Managing the care for patient experiencing unpleasant symptoms is part
of the real world of nursing and what patients encounter on a day-to-day basis. This model offers
increased insight into the reality of unpleasant symptom experiences, and hopefully provides
direction to guide management strategies aimed unpleasant symptoms. There is congruence with
other theories such as symptom management theory (Dodd et al., 2001) and research internal and
external to nursing. This theory contributes to other disciplines such as psychology and can be
readily applied in clinical settings guided by other disciplines. For example, in the psychology
discipline, Hutchinson & Wilson (1998) evaluated the emergent fit of the TOUS for Alzheimer’s

39
disease (AD) patients in an effort to evaluate the usefulness of the theory with AD patients and
designing nursing interventions. The researchers reported that the theory is useful because it
emphasizes the complexity and interaction of symptoms and the interrelationships among
symptoms, influencing factors and symptom consequences/performance outcomes (Hutchinson
& Wilson, 1998). The importance of the caregiver and the social and environmental context,
which are the situational factors in the theory, were especially relevant in AD (Hutchinson &
Wilson, 1998).
Research has helped in the refinement of the original theory, and interactions among
components and their interrelationships with other components were incorporated in the revised
version of TOUS. The TOUS is an inclusive and interactive dynamic theory incorporating
multiple concepts in one encompassing model. The theory is useful as it ranges from simple to
complex depending on the number of unpleasant symptoms and variables a researcher decides to
study. Additionally, the theory seems relevant to many cultural groups and it can be applied to
many situations in different setting(Chen & Tseng, 2005; Gift, 1990; Gift et al., 2004;
Hutchinson & Wilson, 1998; Jurgens et al., 2009; Milligan et al., 1996; Motl & McAuley, 2009;
Pugh & Milligan, 1993; Rychnovsky, 2007; S. J. Woods et al., 2010).
Most importantly, the inclusion of multiple influencing factors that influence the patients’
symptom experience makes the theory valuable because nurses can uniquely design interventions
that are individualized for each patient’s characteristics and patterns of symptoms. One of the
goals of nursing care is to accomplish better outcomes and increase patients’ satisfaction. With
this theory, by individualizing the care, nurses can facilitate in accomplishing this goal. There are
social policy issues related to the theory since Nursing’s Policy Statement claims that theory
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application in nursing is an essential tool that provides nurses with the framework for their
clinical decision-making and ensures accountability by increasing transparency of their actions
(Meleis, 2011). More specifically, one of the nursing accountabilities to society is to support the
development of nursing theory and research to explain observations and guide nursing practice
(American Nurses Association, 2010). Therefore, this TOUS could be useful guide to practice
when assessing patients with unpleasant concurrent symptoms.
Finally, the TOUS has many practice implications and can be used to identify preventive
interventions or develop innovative treatments that could be applied across similar symptoms.
However, more attention needs to be paid to symptom assessment and management where recent
findings suggest potentially useful interventions. These interventions need to be addressed and
examined. For example, these interventions can include prevention interventions after a
traumatic injury aimed to prevent the symptom of stress. Another example is restorative
interventions after the experience of the symptom of stress aimed to restore rather than alleviate
stress.
The concept of symptom clusters. The concept of symptom clusters has recently
become an important concept in symptom related nursing research, especially in cancer
(Donovan & Jacobsen, 2007; B. Given, Given, Azzouz, & Stommel, 2001; B. A. Given, Given,
Sikorskii, & Hadar, 2007; C. W. Given, Given, Azzouz, Kozachik, & Stommel, 2001; Kirkova,
Aktas, Walsh, Rybicki, & Davis, 2010; Kirkova, Walsh, Aktas, & Davis, 2010). The concept of
symptom clusters was initially developed in psychology and psychiatry, and then developed to
general medicine. It has been extensively utilized in these disciplines for many years now.
However, the concept of symptom clusters is comparatively new to the nursing discipline. Even
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though concurrent symptoms are frequently reported in clinical practice symptom management
research, surprisingly, has not reflected this reality (Aktas et al., 2010; Barsevick et al., 2006;
Dodd, Miaskowski, & Lee, 2004). According to Miaskowski, Dodd & Lee (2004), symptom
clusters is the new frontier in symptom management research. Researchers suggest that specific
symptom clusters have a cooperative effect on patient outcomes and prediction of morbidity
(Aktas et al., 2010; Barsevick et al., 2006; Dodd et al., 2004). The purpose of this section is to
explore the concept of symptom cluster by review of literature in three different disciplines:
psychiatry and psychology, nursing, and general medicine.
Symptom clusters in psychology and psychiatry literature. The pathophysiology of
associated symptoms is reasonably well understood and causal relationships are established in
many known diseases. On the other hand, it is well known that it is not easy to identify etiologies
of most mental disorders. More often, an agreement on specific symptoms is recommended for a
common etiology, which is then regarded as sufficient to recognize a psychological syndrome
(Collen, 2008).
It is evident in review of psychology and psychiatry literature that symptom clusters have
long been the basis of disease diagnosis of psychological disorders. Several themes have been
addressed in the literature review with regard to the concept of symptom cluster. These themes
include empirical methods and factor analysis, the associative relationships among symptoms in
a cluster, basic aspects, common etiology of psychological disorders and symptom construction
expressed by symptom clusters, and clinical implication of the concept of symptom clusters
(Eslick, Howell, Hammer, & Talley, 2004; Fernandez-Herlihy, 1988).
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In a recent study by Hybels, Blazer, Pieper, Landerman and Steffens (2009), the
researchers explored the basic aspects of symptom presentation in older adults with major
depression by identifying homogeneous clusters of individuals based on symptom profiles. It
was a secondary data analysis using latent class cluster analysis. In another classic study by
Asmundson, Frombach, McQuaid, Pedrelli, Lenox and Stein (2000), the researchers described
symptom clusters as corresponding to basic aspects of posttraumatic stress disorder (PTSD). But
the researchers questioned whether PTSD symptom clusters derived by experts were truly
corresponding to the basic aspects of PTSD and then proceeded to verify this assumption
statistically by using factor analysis (Asmundson et al., 2000).
However, there has been controversy over the appropriate way to define symptom
clusters for PTSD. Amdur and Liberzon (2001) tested the factor structure of the Impact of Event
Scale (IES) in a sample of 195 male combat veterans with chronic PTSD by using confirmatory
factor analysis. They found that the two-factor model including Intrusion and Avoidance
deviated significantly from being a good fit. In spite of this, a four-factor model, including
Intrusion and Effortful Avoidance subscales—as well as Sleep Disturbance and Emotional
Numbing subscales—was significantly a better fit (Shevlin, Murphy, Dorahy, & Adamson, 2007;
Shevlin, Dorahy, Adamson, & Murphy, 2007). They concluded that essential behavior became
visible in the symptoms of a cluster. Conceptually, one can look at psychological disorder as a
group of symptoms that may be constructed into precise symptom clusters, which distinguish
characteristics of a specific disorder. Subsequently, these symptom clusters present the basis for
diagnosis and classification of mental disorders and syndromes.
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Shevlin, Murphy, Dorahy, and Adamson (2007) conducted a study to describe the
distribution of positive psychosis-like symptoms in the general population by means of latent
class analysis. They used latent class analysis to identify homogeneous sub-types of psychosislike experiences. The latent class analysis showed that psychosis-like symptoms at the
population level could be best explained by four groups that appeared to represent an underlying
continuum (Shevlin et al., 2007).
Shevlin, Dorahy, Adamson, & Murphy (2007) conducted another study that examined the
types of borderline personality profiles, associated psychological disorders and stressful lifeevents. They used data from the British Psychiatric Morbidity Survey to examine homogeneous
subtypes of participants based on their responses to nine borderline personality disorder criteria
(Shevlin et al., 2007).
In psychology and psychiatry, symptom cluster is described using the associative
relationships between symptoms. Amdur and Liberzon (2001) acknowledged the strong
relationship between symptoms within a cluster. Other properties of symptom clusters include
the nature or type of symptoms in a cluster and the number of symptoms in a cluster (Shevlin et
al., 2007).
The number of symptoms in a symptom cluster does not seem to be important. In a
classic study, Rusch, Guastello and Mason (1992) attempted to delineate symptom clusters that
may be considered most distinctive of patients diagnosed with borderline personality disorder
(BPD). Medical records were examined to assess the extent to which each of the eight DSM-IIIR BPD criteria was present in 89 psychiatric in-patients diagnosed with BPD. Structural analysis
revealed three symptom clusters that could explain symptomatology for a majority of the sample.
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It is also evident from the literature review that researchers are studying the etiology of
psychological disorders and they are investigating symptom construction expressed by symptom
clusters. For example, Dunn et al. (2002) determined clustering of depressive symptoms in a
combined group of unipolar and patients with bipolar disorder using Principle Components
Analysis of the Beck Depression Inventory. They also compared unipolar and bipolar. These
symptom clusters were examined for interrelationships, and for relationships to regional cerebral
metabolism for glucose measured by positron emission tomography. Different depressive
symptom clusters may have different neural substrates in unipolar, but clusters and their
substrates are convergent in bipolar (Dunn et al., 2002). These researchers have contributed
essentially to the knowledge of brain regions involved in the expression of depressive symptoms.
Symptom clusters in general medicine literature. In medicine, the concept of symptom
cluster has been used to explore symptom categorization. Siegel, Myers and Dineen (1987)
evaluated premenstrual symptoms in a group of women with severe premenstrual tension
syndrome. They performed a factor analysis to establish the nature of symptom clusters in their
selected sample. Similar to clinical observations reported earlier, their results revealed two
distinct clusters of emotional and behavioral symptoms and two of physical symptoms.
Symptom clusters would possibly help clinicians when looking at etiology of general
medical disorders. For example, Cowey and Hardy (2006) defined metabolic syndrome as
composed of cardiovascular risk factors including increased body mass index and waist
circumference, blood pressure, plasma glucose, and triglycerides, as well as decreased highdensity lipoprotein cholesterol. The researchers noted that essence of the metabolic syndrome
lies in the clustering of these risk factors which are associated with cardiovascular disease.
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Nock, Li, Larkin, Patel and Redline (2009) described Syndrome Z which involves
individual components of Syndrome X (the metabolic syndrome). They performed a factor
analysis that revealed five syndrome components that included insulin resistance, obesity,
hypertension, dyslipidemia, and sleep disturbance (Nock et al., 2009)
Other researchers suggested that symptom clusters could be used to investigate the
etiology in congestive heart failure patients (Martin & Pinkerton, 1983). They recommended that
congestive heart failure in adults should be conceptualized as a clinical syndrome. They
explained that patients with congestive heart failure exhibit clusters of symptoms that define sets
of systemic congestion, pulmonary congestion and inadequate cardiac output. Some were found
to have potentially correctable anatomic or metabolic defects, others had myocardial failure,
while some had both as underlying causes of the syndrome.
Eslick, Howell, Hammer and Talley (2004) conducted a study to determine how clusters
of patients with symptoms compare to a clinical diagnosis in patients with irritable bowel
syndrome and non-ulcer dyspepsia. They used a factor analysis and a k-means cluster analysis.
The factor analysis identified nine symptom factors. These are diarrhea, constipation,
dysmotility, dyspepsia or reflux, nausea and vomiting, bowel, meal-related pain, weight loss, and
abdominal pain. The k-means cluster analysis identified seven distinct subject groups that
included an undifferentiated group.
Symptom cluster can also be used to plan treatment. In a study by Jurgens et al. (2009),
the researchers identified the number, type, and combination of symptoms in hospitalized HF
patients. They also identified the contribution of comorbid illness and age to symptom clusters.
Three conceptually unique symptom clusters were recognized in individuals with heart failure:

46
(1)

acute volume overload cluster which includes shortness of breath, fatigue and poor sleep;

(2)

emotional cluster which includes depression, memory problems and worry; and

(3)

chronic volume overload clusters which includes swelling, increased need to rest and
dyspnea on exertion.
The knowledge of symptom clusters may improve the ability to recognize symptoms

appropriately and make symptom-monitoring more meaningful for patients (Jurgens et al., 2009).
This example demonstrates the clinical application of the concept of cluster in complicated
illnesses.
It has been shown through the literature review that factor analysis and cluster analysis
identify different symptom clusters in different diseases, such as gastrointestinal (GI) syndromes
(Eslick et al., 2004). Talley, Boyce and Jones (1998) conducted a study to determine whether
distinct symptom groupings exist in the community of Sydney residents in Penrith, Australia. In
total, 60% of the population reported four or more gastrointestinal symptoms. There was
considerable overlap of irritable bowel syndrome (IBS) with dyspepsia and among the dyspepsia
subgroups by application of the Rome criteria. Independently, 10 symptom groupings were
identified by factor analysis.
Another example is people with chronic hepatitis C infection. Quality of life has been
shown to be poor among people living with chronic hepatitis C. However, it is not clear how this
relates to the presence of symptoms and their severity. Lang et al. (2006) conducted a study to
describe the typology of a broad array of symptoms that were attributed to hepatitis C viral
(HCV) infection. Principal components analysis identified four symptom clusters of
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neuropsychiatric basis which include mental tiredness, poor concentration, forgetfulness,
depression, irritability, physical tiredness, and poor sleep.
With regard to somatic diseases, researchers found clusters in chronic fibromyalgia
patients. Recent evidence points to the likelihood of heterogeneity in the presentation and
etiology of fibromyalgia (FM). In order to gain insight regarding this condition, a clear
understanding of the symptomatology and consideration of potential FM subtypes is needed.
Rutledge, Mouttapa and Wood (2009)conducted a study to determine whether clusters could be
identified among 20 symptoms that participants in a prior online study identified and to elucidate
the underlying structure of resultant clusters. Factor analysis was used on data from a study
sponsored by the National Fibromyalgia Association. Results revealed that in this well-educated,
primarily Caucasian sample, morning stiffness, fatigue, and not feeling rested in the morning
were the symptoms with the highest severity scores.
Another example of somatic diseases is in multiple sclerosis patients. Motl and McAuley
(2009) examined the symptom cluster of fatigue, pain, and depression and its direct and indirect
prediction of physical activity behavior in a sample of individuals with multiple sclerosis (MS).
The data analysis indicated that fatigue, pain, and depression represented a symptom cluster.
Additionally, the symptom cluster had a strong and negative predictive relationship with physical
activity behavior.
Recently, symptom clusters have been used in general medicine as a statistical method to
describe the relationships between symptoms. For the purposes of this paper, statistical
associations may be essential in defining symptom clusters. On the contrary, a small number of
researchers have clearly described relationships between symptoms when they defined symptom
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clusters. Hunter, Battersby and Whitehead (2008) provided a detailed analysis of the
relationships between menopausal status and psychological and somatic symptoms. They used a
principal components analysis to examine the relationships between symptoms.
Kotagal et al. (1995) analyzed 91 psychomotor seizures from 31 patients, seizure-free at
least one year after temporal lobectomy. The researchers explored fifty symptoms in every
seizure and noted the time of onset and ending. They used statistical analysis to define symptom
clusters and to identify the order of appearance of symptoms. They found that the eighteen most
common symptoms they examined formed a tight cluster showing a high degree of correlation.
They recommended that this high correlation is essential in defining symptom clusters.
In another study, Kay et al. (1996) tried to assess the clustering of abdominal symptoms
in a random population. Data from a cohort study of a 70-year-old Danish population were
analyzed. They indicated that the defined level of significance of clusters was set at 1%. Their
results revealed that in this 70-year-old population, abdominal symptoms occur in clusters
comparable to clusters in younger populations.
There is no evidence in the literature regarding statistical opinions and patients’ real
symptom experience except for one example regarding asthma symptoms and coping. Kinsman
et al. (1973) explored characteristics of subjective symptomatology of asthma within a group of
100 asthma inpatients. Researchers suggested that complex patterning of subjective
symptomatology is common in asthma. Symptom patterns described across each of their
identified five symptom clusters may help to define coping styles related to the role of emotions
in asthma and the course of illness.
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Another evident aspect in the general medicine literature is the underlying dimension in
defining symptom clusters. In factor analysis, the relationship between each symptom and factor
is essential. Barrett et al. (2002)—in an attempt to develop a sensitive, reliable, responsive and
easy-to-use instrument for assessing the severity and functional impact of the common cold
using a factor analysis—identified four underlying symptom dimensions: cough, throat, nasal
and fever aches. In another study, Alvir & Thys-Jacobs (1991) explored the effect of calcium
therapy on peri-menstrual symptom clusters in a randomized, double blinded, crossover trial of
calcium supplementation. Using a factor analysis, they identified four symptom clusters. Internal
consistency was high for scales based on these factors which were negative affect, water
retention, food, and pain. Correlations between the scores ranged from .35 to .69. Scores were
low during the inter-menstrual phase and much higher during both luteal and menstrual phases.
They also looked at dimensions of symptoms that were affected by calcium treatment. They
found that calcium supplementation reduced negative affect, water retention, and pain during the
luteal phase and pain during the menstrual phase.
Another important aspect in defining symptom cluster is concurrence of symptoms within
a cluster as a criterion in defining symptom. However, there is little evidence in the literature to
support this essential aspect. Groppel, Kapitany and Baumgartner (2000) as well as Kotagal et al.
(1995) defined seizure-related symptom clusters in their research as symptoms that occurred
together. However, they didn’t address concurrence in relation to statistical methods; neither did
they discuss the timing of coexisting occurrence for symptoms to form a cluster.
Regarding the number of symptoms involved in a cluster, the existence of several
symptoms appears to be necessary for symptom clusters to develop. More so, there is no
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restriction in the number of symptoms that can be involved in a cluster. For example, Alvir and
Thys-Jacobs (1991) performed a factor analysis in order to investigate peri-menstrual symptoms.
They identified two symptom clusters where each cluster contained two symptoms. The first
cluster is food, which includes increased appetite and craving for sweets. The second cluster is
pain, which includes abdominal cramps and back pain.
Hammer et al. (2003) performed cluster analysis and factor analysis in order to
investigate gastrointestinal symptoms in a subsample of patients with diabetes mellitus. The
researchers identified only one cluster which included two symptoms; nausea and vomiting.
Groppel et al. (2000) performed a cluster analysis of clinical seizure of psychogenic nonepileptic seizures. They identified three clusters. Two of those clusters contained seven
symptoms while the remaining one contained only one symptom clusters. Collectively, these
results propose that there is no specific number of symptoms restricted in a cluster.
Symptom clusters in nursing literature. In nursing literature, the concept of symptom
clusters is a relatively new one. Several approaches to the concept of symptoms have been
addressed, including symptom occurrence, symptom distress, and unpleasant symptoms.
However, there is limited research and publications in literature about the use of the term
“symptom clusters” and additionally there are changeable definitions.
Some researchers borrowed this concept from general medicine, and the disciplines of
psychology and psychiatry. Others used this term to explain several symptoms appearing
together. Hall (1988) invented a very useful method of understanding and teaching about the
multiplicity of symptoms in Alzheimer’s disease (AD). Each person with AD presents many
different symptoms that change over time (Richards, 1990). Rather than compile a list of
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symptoms and losses associated with various stages, Hall (1988) identified four symptom
clusters that groups change associated with AD. These are intellectual losses, personality losses,
planning losses, and progressively lowered stress threshold. Richards (1990) noted that each
patient exhibits some symptoms from each category. Using this approach, Richards discussed
that the goal for planning care is to compensate for the losses and to help the patient function
better within their neurological capacity. Richards concluded that this approach is promising for
practice and research as it is based on existing theories of stress and coping.
Earlier works in the oncology nursing literature attempted to address concurrence of
symptoms and associative relationships among symptoms presented in oncology patients (B.
Given et al., 2001; B. A. Given et al., 2007; Lenz et al., 1997; Sarna, 1993; Sarna & Brecht,
1997).
However, although researchers in oncology nursing literature did not specifically relate
their findings to the concept of symptom cluster, their contribution have formed the foundation
for the newly promising concept of symptom clusters. Recently in the oncology nursing
literature, there is a fair amount of research that relates oncology patients’ symptoms to the
concept of symptom clusters (Armstrong, Cohen, Eriksen, & Hickey, 2004; Barsevick et al.,
2006; Cheung, Le, & Zimmermann, 2009; Donovan & Jacobsen, 2007; Fan, Hadi, & Chow,
2007; Fox & Lyon, 2007; Gift, 2007; B. A. Given et al., 2007; Kim, McGuire, Tulman, &
Barsevick, 2005; Kirkova et al., 2010; Lacasse & Beck, 2007; Liu et al., 2009; Maliski, Kwan,
Elashoff, & Litwin, 2008; Miaskowski & Aouizerat, 2007).
Following the previously addressed concept analysis, Armstrong et al. (2004) reviewed
and analyzed the literature to provide a critical analysis of the state of the science of research on
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symptom clusters in the general oncology population compared to symptom research in the
primary brain tumor population. They addressed symptoms as multidimensional experiences that
include perceptions of frequency, intensity, distress, and meaning as symptoms occur and are
expressed. They emphasized that a symptom can influence the occurrence and meaning of other
symptoms. They found that symptoms occur in clusters in general oncology patients, and these
clusters have been shown to influence functional status. The potential effect of tumor biology on
symptom clusters is shown by the cluster of symptoms theorized to be associated with proinflammatory cytokine production. Unfortunately, studies of symptom clusters have not been
reported for patients with primary brain tumors. They recommended that application of the
symptom cluster paradigm to guide research is needed.
With regard to defining the symptom cluster, Dodd et al. (2001) conducted a study to
determine the effect of the symptom cluster of pain, fatigue, and sleep insufficiency on
functional status during three cycles of chemotherapy. They defined the concept of symptom
cluster as follows: “When three or more concurrent symptoms are related to each other, they are
called a symptom cluster. The symptoms within a cluster are not required to share the same
etiology.” (Dodd et al., 2001, p. 465). They identified relationship and concurrence as the key
attributes of a symptom cluster in cancer patients. However, they did not address the associative
relationships or timing of symptoms occurring together (Dodd et al., 2001).
With regard to underlying dimensions of symptoms in defining symptom clusters, Woods
et al. (1999) identified the clusters of symptoms women experience during the premenstrual
period and assessed the reliability of the symptom clusters as reported by women with three perimenstrual symptom patterns. They also compared the levels of severity for the symptom clusters
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across menstrual cycle phases and by symptom patterns and estimated the stability of the
symptom cluster rankings across three menstrual cycle phases. Using a factor analysis, they
identified four symptom clusters representing the underlying dimensions of symptoms: turmoil,
fluid retention, somatic symptoms, and arousal symptoms. With regard to the number of
symptoms included in a cluster, it appears to be very diverse in nursing literature. Dodd et al.
(2001) addresses the number of symptoms in the oncology population as a minimum of three
symptoms in a cluster.
With regard to shared etiology between symptom clusters, Dodd et al. (2001) noted that
symptoms in a cluster are not required to share the same etiology. On the other hand, Gulick
(1989), in an attempt to validate a multiple sclerosis-related symptom checklist, made an
assumption that symptoms would cluster together according to neurological functional systems
affected by multiple sclerosis. Using a factor analysis, the author tested this hypothesis and the
results supported this hypothesis. Mitchell and Woods (1996) conducted a study to describe the
type and stability of symptoms experienced by midlife women. They recommended that within
the five different symptom clusters they identified, it is possible that the underlying etiology of
each symptom cluster may be diverse.
Link Between the Frameworks
PNI, TOUS, and Genetics
The primary aim of this research is to identify behavioral symptom clusters post-MTBI
and to determine if there are differences in functional and cognitive outcomes based on symptom
cluster. It is possible that these behavioral symptoms (depression, fatigue, and poor sleep) may
share a common inflammatory etiology, and may develop as a result of pro-inflammatory
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cytokine elevation (Kossmann et al., 1996; Shohami et al., 1994; S. H. Su et al., 2014;
Woodcock & Morganti-Kossmann, 2013) that occurs post-injury and which may persist beyond
the acute phase of injury. Inflammatory molecules from sites of injury or infection are known to
signal the brain to engender inflammatory-related sickness behaviors, such as depressed mood,
fatigue, and poor sleep (Dantzer et al., 1999; Dantzer, 2001; Dantzer & Kelley, 2007; Dantzer et
al., 2008; Dantzer, 2009; Dantzer et al., 2011; Kelley et al., 2003). This is congruent with the
PNI framework, which seeks to understand the impact of environmental stimuli, especially
psychosocial stimuli on behaviors, emotions, neuroendocrine stress responsivity, and immune
functions (Mathews & Janusek, 2011).
Furthermore, there is a compelling impetus for further exploration of genetic variants
linked to inflammatory-related behavioral symptoms in individuals who suffer MTBI.
Determining the extent to which genetic variants might contribute directly or indirectly to the
symptoms of depression, fatigue, cognitive impairment, and poor sleep in MTBI patients is
innovative, as results may provide novel biomarkers to predict more intense and persistent
symptoms as early as possible. Thus, there is strong rationale for this research, which can
improve long-term outcomes for MTBI survivors, who overcome their acute injury but who
remain at risk for chronic and disabling behavioral symptom clusters. The addition of genetics
adds another dimension to the PNI framework, since it is possible that genetic variants may
predispose to more persistent behavioral symptoms post-MTBI. Above and beyond, the
interconnectivity between the brain, emotions, behaviors, and immunity may in fact be guided
and coordinated genetically.
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Understanding these physiological (genetic) factors may lead to effective symptom
management approaches and/or tailored strategies. Furthermore, the Theory of Unpleasant
Symptoms (TOUS) (Lenz et al., 1995; Lenz et al., 1997) will guide the symptom-clustering aim,
since it illustrates the importance of inclusion and consideration of the symptom experience as
clusters. Incorporating the experience of symptom “as clusters” (adapted from TOUS) would
allow researchers to have a broader view of the symptom-related variables (e.g., genetic variants)
that contribute to the symptoms clusters, as well as the symptoms-related recovery outcomes
(e.g., cognitive and functional recovery). The theory has positively influenced researchers’
viewpoint on many issues related to symptom management, which they are accounting for in
their research (Barsevick et al., 2006; Barsevick, 2007; Dodd et al., 2001; Miaskowski,
Aouizerat, Dodd, & Cooper, 2007). Additionally, the TOUS has been compared to the symptom
management model published by Dodd et al. (2001). Although the symptom management model
is focused more on the selection of symptom management strategies than on an explanation of
the symptom experience, researchers have acknowledged the importance of this comparison.
The “Perfect Fit” of the Chosen Frameworks
Adding the TOUS framework as a third dimension to learn more about physiologic and
psychological aspects and the experience of unpleasant symptoms “as clusters”, and blending it
with the PNI and genetic framework, will contribute significantly to the nursing body of
knowledge in understanding unpleasant symptoms and guiding management strategies.
Specifically, The PNI framework will help clarify these relationships, where it is possible that
these co-occurring symptoms synergize to negatively impact cognitive and functional recovery,
in addition, to the relationship between genetic variants and persistent behavioral symptoms
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post-MTBI. This is suggestive that these relationships are correlated to the unique mind and
body connection and that the frameworks of PNI, genetics, and TOUS are all a perfect fit. The
use for these frameworks in viewing the aim of this research “3-dimensionally” and their
“perfect fit/blend” will guide the discovery and lead to remarkable advancement in the
knowledge regarding improvement of quality of life and cognitive and functional recovery postMTBI.
MTBI and Health Outcomes: Overview
MTBI: Health Outcomes MTBI and Psychological Long-term Comorbidities
Symptoms experienced. Although experiences of MTBI patients are described in
literature, there is lack of evidence to guide health care providers to identify which MTBI
patients are at greater risk for behavioral symptoms. Explication of the psychobiological
mechanisms that underlie behavioral symptom expression in trauma survivors is a critical first
step that will improve risk assessment and ultimately lead to prevention and/or better
management of trauma-associated behavioral symptoms. In the following section, previous
evidence describing behavioral symptoms experienced by MTBI after the injury will be
addressed; specifically, anxiety, depression, fatigue, and sleep disturbance. Then, evidence of
symptom cluster in MTBI patients and outcomes (cognitive impairments) will be addressed in
the following section.
MTBI and anxiety. Ample research indicates that anxiety symptoms are prevalent in the
aftermath of a mild TBI (Hiott & Labbate, 2002; Koponen et al., 2002; Ma et al., 2014; Mooney
& Speed, 2001; Moore et al., 2006; Rao & Lyketsos, 2002; Rao et al., 2010; R. Ruff, 2005; R.
M. Ruff, 2011; Stulemeijer et al., 2006; Woodcock & Morganti-Kossmann, 2013). Anxiety in
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general is reported at rates as high as 70% in patients with TBIs (Rao & Lyketsos, 2002).
Mooney & Speed (2001) classified 24% of their participants with mild TBIs as having developed
an acquired anxiety disorder. The most commonly reported anxiety symptoms after MTBI
include free-floating anxiety, fearfulness, intense worry, generalized uneasiness, social
withdrawal, inter-personal sensitivity, and anxiety dreams (Rao & Lyketsos, 2002).
Recently, Ma et al. (2014) conducted a study to determine the course of depression,
anxiety, and sleep disturbance in patients with MTBI compared to healthy participants. They
assessed patients at baseline after the injury and then at six weeks post-MTBI using the Beck
Anxiety Inventory (BAI), the Beck Depression Inventory II (BDI), and the Pittsburgh Sleep
Quality Index (PSQI). Their findings revealed that the average scores of the MTBI group were
significantly higher than those of the control group only at baseline, and average scores all had
improved and decreased significantly six weeks later.
Interestingly, only the PSQI score improved to a level that was not significantly different
from that of the control group. They concluded that MTBI causes depression and anxiety and
diminished sleep quality. However, patients recovered six weeks post-MTBI, and sleep quality
improves to a pre-MTBI level (Ma et al., 2014). The researchers identified that one of the major
limitations of this study was that some of the patients were using medications before or after
suffering MTBI that may have influenced their results; however, there was no mention of the
type of medications the study participants were using. It is a noteworthy limitation and other
researchers should account for pre- and post-injury medications. Regardless of the limitations,
these results provide valuable information for understanding the development and recovery of
long term outcomes following an MTBI. This highlights the importance of the need for more
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research in this area in combination with biomarkers to better identify which patients are at more
at risk for suffering anxiety and other symptoms, allowing early intervention.
MTBI and fatigue. Fatigue is a prominent symptom following TBI, with self-report
prevalence rates ranging from 43%–73% (Belmont et al., 2006). Fatigue can also endure as a
predominant symptom several years after the TBI (Cantor et al., 2008; Ouellet et al., 2004).
Fatigue after TBI has the potential to impact activities of daily functioning, occupational and
leisure activities, and thus quality of life (Cantor et al., 2008; Ouellet et al., 2004). It has been
emphasized that researchers need to conceptualize fatigue after TBI as a multidimensional
symptom that includes components of physical, psychological, motivational, situational, and
activity (Cantor et al., 2008; LaChapelle & Finlayson, 1998). Several factors are found to be
highly correlated with post-TBI fatigue, including sleep disturbance, perceived stress, somatic
symptoms, anxiety, and depression (Bay & Xie, 2009; Bushnik, Englander, & Wright, 2008;
Ponsford et al., 2000). For example, Bushnik et al. (2008) conducted a prospective longitudinal
study to quantify fatigue and associated factors during the first two years after TBI. Patients were
assessed at three time points (6, 12, and 18-24 months after TBI). Self-reported fatigue improved
during the first year, as did pain, sleep quality, cognitive independence, and involvement in
productive activity. However, they found that further changes up to two years after TBI were not
observed, but the subset of individuals who reported significant increases in fatigue over the first
two years demonstrated poorer outcomes in regards to cognition, motor symptoms, and general
functioning than those with decreased or stable fatigue (Bushnik et al., 2008)
Systematic and comparative studies on fatigue after MTBI are limited. However, in an
important study (Bay & Xie, 2009), researchers examined the relationships between chronic
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perceived stress, cortisol levels, and posttraumatic brain injury fatigue in outpatients. Seventyfive injured persons with TBI and their relatives/significant others participated in this crosssectional study. Data collection including interviews and self-reported data from the Neurofunctional Behavioral Inventory, the Perceived Stress Scale, the Profile of Mood States-Fatigue
subscale, the McGill Pain Scale, as well as self-collection of salivary cortisol over a 12-hour
period (N = 50). In their analysis, researchers regressed fatigue on perceived health, cognitive,
somatic, and depressive symptoms, present level of pain, cortisol levels, and perceived chronic
stress. Interestingly, they found that only perceived stress and somatic symptoms were
significantly associated with post-TBI fatigue (p = .03; p = .05, respectively). Additionally,
perceived chronic stress alone explained 37% of the variance in post-TBI fatigue. When somatic
symptoms were included in the model, perceived chronic stress accounted for 50% of the
variance in post-TBI fatigue. The Centers for Disease Control Acute Concussion guidelines has
strongly suggested fatigue and stress management interventions that are beneficial in reducing
these post-MTBI symptom (Bay & Xie, 2009; Stulemeijer et al., 2006).
Subsequently, trauma comparison groups were examined to determine whether the
persistence of fatigue was attributed to the brain injury. Stulemeijer et al. (2006) conducted the
first study to determine the severity of fatigue six months after MTBI and its association to other
outcomes. For example, these investigators tested whether injury indices, such as Glasgow Coma
Scale scores, are related to higher levels of fatigue. In their study, they recruited a total of 299
MTBI patients and 287 minor-injury patients with an ankle or wrist distortion (control group).
They reported that 32% of MTBI patients and 12% of the control patients were severely fatigued.
They found that severe fatigue was highly correlated with the experience of other symptoms,
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limitations in physical and social functioning, and fatigue-related problems like reduced activity.
Furthermore, they reported that nausea and headache experienced in the ED were significantly
related to higher levels of fatigue at six months (Stulemeijer et al., 2006). Their findings call for
further investigation since higher levels of fatigue seems to be related to acute symptoms and
mechanism of injury rather than injury severity indices.
In a longitudinal prospective study researchers examined fatigue prevalence, severity,
predictors, and covariates over six months post-MTBI. Post-MTBI fatigue was prevalent at one
week (68%), at three months (38%), and at six months (34%) (Norrie et al., 2010). Interestingly,
depression and earlier prevalence of fatigue were highly correlated with later fatigue (Norrie et
al., 2010). Although fatigue was exacerbated by depression, it was not related to increased
anxiety. Another noteworthy finding is that fatigue was categorized or labeled as “laziness” by
family or friends in 30% of cases, which could reduce care-seeking behavior. Most importantly,
their findings revealed that fatigue was a persistent post-concussion symptom that mainly
resolved in the first three months, and highly recommended that the optimum intervention
placement be at three months post-MTBI. Thus, assessing fatigue early on post-injury is valuable
and there is more need for studies regarding the prevalence and mechanism of fatigue post-TBI
(Norrie et al., 2010)
Post-TBI fatigue appears to be persistent after mild-to-moderate TBI. For example, in
those who were hospitalized and followed prospectively for symptom persistence and disability
outcome, fatigue was present in 57% and persisted in 42% of the sample at one year (van der
Naalt, van Zomeren, Sluiter, & Minderhoud, 1999). These studies highlight the importance of
addressing fatigue after MTBI to identify biomarkers that can discern which MTBI patients are
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at risk for more severe symptoms. Such identification will permit the implementation of
interventions earlier for better quality of life.
MTBI and sleep disturbance. The increased incidence of sleep disorders after TBI
relative to the general population has been increasingly recognized (Castriotta et al., 2007;
Watson et al., 2007). Sleep disturbance is a common complaint following TBI, and it is more
common with MTBI than severe or mild TBIs (Beetar et al., 1996; Clinchot et al., 1998;
Fichtenberg et al., 2000; Mahmood et al., 2004). In recent reviews, 30–70% of TBI survivors
reported sleep disturbances (Orff et al., 2009). Sleepiness may present as a separate symptom or
along with other sleep disorder (e.g., sleep apnea, narcolepsy, or post-traumatic hypersomnia,
delayed sleep phase, insomnia, fatigue, and alteration of sleep-wake schedule to movement
disorders) (Castriotta et al., 2007; Orff et al., 2009; Watson et al., 2007). However, insomnia has
been found to be more prevalent in mild TBI individuals (Ouellet et al., 2004). Most of the time
the sleep disturbances are directly related to the TBI, enduring for months and/or years after the
injury, consequently hindering the recovery process and return to pre-injury function (Orff et al.,
2009).
In the previous section the importance of fatigue subsequent to traumatic brain injury was
described. Although fatigue and poor sleep are related, the cause-effect relationship between
MTBI-related sleep disturbance and MTBI-related fatigue remain unclear. Thus, it is important
to include an assessment of sleep disturbance, along with fatigue, in this investigation of
behavioral symptoms post-MTBI. In support of this, Beaulieu-Bonneau and Morin (2012)
reported results of a prospective controlled study examining the correlation between sleepiness
and fatigue in 22 adults with moderate to severe TBI, who were evaluated between one and 11
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years post-head injury. These investigators assessed outcomes using polysomnography,
maintenance of wakefulness test, Epworth Sleepiness Scale, Functional Outcomes of Sleep
Questionnaire, Multidimensional Fatigue Inventory (MFI), Visual analogue scales (VAS), sleep
diary, Insomnia Severity Index (ISI), Beck Depression Inventory (BDI-II), and State-Trait
Anxiety Inventory (STAI-Trait). Their results revealed that the participants with TBI reported
higher subjective fatigue as a more prominent symptom than sleepiness; the TBI participants also
used compensatory strategies to reduce fatigue (e.g., napping and spending an increased amount
of time in bed). This study is limited; however, due to the heterogeneity of the degree of brain
trauma (i.e., moderate to severe) and the long time frame post-trauma of study participants
(Beaulieu-Bonneau & Morin, 2012). Although this study excluded mild TBI patients, the
findings have implications for research evaluating behavioral symptoms in this group.
Orff et al. (2009) summarized the current literature and remaining issues regarding the
significant prevalence and potential consequences of sleep disturbance following mild TBI.
Fascinatingly, the majority of research indicates that MTBI is highly correlated with increased
sleep disturbances when compared to severe TBI (Orff et al., 2009). In their review they
highlight the limitation of research in the inability to explain the reason why MTBI is more
commonly associated with sleep disturbances. They speculated that it could be attributed to the
differences in the nature of the injury, where diffuse injuries and axonal shearing (common with
MTBI) could lead to impaired global functioning and arousal, as opposed to the more acute and
focal trauma injuries (severe TBI). Another issue is differences in treatment modalities with less
severe injuries. Most of these patients are discharged at the ED, thus they may not be receiving
the adequate follow-up, which aggravates their recovery, impeding their sleep quality and quality
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of life in general (Orff et al., 2009). Further, Mahmood et al. (2004) hypothesized that severe
TBI patients maybe be unaware of their deficits and underreported sleep issues, which is most
likely the case in this population. On the other hand, MTBI patients may be inflating their sleep
disturbances issues because of the difficulties of going back to their daily routine in the face of
increased stress in the aftermath of their injuries, which although mild, could be worrisome
(Mahmood et al., 2004). It is also speculated that differences in neurobiological mechanisms
between mild and severe brain injuries may explain the greater incidence of sleep disturbance
with MTBI (Mahmood et al., 2004).
The above-mentioned studies emphasize the need for more research regarding sleep
disturbance in those who suffered an MTBI. Sleep disturbance has many implications as it
impedes the physical and cognitive recovery of TBI patients (Orff et al., 2009), hinders patients
from the vitality of regaining lost functions, hampers patients from engaging in activities of daily
living, and further reduces quality of life (Parcell, Ponsford, Rajaratnam, & Redman, 2006). In
addition, MTBI patients with sleep disturbances are more likely to suffer from concomitant
headaches, depressive symptoms, and irritability. Of note, patients with MTBI who experienced
sleep disturbance also reported feeling depressed at ten days and six weeks after their injury
(Chaput et al., 2009).
Furthering the understanding of sleep disorders after MTBI is needed which will lead to
earlier diagnosis and earlier treatments of sleep disorder to provide better care to the patients and
to understand this less communicated and recognized symptom. Future research to elucidate the
nature and extent of the relationship between MTBI and sleep disturbance is needed, especially
to uncover the specific types, causes, and severity of TBI that most often lead to sleep problems,
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as well as the specific consequences of sleep disturbance post- MTBI (e.g., impaired physical or
cognitive recovery)(Orff et al., 2009).
MTBI and depression. MTBI patients are at risk of depression (Auxemery, 2012; Bay &
Donders, 2008; Bay, 2009; Beaulieu-Bonneau & Morin, 2012; Guskiewicz et al., 2007; Kristman
et al., 2014; Levin et al., 2005; Mooney & Speed, 2001; Ponsford et al., 2011; Rapoport et al.,
2003; Rapoport et al., 2006) and depression is highly correlated with poor recovery
(Guskiewicz et al., 2007; Mooney & Speed, 2001). Prevalence of depression is 15% in the first
three months post-MTBI (Rapoport et al., 2003) and 18% up to a year after MTBI (Rao et al.,
2010). Few studies have investigated the relationship between MTBI and depression, as well as
the risk factors related with the development of depression after MTBI (Levin et al., 2005; Rao et
al., 2010). Of those studies, older age and abnormal computerized tomography (CT) scans are
reported as risk factors for developing major depression in MTBI within three months of injury
and could possibly predict the development of depression within the first three months post-TBI
(Levin et al., 2005).
These findings are similar to a longitudinal study that followed a sample of 43 MTBI
patients for one year and found that increased age and presence of frontal subdural hemorrhage
were the only two significant findings noted in the depressed group compared to the nondepressed group (Rao et al., 2010). The results of these studies are suggestive that other
biological factors could be identified as predictors in future research. Using predictive
parameters can help ED personnel identify MTBI patients, who are at higher risk before
discharge and thus appropriate referrals can be made to prevent the suffering from debilitating
symptoms.
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In conclusion, although experiences of MTBI patients are described in literature,
understanding the psychiatric morbidity following MTBI remains limited, even though these
comorbidities are prevalent. Several studies have reported short- and long-term increased rates of
comorbidities following TBI; most studies however, combined mild and moderate to severe TBI
in their analyses. Hence, it is difficult to draw conclusions regarding psychiatric outcomes
following MTBI separately. Additionally, there is lack of evidence to guide health care providers
to identify which MTBI patients are at greater risk for behavioral symptoms clusters.
MTBI: Symptom Clusters and Cognitive and Functional Outcomes
Symptom clusters in MTBI population. In this literature review, we demonstrated that
MTBI research has primarily focused on studying symptoms (single, paired, or all symptoms)
experienced three, six, and twelve months or years post-injury. As mentioned earlier, MTBI
patients can suffer from depressive mood, fatigue, and poor sleep for weeks and months after
injury (Ayalon et al., 2007; Bay & Xie, 2009; Beaulieu-Bonneau & Morin, 2012; Beetar et al.,
1996; Chaput et al., 2009; Levin et al., 2005; Norrie et al., 2010; Ponsford et al., 2000; Rapoport
et al., 2006). Prevalence of depression is 15% in the first three months post-MTBI (Rapoport et
al., 2003) and 18% up to a year after MTBI. (Rao et al., 2010) Sleep disturbance is also a
common complaint, (Beetar et al., 1996; Clinchot et al., 1998; Fichtenberg et al., 2000;
Mahmood et al., 2004) and MTBI patients with sleep disturbance are more likely to suffer
depressive symptoms (Chaput et al., 2009). Likewise, fatigue is a frequent burdensome symptom
post-TBI, and although the nature of fatigue may change with time, it can persist for years after
the initial injury (Mollayeva et al., 2014). The incidence of fatigue after TBI varies from 21%
to73%, depending on patient characteristics (e.g., severity of injury, time since injury, etc.) and
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how fatigue is measured (Belmont et al., 2006; Borgaro et al., 2005; Lidvall et al., 1974;
Middleboe et al., 1992; Ponsford et al., 2011). Although fatigue is linked to poor recovery postTBI, a recent systematic review concluded that the impact of fatigue on patient outcomes is
unclear and more intensive investigation is essential (Mollayeva et al., 2014). Depression,
fatigue, and poor sleep have been independently associated with impeded recovery from MTBI
for cognitive function (Guskiewicz et al., 2007; Mooney & Speed, 2001; Orff et al., 2009) and
the resumption of pre-injury lifestyle and responsibilities (Patterson & Holahan, 2012; Silver et
al., 2009). However, predictive power may be gained by evaluating clusters of symptoms that cooccur and which may portend slower recovery. Determining the existence of symptom clusters is
vital in MTBI patients and will lead to further crucial investigation into the mechanisms that
underlie these clusters that will advance the knowledge regarding cognitive and functional
outcomes. Although there is ample of research in the literature about symptoms experienced
post-MTBI, to date only six studies used cluster analysis to identify symptom profiles related to
recovery (Goldstein, Allen, & Caponigro, 2010; Hellstrom et al., 2013; Hoffer et al., 2016; Snell
et al., 2015; Velikonja et al., 2010).
In one study, Snell et al. (2015) conducted a prospective observational study to examine
associations between baseline demographic, clinical, psychological variables, and six-month
follow-up outcome. They analyzed the data using a two-step approach to cluster analysis, which
revealed three clusters of psychological adaptation (high, medium, and low) related to injury
outcomes (Snell et al., 2015). The identified cluster-group membership was significantly
correlated with outcomes squeal. This study supports the notion that groups could be identified
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early post-injury based on psychological factors, and that different group membership is
correlated with different recovery outcomes and sequelae.
A second study used cluster analysis to identify subgroups of MTBI patients based on a
symptom intensity profile (Hellstrom et al., 2013). Findings revealed that those with minor
symptoms had a reduced risk for a positive CT or MRI findings, whereas the high symptom level
group experienced difficulty returning to work and reported high levels of anxiety, depression,
and disability.
In a recent study, researchers (Hoffer et al., 2016) compared MTBI patients to controls to
examine the use of vestibular testing to diagnose MTBI. They identified five symptom clusters:
(1) Post-Traumatic Headache/Migraine, (2) Nausea, (3) Emotional/Affective, (4)
Fatigue/Malaise, and (5) Dizziness/Mild Cognitive Impairment. They highlighted the importance
of considering other symptoms to critically provide prognostic value and treatment for best
short-term outcomes or prevention of long-term complications (Hoffer et al., 2016).
Goldstein, Allen, and Caponigro (2010) performed two cluster analyses using
retrospective data from veterans with TBIs to explore whether subtypes emerged based on
cognitive performance on test batteries. They found cluster membership was associated with
education, age, and employment status, but not with neurological findings (e.g., lesion location)
(Goldstein et al., 2010)
In addition, Velikonja, Warriner, and Brum (2010) used the Personality Assessment
Inventory (PAI) to detect emotional and behavioral profiles in acquired brain injury (ABI)
patients (n=440). They analyzed their data by a three-step cluster analytic approach, and seven
clusters were identified: (1) multiple high symptoms with antisocial and borderline personality
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features and substance use; (2) high somatic and depressive symptoms; (3) high depression; (4)
normal/no major concerns; (5) high substance use with antisocial personality features; (6) normal
with possible minimization of concerns; and (7) multiple high symptoms with borderline
personality features but no substance use.
An interesting approach when taking the demographic information in combination would
provide descriptive insight into the nature of post-injury affective and behavioral symptoms,
which in turn could lead to establishing a more inclusive conceptualization of needs with
specifically customized treatment modalities (Velikonja et al., 2010)
Lastly, Bailie et al. (2016) explored the taxonomy of combat-related MTBI (n=1341
military personnel) based on symptom patterns within two years of evaluation. Cluster analysis
revealed four subtypes (primarily psychiatric PTSD group, a cognitive group, a mixed symptom
group, and a good recovery group. Their results are indicative of the need for unique treatment
resources and programs (Bailie et al., 2016).
However, although each of these studies supports this proposal, neither evaluated
inflammation-related behavioral symptom clusters as a potential predictor of cognitive recovery.
Thus, there is a critical need to further develop prognostic models of MTBI to identify those at
greater risk for poorer cognitive and functional recovery and who will most benefit from targeted
therapy (McMahon et al., 2014). Explication of the cluster of behavioral symptoms (i.e.,
depressive mood, fatigue, and poor sleep) posited to underlie cognitive and functional recovery
in MTBI survivors is a critical first step to improve risk assessment and to better manage postMTBI outcomes (Lingsma et al., 2014).
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Symptom clusters and outcomes. Cognitive impairment is prevalent in the acute phase
after MTBI, and these impairments include impaired verbal memory and slowed speed of
language comprehension and information processing (De Monte, Geffen, May, & McFarland,
2004), difficulties in attention, episodic memory, executive functions, working memory,
information-processing speed, language functions, and visio-spatial processing that can last for
months or even years (Kinnunen et al., 2011). MTBI patients with a decreased Glasgow Coma
Scale score in the acute phase exhibit significantly decreased and disturbed cerebral perfusion in
the frontal and occipital grey matter as seen on a normal non-contrast CT; moreover, these
observations correlated with severity of injury and cognitive impairment (Metting et al., 2009).
While these acute cognitive impairments are overwhelming, MTBI patients also have
long-term cognitive impairments related to trauma-induced neuro-degeneration. These
impairments include impairment of memory, changes in executive cognitive function affecting
the accomplishment of tasks involving complex cognition, emotional instability causing deficient
judgment and insight, impaired attention and concentration, struggles with speed of information
processing (slowed), and sensorimotor impairments (Binder, Rohling, & Larrabee, 1997;
Patterson & Holahan, 2012; Silver et al., 2009). In general, MTBI patients experience problems
with attention and concentration to accomplish one goal for a given time, they are unable to
efficiently shift attention to another goal, and/or they are unable to handle interruptions
effectively (Binder et al., 1997).
The long-term higher-level cognitive processes impairments following MTBI are more
problematic to these patients than simpler cognitive tasks, such as keeping track of daily
activities, responsibilities, and/or appointments that might not be affected as much (Silver et al.,
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2009). The incidence of these long-term cognitive impairments following MTBI lead to a
debilitating failure to resume their pre-injury lifestyle, such as returning to work, academic,
and/or social life. In addition, MTBI patients can have adverse long-term psychiatric, neurologic,
and psychosocial morbidities (Vanderploeg, Curtiss, Luis, & Salazar, 2007). For example, MTBI
patients report poor psychosocial outcomes, including an increased self-reported disability,
under-employment, low income, and marital problems (Vanderploeg et al., 2007). Usually, the
expected recovery from cognitive impairments after MTBI varies from week to months. Yet, 1020% of MTBI patients will experience persistent cognitive impairments beyond the acute phase,
which significantly disrupts their capacity to resume many pre-injury activities (Patterson &
Holahan, 2012; Silver et al., 2009)
At present, it still remains indistinguishable whether the long-term cognitive impairments
correlate with pathophysiological factors of the injury itself, or if these impairments are a result
of the influence of other psychological adverse outcomes such as fatigue, sleep, anxiety, and
depression (Bigler, 2008; Wood, 2004).
Historically, researchers attempted to theorize and explain the development of long-term
cognitive impairment post-TBI. Some suggested that psychological distress post-MTBI
influences the occurrence and maintenance of cognitive impairments experienced by MTBI
(Ryan & Warden, 2003). Yet, the research related to the influence of symptoms on cognitive and
functional outcomes in MTBI patients is limited. However, relevant to this proposal, Ramati et
al. (2009) examined the association between psychiatric morbidity and cognitive functioning in
86 electrical injury patients. They found that patients with multiple psychiatric morbidities
showed worse cognitive impairment (verbal memory, executive functioning, and attention) when
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compared to electrical injury patients with one or no post-injury psychiatric morbidities. Their
results delineate the relationship between psychological symptoms and cognitive and functional
recovery, and this worthy of investigation in the MTBI population. Others noted a relationship
between level of depression and performance on cognitive tests. The incidences of depression
were correlated with worse cognitive impairment and poor social functioning (Busch & Alpern,
1998). In particular, worse prognosis of depression was highly associated with impaired mental
flexibility and visuomotor tracking (Veiel, 1997). This is suggestive of the association between
depression and TBI, and there is a need for more research to explore whether subgroups of
patients with MTBI could be identified according to their symptom clusters to delineate those
who are at risk poor cognitive and functional outcomes.
On the other hand, it is well established that one of the causative factors linked to
cognitive impairment following MTBI is neuro-inflammation. For example, the proinflammatory
cytokine IL-1β is known to affect hippocampal-dependent memory tasks (Huang & Sheng,
2010). Increased pro-inflammatory cytokines IL-1beta, IL-6 and TNF-alpha are known to play a
role in complex cognitive processes at the molecular and cellular level, as these cytokines reduce
synaptic plasticity, affect neurogenesis and neuromodulation, and result in neurodegeneration
(McAfoose & Baune, 2009; J. A. Smith, Das, Ray, & Banik, 2012). In other words, cognitive
functions are at risk when disruption of cytokine levels exists. Most importantly, it is suggested
that cytokine dysregulation could orchestrate the long-term development and pathogenesis of
neuropsychiatric disorders such as major depression (McAfoose & Baune, 2009). When the
microglia are activated post-injury, they release pro-inflammatory cytokines (e.g., IL-1, IL-6,
and TNF-α). Acute microglial activations of these pro-inflammatory cytokines are beneficial and
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neuroprotective, but chronic microglial activation may also be toxic and lead to
neurodegeneration (J. A. Smith et al., 2012).
Recent findings suggest that microglial activation and pro-inflammatory cytokines could
be used as targets in the treatment of neuro-degeneration (J. A. Smith et al., 2012). Briones,
Woods, and Rogozinska (2013) conducted a study to determine the effects of environmental
enhancement (EE) (refers to conditions that provide increased social, cognitive, and physical
stimulation) in attenuating the long-term consequences of MTBI subsequent to neuroinflammation, alterations in brain energy metabolism, and cognitive impairment. The study was
conducted using rodents that were randomly assigned to receive either MTBI using the
controlled cortical injury model or sham surgery. The animals were then randomized again to EE
housing or standard laboratory housing. Cognitive and behavioral testing, and the levels of the
pro-inflammatory cytokines IL-1β and TNF-α and the anti-inflammatory cytokine IL-10 were
measured after 4 weeks of recovery in the brains tissue, specifically the ipsilateral region. The
results revealed that EE correlated with decreased levels of the pro-inflammatory cytokines IL1β and TNF-α and enhanced levels of the anti-inflammatory cytokine IL-10 after MTBI.
Additionally, EE alleviated MTBI-induced cognitive impairment. Thus, these findings
demonstrate the potential of EE to attenuate the persistent neuro-inflammatory state, which
occurs after MTBI.
Primarily, it is crucial to advance the knowledge symptom clusters and cognitive and
functional outcomes especially in this understudied MTBI population. Despite the evidence that
supports the association between specific symptoms and cognitive impartment, the research on
symptom clusters and their influence on cognitive and functional outcomes remains limited,
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suggesting the need for more research regarding their associations. Thus, it is imperative to
attempt to identify subgroups within the MTBI patients that may account for the differences in
experiences, symptoms, and variation in cognitive and functional recovery outcomes following
MTBI. This will address the gap in the literature and improve understanding of symptomclustering in MTBI patients and will aid in the development of rehabilitation programs that are
tailored to specific profiles.
It is hoped that the symptom cluster approach and analyzing the symptoms that are
experienced concurrently will aid in profiling MTBI patients. The evolution of innovative
cognitive and functional outcome initiatives and treatment modalities aimed to manage the
consequences of MTBI, along with evidence from behavioral psychotherapy and cognitive
remediation, could be applied to help improve cognitive function in MTBI (Tiersky et al., 2005).
This highlights the need for more studies to identify predictive tools to identify patients who are
at more risk for these persistent long-term cognitive impairments in order to intervene early on.
Again, the devastation resulting from long-term impaired cognitive functioning could correlate to
other adverse long-term outcomes. There is a need for the earlier assessment of cognitive and
functional impairments for the purposes of identifying patients at risk for long-term outcomes.
More broadly, there is a need for increasing the knowledge regarding the most prevalent
impaired cognitive functions, understanding the recovery timeframe for these patients, and early
interventions.
MTBI and Biological Mechanisms
MTBI and Genetic Variants (SNPs)
Several studies have described the possible adverse behavioral outcomes following MTBI
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(Bay & Donders, 2008; Bay & Xie, 2009; Bay, 2009). In particular, study findings reveal that
patients suffer from fatigue, sleep disturbances, and depression for weeks and months following
MTBI (Ayalon et al., 2007; Bay & Xie, 2009; Beaulieu-Bonneau & Morin, 2012; Beetar et al.,
1996; Chaput et al., 2009; Levin et al., 2005; Norrie et al., 2010; Ponsford et al., 2000; Rapoport
et al., 2006). Yet, few studies have attempted to investigate predictive factors to identify the
long-term development of symptoms following MTBI (R. M. Ruff et al., 2009). A
comprehensive review emphasized the need for research to develop predictive tools to identify
risk for poor outcomes post-MTBI (R. Ruff, 2005). Furthermore, as Lingsma et al. (2014) has
pointed out, “explication of the psychobiological mechanisms that underlie behavioral symptoms
in MTBI survivors is a critical first step to improve risk assessment, and ultimately prevent
and/or better manage post-MTBI behavioral symptoms” (Lingsma et al., 2014). The
pathogenesis of psychological long-term outcomes following MTBI is not fully understood.
Genetic variants might contribute to the development of psychological long-term
outcomes in patients with MTBI. Studies that focused on the relationship between behavioral
outcomes and genetic variants following MTBI are limited and it still remains unknown as to
whether the genetic variants could be used to predict adverse psychological outcomes postMTBI. Thus, it presents a fruitful area of research, in view of the fact that although experiences
of MTBI patients are described in literature, there is lack of evidence to guide health care
providers to identify which MTBI patients are at greater risk for behavioral symptoms.
Explication of the psychobiological mechanisms that underlie behavioral symptom expression in
MTBI survivors is a critical first step that will improve risk assessment and ultimately lead to
prevention and/or better management of trauma-associated behavioral symptoms. It is prevalent
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that the recovery from MTBI is a nonlinear process and the time-frame for complete recovery,
for some, may endure for months and years or never be achieved (R. M. Ruff, 2011). First there
is a need to develop standardized behavioral measures linked to behavioral symptoms, which
would greatly benefit MTBI patients by attending to those who are at risk for behavioral
symptoms at their early stages of treatment. Furthermore, since it is shown in many studies that
the behavioral outcomes seem to be independent of severity of injury, it is therefore useful to
examine the role of other unique factors of MTBI, such as genetic variants which may contribute
to the development or susceptibility of persistent behavioral symptoms clusters. Researchers
have suggested and highlighted the need for the development of prognostic models of MTBI that
will serve the symptomatic subgroups of MTBI patients that warrant elucidation (McMahon et
al., 2014).
Genetic variants and symptoms clusters. Genetic variants may contribute to risk for
clustering of behavioral symptoms (depressive mood, fatigue, and poor sleep) following MTBI.
Yet most studies to date have not evaluated whether genetic variants predict a more intense
and/or prolonged clustering of these behavioral symptoms. Further, genetic association analyses
suggest that certain common single nucleotide polymorphisms (SNPs) may negatively influence
recovery from MTBI (Feng et al., 2015; Lanctot et al., 2010; McAllister et al., 2005; McAllister
et al., 2008; Pap et al., 2012; Roetker et al., 2012). It is possible that certain SNPs may
predispose individuals to experience persistent behavioral symptom clusters after MTBI, further
impeding recovery. Identification of such associations will permit earlier intervention for those at
risk for behavioral symptoms clusters. McAllister et al. (2005) found that rs1800497 allele status
was associated with cognitive function post-mild-to-moderate TBI (McAllister et al., 2005;
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McAllister et al., 2008). Subsequently, others examined the influence of the (C/T) SNP
rs1800497 on post-TBI outcome using data from two multicenter studies: the Citicoline Brain
Injury Treatment trial and the TRACK-TBI Pilot. Findings showed that the ANKK1 T/T
genotype is related to poorer verbal learning performance at six months post-TBI(Yue et al.,
2015). Previous evidence also suggests that SNPs play a role in predisposing patients to
depression (Feng et al., 2015; Pap et al., 2012; Roetker et al., 2012) and also may explain
differential response to treatment (Lanctot et al., 2010). The identification of these genetic
variants may shed light on the mechanisms involved in treating non-response and lack of
tolerance to treatment in TBI patients (Lanctot et al., 2010).
Moreover, depression has been linked to inflammation and has been strongly associated
with increased inflammatory cytokines (Haroon et al., 2012; A. H. Miller et al., 2009), and there
is possibly interaction between SNPs and inflammatory cytokines (Lotrich, Albusaysi, & Ferrell,
2013). Thus, patients with Val/Met polymorphisms rs6265 are at greater risk for inflammatory
cytokine-associated depression, where Val66Met BDNF polymorphism (rs6265) and BDNF
levels have been associated with depression (Lotrich et al., 2013)—notably, the distinct genetic
variant APOE genotype (Feng et al., 2015) and polymorphism (e.g., rs6265) (Lotrich et al.,
2013), The variants rs1800479 (Roetker et al., 2012) and rs4680 (Nyman et al., 2011; Pap et al.,
2012; Vrijsen et al., 2014) may aid in predicting distinct sets of depression symptoms (Lotrich et
al., 2013), greater treatment response and tolerability (Lanctot et al., 2010), and/or occurrence of
intense adverse events (Lanctot et al., 2010) . SNPs, therefore, are viable targets for improving
resiliency against developing inflammatory cytokine-associated depression (Lotrich et al., 2013).
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Additionally, SNP rs6311 is correlated with fatigue and reveals allele-specific binding of
a transcription factor at that serotonergic system locus.(A. K. Smith et al., 2008). Meanwhile,
SNP rs6311 can affect both transcription factor-binding and promoter methylation, and this
along with stress response can influence the rate of HTR2A transcription in a genotype and
methylation-dependent manner. This highlights the importance of molecular determinants of
transcriptional regulation of major genes and the medical importance of integrating functional
genomics (Falkenberg, Gurbaxani, Unger, & Rajeevan, 2011). Since previous studies focused on
TBI in general, it is thus the purpose of this project to explore which SNPs are associated with
more intense and/or persistent behavioral symptom cluster (depressive mood, fatigue, and poor
sleep) post-MTBI, which may negatively influence recovery. Thus, there is a need to explore the
linkage of the SNPs to vulnerability for more intense and enduring depressive symptoms—
fatigue and poor sleep—common behavioral symptoms which may share a similar inflammatory
etiology in individuals following MTBI.
In conclusion, several SNPs have been proposed in earlier studies, yet there is a need for
replication or validation that the SNPs may be useful in the clinical setting. Genetic variants
underlying behavioral symptoms clusters might eventually aid in predicting prognoses and
responses to treatment. Therefore, investigation of these biomarker genetic variants (SNPs) may
provide a valuable means to predict persistent and lingering behavioral symptoms in MTBI
patients. This investigation is significant because it will fundamentally advance knowledge of
behavioral symptoms in the subgroup of MTBI patients, as well as the genetic variants and their
role in the etiology of behavioral symptom clusters post-MTBI.
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Clinical Implications and Future Directions
Clinical Implications
One of the important contributions of the symptom clusters analysis is that in addition to
profiling subgroups, it also to a certain extent reveals symptom interrelationships (Aktas et al.,
2010). This notion primarily facilitates in exploring the influence of symptoms on each other,
and aids in tailoring specific treatments accordingly. Historically, clinicians and researchers
acknowledged the multiple, concurrent symptom-experience reality and highlighted the literature
gap posited by the single-symptom focus of the majority symptom-management research, which
led to the development of the concept of symptom clusters (Barsevick et al., 2006; Dodd et al.,
2001). This conceptualization of symptom clusters is visualized as a paradigm shift in the
symptom management research, which addresses the reality of the concurrent symptoms
experiences in different populations and is supposed to lead to more promising research that will
potentially generate knowledge needed for rapid improvement in symptom management. The
shift helped bridge the gap between research and bedside nursing by addressing symptoms (as a
cluster), which is the most common reason that individuals seek healthcare (Larson et al., 1994).
Furthermore, advancing the knowledge regarding symptom interrelationships within a
cluster might overall help manage symptoms, ultimately leading to reducing symptom burden
(Aktas et al., 2010). A more recent study demonstrated that military MTBI patients with a selfreported history of an MTBI who completed multidisciplinary treatment reported a reduction in
both persistent post-concussive and PTSD symptoms (Janak et al., 2015). Thus, it is hoped that
with profiling subgroups of MTBI patients this will improve clinical practice, inform clinical

79
practice guidelines, and ultimately provide patients with the most effective and innovative
treatment modalities (Barsevick et al., 2006; Dodd et al., 2001; Kim & Abraham, 2008).
Additionally, enhanced understanding of cluster symptoms related to the development of
specific cognitive profiles of MTBI patients would allow for the development of future
rehabilitation programs that target specific cognitive deficits. Furthermore, clinicians will
identify patients at risk for poor cognitive and functional outcomes based on post-MTBI
symptoms experiences/presentations (perhaps symptom clusters), which will allow tailoring
earlier interventions to better serve this population promoting better quality of life.
Moreover, the above-mentioned paradigm shift will potentially help in identifying
underlying mechanisms such that treating the mechanism may relieve or prevent several different
symptoms. Specifically, this may lead to new discoveries at the molecular level of geneticsepigenetic and inflammation-cytokines:
Implications for Genetics and Epigenetics
Epigenetic modifications have revitalized the interest in the interaction between the
environment and the genome. Results from numerous studies demonstrate that the environment
influences epigenetic modification. However, a key feature that distinguishes epigenetic
modifications from genetic changes is their reversible nature that provides opportunities for
identification of a multitude of preventive and/or therapeutic interventions for a disease across
the lifespan. It also ascertains the fact that our genes are not our destiny (Stein, 2012). Further
knowledge and understanding regarding epigenetic modifications may help in identifying
susceptibility for certain diseases through categorization of molecular mechanisms that are
triggered in vulnerable populations. Humans are found to differ in gene expression because of
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changes in methylation caused by factors such as diet, chemicals in the environment, and
relational experiences during early development, including the quality of caregiver-infant
interactions (Hochberg et al., 2011).
The development of interventions will aid in adjusting the influence of the environment
upon the genome while reversing and/or preventing epigenetic modifications in order to improve
health and quality of life. There are several behavioral, nutritional, and pharmacological
strategies that may target adverse epigenetic marks with the potential for reducing the risk of
diseases over the human lifespan.
First of all, behavioral therapies could be exploited to alleviate stress and other adverse
environmental factors that may potentially lead to epigenetic modification. For example, exercise
can result in weight loss and help provide resistance to stress-induced chromatin remodeling
within the brain. It has been shown that rats that were exposed to greater physical activity prior
to stress exposure exhibit resistance to stress-induced chromatin remodeling within the dentate
gyrus (Bilang-Bleuel et al., 2005). These findings demonstrate that stress-related learning results
in hippocampal chromatin remodeling, which may facilitate behavioral adaptation to
environmental changes. This presents an opportunity for the exploration of other behavioral
lifestyle changes that could aid in the prevention or restoration of epigenetic modification
(Mathews and Janusek, 2011).
Recently, Yehuda et al. (2013) examined the association between methylation of the GR
and FKBP5 genes, downstream neuroendocrine measures, cortisol, and NPY, and before-andafter prolonged exposure psychotherapy in combat veterans with PTSD (n = 8). The purpose was
to determine if cytosine methylation in promoter regions of the glucocorticoid-related NR3C1

81
and FKBP51 genes would predict or correlate with treatment outcome (prolonged exposure
psychotherapy) in these patients. Blood samples were analyzed for methylation at three-time
points (pre-treatment, 12 weeks post-treatment and 3-month post-treatment follow-up). In
addition, glucocorticoid receptor (GR) activity (i.e., plasma and 24-hr. urinary cortisol, plasma
ACTH, lymphocyte lysozyme IC50-DEX, and plasma neuropeptide-Y) was assessed. Findings
revealed that the methylation of the GR gene (NR3C1) exon 1F promoter at pre-treatment
predicted treatment outcome. On the other hand, methylation of the FKBP5 gene (FKBP51) exon
1 promoter region decreased in association with treatment, but was not predictive of treatment
outcomes. These results denote that specific genes can be correlated with prognosis and
symptom state. Although these preliminary results require replication and validation, they
support research indicating that some glucocorticoid related genes are subject to environmental
regulation throughout lifespan, and also that psychotherapy treatment may alter epigenetic state
through environmental regulation. This is the first longitudinal study of an epigenetic alteration
in association with behavioral treatment outcomes. This study represents an important initial step
in establishing relevant molecular markers for PTSD therapies (Yehuda et al., 2013), and perhaps
injury-related traumatic events that results in MTBI.
It is widely known that epigenetic modification is reversible. This makes modulation of
epigenetic states a potential therapeutic option for cancer and other diseases (Corpet &
Almouzni, 2007). A number of agents that alter patterns of DNA mythelation are being tested in
clinical trials (Egger, Liang, Aparicio, & Jones, 2004) along with ongoing research for agents
that can inhibit methyltranferases directly to target other epigenetic regulators (Corpet &
Almouzni, 2007). There is a promising potential regarding the development of epigenetic
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therapies that have shown positive anti-tumorigenic effects for some malignancies. These
epigenetic therapies could include several inhibitors of enzymes controlling epigenetic
modifications through DNA methyltransferases and histone deacetylases (Egger et al., 2004).
Finally, the development of more specific agents capable of targeting discrete brain regions is
another area that needs more research (Mathews & Janusek, 2011).
Implications for Cytokine Brain-Signaling
Several symptoms (e.g., pain, sleep disruption, and fatigue) can result from the persistent
release of cytokine as a response to inflammation; thus, specific treatments aimed to block the
cytokine production would have a direct effect on symptoms relief. Furthermore, the model of
cytokine-induced depression provides valuable insights into the relationship between cytokines
and depression (Dantzer, 2009). Clinicians may explore the implications of sickness behavior
related to depression and specific disease-related symptoms. Nurses would benefit from
awareness and understanding of the relationship between pro-inflammatory cytokine and
sickness behaviors. Enhanced knowledge in this arena will aid nurses in assessing and
identifying vulnerable patients at risk for these sickness behavior symptoms. Additionally, nurses
can participate in educating patients to promote quality of life.
There are several interventions that can interrupt the cytokine brain-signaling pathway,
such as pharmacological and non-pharmacological interventions. First, for pharmacological
interventions, there is a crucial need for the discovery and the development of novel
antidepressant drugs that target the brain immune system or its secondary consequences of
activating IDO or the enzymes responsible for degradation of kynurenine. These neural circuits
process affective and reward-based information for optimal cost-benefit decision-making, a
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function that may link cytokine-evoked changes in synaptic plasticity to translatable measures of
specific behavioral impairments observed in depressed patients (Piser, 2010). For example, the
administration of insulin-like Growth Factor-I into the lateral ventricles of the brain inhibits
sickness behavior induced by a central injection of LPS (Dantzer, Gheusi, Johnson, & Kelley,
1999). Furthermore, evidence shows that central administration of IGF-I decreases depressivelike behavior and brain cytokine expression in mice (Park, Dantzer, Kelley, & McCusker, 2011).
The anti-depressant activity of IGF-I may have clinical implications for psychiatric conditions
with or without the presence of inflammatory diseases (Park et al., 2011). Park et al. (2011)
conducted a study to investigate the extent to which central IGF-I would impair the development
of depressive-like behavior by tempering the neuro-inflammatory processes within the brain.
Additionally, they examined the extent it would do so by inducing expression of the brainderived neurotropic factor while decreasing pro-inflammatory cytokine expression in the brain.
Their results revealed that the central IGF-I significantly impaired development of depressivelike behavior in LPS-challenged mice by an anti-inflammatory response in the brain, which in
turn decreases the expression of inflammatory proteins in naïve and LPS-challenged mice. In
other words, these findings showed how IGF-I down-regulates glial activation and induces
expression of an endogenous growth factor that shares anti-depressant activity. This is the first
study which evaluated IGF-I for anti-depressive actions within the brain, which forms the basis
for future studies defining the mechanism for IGF-I’s anti-depressant activity in humans (Park et
al., 2011).
Another example is the use of anti-cytokine therapies for depressed mood. In a large
double-blind placebo-controlled trial, the administration of TNF-alpha antagonist in patients with
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psoriasis showed significant improvement in depressive symptoms independent of symptoms
related to the disease etiology (Tyring et al., 2006). Furthermore, in a small double-blind
placebo-controlled trial, a COX-2 inhibitor administered to healthy patients with major
depression increased the antidepressant efficacy of the norepinephrine reuptake inhibitor (Muller
et al., 2006). These implications emphasize the importance and significance of targeting
signaling pathways of cytokines to enhance antidepressant activity. Additionally, chemokines,
such as MCP-1, which can attract monocytes to multiple tissue sites including the brain, enable
inflammatory responses (D'Mello et al., 2009). These is another class of targets that have unique
applicability to behavioral disorders associated with increased inflammation (Capuron & Miller,
2011). Finally, the cytosolic enzyme indoleamine 2, 3-dioxygenase (IDO) can be manipulated to
treat a range of chronic inflammatory diseases. There are studies of IDO inhibitors to improve T
cell activity in inflammatory states and cancer, thus indicating broad interest in the development
of pharmacologic agents that target IDO (Johnson, Baban, & Mellor, 2009). These are some
examples of the development of pharmacological interventions relevant to immuno-biology and
neurobiology, which emphasize the need for implication, and support opportunities for
collaborative effort between disciplines to advance the understanding of the mind-body
connection (Capuron & Miller, 2011)
For non-pharmacological interventions, the immuno-modulatory and anti-inflammatory
effects of specific nutritional factors help prevent or modulate neuropsychiatric symptomatology
in chronic low-grade inflammation using nutritional interventions. For example, polyunsaturated
fatty acids are essential nutrients and essential components of neuronal and glial cell membranes
(Laye, 2010). These polyunsaturated fatty acids regulate prostaglandin and pro-inflammatory
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cytokine production. For example, n-3 fatty acids are anti-inflammatory, while n-6 fatty acids are
precursors of prostaglandins. Inappropriate amounts of dietary n-6 and n-3 fatty acids can lead to
neuro-inflammation because of their abundance in the brain. However, future investigations need
to account for the two key enzymes in the metabolism of polyunsaturated fatty acids such as
phospholipase A2 (PLA2) and cyclooxygenase 2 (COX2). These enzymes have significantly
crucial roles in cytokine-induced depression. Elucidation of the genetic variations in the COX2
and PLA2 genes increase the risk of IFN-alpha-induced depression, possibly by affecting the
levels of docosahexaenoic and eicosapentaenoic acid (K. P. Su et al., 2010).
Additionally, the abovementioned vulnerability features may help in using cytokines as
markers for prediction of patients at risk for depressive symptoms, as well as a guide in the
development of interventions to prevent the occurrence of depression and improve life. For
example, since obesity is correlated with low-grade inflammation status (Perry, 2004), weight
loss intervention will benefit obese vulnerable patient accordingly. Finally, it is well established
that stress predisposes laboratory animals and humans to activate the inflammatory response (A.
H. Miller et al., 2009). Behavioral interventions focused on stress management, as well as coping
strategies that adjust sympathetic and parasympathetic tone (e.g., meditation, behavioral
cognitive therapies, and yoga), should also be implemented and considered for further research.
In conclusion, advancing the knowledge regarding the interrelationships among
symptoms and addressing their influence on cognitive and functional outcome will pose
important implications for clinical practice through development of specific innovativetherapeutic interventions.
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Future Directions and Research
The evidence described in this paper reveals the increasing knowledge regarding the
body-to-brain communication, but there is a need to increase such evidence in human paradigms
for translation to clinical practice. Furthermore, the neurobiological mechanisms underlying the
behavioral effects of pro-inflammatory cytokines have not been investigated in a manner that
correlates a given behavioral effect of a cytokine to a specific action in a well-defined area in the
brain. For this reason, micro-pharmacology experiments that target inflammatory mediators in
specific brain areas must be implemented to define the cause-effect relationships (Dantzer et al.,
2008). The identification of the intracellular association between inflammation and depression
will provide valuable targets for the development of new antidepressant drugs if the activation of
brain pro-inflammatory cytokine signaling is proven to represent the final common pathway for
the various conditions that lead to depression (Dantzer et al., 2008).
Investigation of the responses of acute circulating inflammatory markers is a fruitful area
which may provide insight into the role of psycho-neuro-immunological processes in patients.
Additionally, standardization of appropriate markers of inflammation and a systematic approach
for investigation of the risk factors will improve outcomes and quality life. Furthermore, it is
possible to develop clinical trials aimed at blocking cytokine production or action, attenuating
the production of second messengers, or deactivating glial cells which produce excessive
quantities of pro-inflammatory cytokines. More research is needed in this area to enhance its
innovative potential and avoid the duplication of efforts likely to occur because of the diversity
of pathological conditions that lead to non-specific clinical signs of sickness behavior (Dantzer
& Kelley, 2007).

87
Taken together, future studies are warranted to illuminate the precise effects of certain
cytokines and explore targets for interventions and therapies. For example, the potential targeting
of inflammatory pathways for depression treatment, such treatments can provide valuable
starting points for the identification of vulnerable subgroups of depressed patients who may be
most appropriate for immune-targeted therapies. For example, the potential targeting of
inflammatory pathways for depression treatment can provide valuable starting points for the
identification of vulnerable subgroups of depressed patients who may be most appropriate for
immune-targeted therapies. Finally, findings from warranted studies can lead to the development
of feasible effective interventions aimed at identifying patients at risk for sickness behaviors,
preventing or decreasing the negative effects of cytokine-induced inflammatory responses to
improve outcomes of quality of life.
Environmental exposures have been shown to affect the activity of the methylation
machinery, and would also lead to behavioral and mental pathologies. Future studies should
address and explore the specific mechanisms responsible for the observed epigenetic drift of MZ
twins. Such studies can provide key insights into the impact of environment-gene interaction on
behavior and vulnerability to diseases over the human lifespan. In conclusion, it is likely that
epigenetic patterns affect and/or contribute to the relationship between the environment and
human health (Mathews & Janusek, 2011). The good news is that evidence shows that epigenetic
modifications are reversible; the supportive evidence addressed earlier opens a window for a
variety of novel epigenetic-based interventions that could be implemented at periods of
biological vulnerability to prevent the harmful effects of stress and reduce incidences of diseases.

88
More specific to symptom clusters paradigm shift, in order to address gaps in the
literature, identification and comparison of symptom clusters within the MTBI population is
warranted with the consideration of profiling subgroups and identifying those who are at risk for
intense behavioral symptom clusters while accounting for influencing factors causing symptom
clusters and assessing symptom intensity overtime. It has been long emphasized that longitudinal
research regarding post-discharge cognitive impairment in MTBI patients is needed, as it is
possible that persistent intense behavioral symptoms sustain cognitive and functional outcomes
in the absence of long-term structural damage (Bernstein, 1999). These studies will help inform
the development of the most appropriate and treatment approaches for MTBI patients with
persistent intense symptoms and poor cognitive and functional outcomes. Following the aims of
the TRACK-TBI initiative, it is hoped through this current secondary analysis that we will help
in identifying if symptom clusters account for variability in cognitive and functional outcomes
post-MTBI.
The aforementioned clinical implications are suggestive of the need for more future
prospective studies of symptom management designed to identify components of specific
innovative therapeutic interventions that will be collaborative and multidisciplinary and will
specifically contribute to symptom reduction and improvement of cognitive and functional
outcomes. Then, future research will call for further investigation of the prevalence of cognitive
impairments after the reduction or elimination of symptoms.
The evidence reveals the increasing knowledge regarding genetic-to-brain
communication, but again there is a need to increase such evidence in human paradigms for
translation to clinical practice. Experienced symptoms could negatively affect patients who
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sustain injury, like MTBI. Further, preliminary evidence also suggests that specific pre-existing
genetic variants may predispose certain individuals to more persistent behavioral symptoms postinjury. Determining the extent to which genetic variants contribute to the symptomatology of
depression, fatigue, and poor sleep in MTBI patients can lead to novel biomarkers to predict
behavioral symptoms as early as possible. The identification of these genetic variants may shed
light on and aid development of viable targets in predicting distinct sets of behavioral symptoms,
and eventually help in genetic-targeted intervention tailored for greater treatment response and
tolerability, and improvement of resiliency against developing inflammatory cytokine-associated
behavioral symptoms.
Collectively, the compelling evidence provides impetus for further exploration in the
genetic and PNI paradigm. The possibility that symptom clusters might participate directly or
indirectly in the symptomatology of cognitive impairment in trauma patients is fascinating and
worth further investigation. This is especially so due to the lack of evidence about predicting
symptom clusters in MTBI patients. Investigation of genetic variants might provide valuable
information for the prediction of symptom clusters as early as possible in MTBI patients. As
such, this proposal presents promising areas in genetics, symptom clusters, PNI, and MTBI
research.

CHAPTER THREE
RESEARCH METHODOLOGY
Review of the Study Purpose, Research Questions, Aims, and Hypotheses
In summary, the long-range objective of this research is to develop novel approaches to
predict risk for behavioral symptoms in mild traumatic brain-injured (MTBI) patients at
discharge from the emergency department (ED). The outcomes of the proposed study will build a
foundation to establish clinically based strategies to identify MTBI patients at risk and to target
interventions to reduce behavioral symptoms and improve quality of life in trauma survivors and
their families. Thus, there is strong rationale for this research in its potential to improve longterm outcomes for MTBI survivors who overcome their acute injury but who remain at risk for
chronic and disabling behavioral symptom clusters.
The central hypothesis is the following: There will be differences in cognitive and
functional outcomes in patients at six months post-MTBI based on inflammation-related
behavioral symptoms (depressive symptoms, fatigue, and poor sleep), independently or as a
cluster; and there will be differences in behavioral symptoms at six months post-MTBI based on
SNP phenotype. The evaluation of inflammation-related behavioral symptom clusters post MTBI
with respect to outcomes and genetic variants is an innovative approach that can result in novel
predictive biomarkers for early risk assessment. Thus, there is strong rationale for the proposed
research, which can improve long-term outcomes for MTBI survivors who overcome their acute
injury but who remain at risk for chronic and disabling behavioral symptoms.
90

91
Specific Aims and Hypotheses
Aim 1: Identify different behavioral profiles of MTBI patients based on the intensity of
depressive mood, fatigue, and sleep quality. Hypothesis 1: There will be individual differences in
the profiles of MTBI patients based on the intensity of depressive mood, fatigue, and poor sleep.
Aim 2: Determine whether there are differences in cognitive and functional outcomes at
six months post-MTBI among the identified behavioral cluster profiles.
Hypothesis 2: There will be differences in cognitive and functional outcomes at six
months post-MTBI among the identified behavioral cluster profiles.
Aim 3: Explore differences in the intensity of behavioral symptoms at six months postMTBI based on SNP genotype.
Hypothesis 3: There will be differences in behavioral symptoms at six months post-MTBI
based on SNP genotype.
Research Design and Methods
Research Design
This investigation was a secondary data analysis of the database from the International
Traumatic Brain Injury Initiative (TRACK-TBI), which previously recruited TBI patients from
two level I trauma centers. Transforming Research and Clinical Knowledge in TBI (TRACKTBI) study (NCT01565551) is a prospective cohort study of all TBI patients presenting to one of
two level I trauma centers with in-house neurosurgical coverage(Dams-O'Connor et al., 2013;
McMahon et al., 2014; Yue et al., 2013). Institutional review board approval was obtained for
this study from the participating institutions. For the secondary data analysis, approval was
received from the Loyola University Health Science Division Institutional Review Board.
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Participants in the original TRACK-TBI study completed a battery of psychometric and
health-related instruments and provided a blood sample for genetic analysis; these data were
available to accomplish the aims of the present study. Latent cluster analysis was used to
evaluate the differences in functional and cognitive outcomes at six months post-MTBI with
respect to behavioral symptom cluster (depressive mood, fatigue, and poor sleep.
Sample and Setting
From the TRACK-TBI database, a convenience sample (n=304) of male and females (ages
>18years to 85 years) who suffered external force trauma to the head, and who had an MTBI
with classification by emergency department arrival Glasgow Coma Scale (GCS) is as follows:
mild (GCS 13–15, TRACK-pilot has 83 % mild) was selected. Only individuals who completed
the three- and six-month follow-ups were eligible.
Sample size. That primary study enrolled a total of 600 TBI patients; 340 of which
suffered MTBI and who were thus considered for potential inclusion in the current study. Six
hundred TBI patients were enrolled in the TRACK- TBI Pilot study. However, of these, 68 cases
were excluded because of Glasgow Coma Scale < 13 upon arrival to the ED; 17 cases were
excluded because of a reported LOC > 30 minute; 13 cases were excluded because of reported
PTA > 24 hours; and 76 cases were excluded because of assault as mechanism of injury and
reported injuries inflicted by other persons or resulted from domestic violence. Then 31 cases
were excluded because of serious psychiatric disorders that interfere with outcome assessment. A
sample of N=340 who suffered MTBI and who met the inclusion criteria were considered for
potential inclusion in the current study. However, 139 MTBI patients had missing data and
uncompleted biological data. Thus, the final sample for Aim1 and 2 consisted of 201 patients.
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Also, of the sample that met the inclusion criteria (n=340), 187 MTBI patients had missing data
and uncompleted biological data, and so the final sample for Aim 3 consisted of 153 patients.
Sample Characteristics
Sample. A convenience sample of male and females (ages >18 years) who suffered
external force trauma to the head, an MTBI with classification by emergency department arrival
GCS as follows: mild (GCS 13–15, TRACK-pilot has 83 % mild), and who have completed the
three- and six-month follow-ups.
Sample inclusion criteria. Concussion/MTBI patients who suffered minor injuries who
were alert, oriented, read, write and speak English. All races are included. Mechanisms of injury
to be included are the following: motor vehicle accident, motorcycle/bicycle accident, pedestrian
struck by vehicle, struck by/against object, falls, and other accidental causes of injury.
Exclusion criteria. Patients who had history of sleep apnea, cognitive impairment, and/or
serious psychiatric and neurologic disorders that interfere with outcome assessment were
excluded. Individuals who suffered assault as mechanism of injury in which other persons
inflicted the injury or if the injury resulted from domestic violence were excluded. Covariates
(age, race, education, gender, demographics, and injury/health history) were controlled
statistically.
Data Collection & Management
The Study Procedure and Recruitment
The Transforming Research and Clinical Knowledge for Traumatic Brain Injury (TRACKTBI) is a series of two large-scale prospective multicenter observational trials for improving TBI
diagnosis, and therapeutic targeting (Yue et al., 2013). The TRACK-TBI pilot phase
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(ClinicalTrials.gov Identifier: NCT01565551, 2010–13) consisted of three centers and collected
data from 600 TBI patients from April, 2010 until December, 2013 with a primary completion of
data collection on August, 2012. This secondary data analysis used only data derived from the
pilot study.
The TRACK-TBI project applies the official NIH/NINDS TBI Common Data Elements
(TBI- CDEs) and standardized collection protocols for bio-specimens (Diaz-Arrastia et al.,
2014), imaging (Yue et al., 2013; Yuh et al., 2013; Yuh et al., 2014), and neurocognitive and
neuropsychiatric outcome metrics (Dams-O'Connor et al., 2013). These processes have been
expanded upon in the current TRACK-TBI study (ClinicalTrials.gov Identifier: NCT02119182,
ongoing 2014–18) funded for 11 centers with goals of an estimated enrollment of 3000 TBIpatients from February 2014 until August 2018 (estimated study completion date).
The TRACK-TBI pilot study was conducted by UCSF/SFGH. Patients were asked to
participate in the study if they suffered a traumatic brain injury (TBI) within the preceding 24
hours and had had a CT scan completed at San Francisco General Hospital as part of their
clinical care. The main study procedures took place at SFGH and the UCSF China Basin
Imaging Center. Upon enrolment, medical information regarding the injury was obtained from
SFGH medical record and general history were obtained from the patient as well. SFGH medical
record, including your CT scan were reviewed. The study consisted of five components and the
entire study required approximately five hours over the course of six months:
(1)

Component 1 (Case Report Forms) takes approximately 30 minutes after enrollment.

(2)

Component 2 (blood draw) will take 10 – 15 minutes after enrollment.

(3)

Component 3 (MRI in one or two weeks after enrollment) takes about one hour
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(4)

Component 4 (three-month follow-up phone call) takes up to 30 minutes included
functional and neuropsychological questionnaires.

(5)

Component 5 (six-month follow-up phone call or meeting here at San Francisco General
Hospital) takes approximately 2–3 hours and included behavioral symptoms and
cognitive impairments questionnaires.
Study Variables Instrumentations with Psychometric Evidence
For this secondary data analysis, genetic variants (i.e., SNPs) and symptoms cluster of

behavioral symptoms (i.e., fatigue, depression and sleep) were the main independent variables.
The dependent variables are the functional outcomes, cognitive outcome (i.e., nonverbal
processing speed, mental, and verbal learning), and quality of life outcomes. Also, behavioral
symptoms included were the following: Post-Traumatic Stress Disease (PTSD), somatization,
depression, and anxiety. In addition, this study controlled for the following confounding
variables: history of depression and anxiety. These variables were clearly and explicitly linked to
the framework and aims of the study.
In this section, conceptual and operational definitions will be addressed for each variable
along with corresponding measurement instruments, which are utilized in quantitative research
for the purposes of quantifying phenomenon to resolve research questions and inquiries.
Researchers acknowledge that inappropriate measures can lead to inaccurate data (DeVellis,
2012). As such, evaluation of measurements is essential. Although it might be time consuming,
evaluation helps to prevent problems and errors that could result from the selection and use of
inappropriate or psychometrically inadequate measures (Waltz, Strickland, & Lenz, 2010).
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Therefore, the purpose of this section is to review the measurements used in this research. Table
1 lists study variables, and Table 2 list instruments and time points (refer to Appendix B).
Biological Measures
Serum Sample Collection and Biomarker Measurement
The blood samples for DNA genotyping analysis for TRACK-TBI Pilot patients were
collected within 24 hours of injury, processed and stored in a -80°C freezer within two hours of
collection, as previously described (Manley et al., 2010). Specimen acquisition is previously
described (Yue et al., 2013), detailed protocols for collection, processing, and shipping of blood
bio specimen, developed for the TRACK-TBI pilot are available on the NINDS TBI-CDE
website (TBI Standards–NINDS Common Data Elements, 2016). The TBI-CDE bio specimens
protocol was used effectively to collect, process, and store blood bio specimens for proteomic
and genetic analyses (Manley et al., 2010).
In brief, blood samples for DNA genotyping analysis were collected via peripheral
venipuncture or existing peripheral venous indwelling catheters within 24 h of injury. Samples
were collected in BD Vacutainer K2-EDTA vacutainer tubes, and subsequently aliquoted and
frozen in cryotubes at −80 °C within 2 h of collection in accordance with recommendations from
the NIH-CDE Biomarkers Working Group (Manley et al., 2010). DNA was extracted then the
Single nucleotide polymorphisms (SNPs) (rs1800497 (ANKK1) rs1799971 (OPRM1), rs279836
(GABRA2), rs279845 (GABRA2), rs279871 (GABRA2), and rs4680 (COMT) was genotyped
(please refer to Table 3). SNPs are variations at a single position in a DNA sequence among
individuals and patients were categorized by genotype, and each SNP was categorized into the
following six groups:
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SNP rs1800497 (ANKK1) categorized into 3 groups (A1/A1, A1/A2, and A2/A2).



SNP rs1799971 (OPRM1) categorized into 3 groups (A/A, A/G, and G/G).



SNP rs279836 (GABRA2) categorized into 3 groups (A/A, A/T, and T/T).



SNP rs279845 (GABRA2) categorized into 3 groups (A/A, A/T, and T/T).



SNP rs279871 (GABRA2) categorized into 3 groups (C/C, C/T, and T/T).



SNP rs4680 (COMT) categorized into 3 groups (Met/Met, Met/Val, and Val/Val).

Functional Outcomes
Glasgow Outcomes Scale—Extended (GOS-E). Global functional outcome and
functional dependence was assessed using the GOSE (Jennett, Snoek, Bond, & Brooks, 1981;
Shukla, Devi, & Agrawal, 2011; Wilson, Pettigrew, & Teasdale, 1998). GOSE is used with
patients 18 years and older, and includes eight questions with subparts. Research assistants
trained to uniformly assess the GOS-E administered the GOSE at three and six months postMTBI through structured phone-interview with each participant, employed to measure the
impact of the TBI on the patient’s level of functioning. The GOSE is a multi-dimensional scale
(depression, anxiety, and somatization subscales), which assesses various aspects of functional
outcome. Specifically, it measures patient’s consciousness; independence; ability to return to
work and/or previous lifestyle including social and leisure activities, social relationships, and
other sequelae of TBI (Wilson et al., 1998). A major strength of the GOSE as opposed to other
functional outcomes measures is that it includes activity or participation components that
importantly illustrate patient recovery and aids in measuring functional outcome and burden of
illness (Nichol et al., 2011) It is a revision of the original Glasgow Outcome Scale (GOS), which
was the most widely used method for classifying outcome in TBI survivors (Wilson et al., 1998).
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The GOSE is considered the ‘‘gold standard’’ for assessing patient outcomes after TBI (Shukla
et al., 2011). Another acknowledged strength of the GOSE is that it attempts to deal with the
potential confounding effects of pre-existing factors in post-TBI patients (Nichol et al., 2011).
Several limitations of the GOS led to the development of the extended version; such as the
perceived allocation bias in the higher functional end of the scale, and the ‘open ended’ and
unstructured format of the interviews (Wilson et al., 1998). These limitations speculate the
insensitivity of the GOS, which was addressed in GOSE by separating each of the three higher
function categories into two (Jennett et al., 1981). The GOSE (extended version of the GOS)
provides eight, rather than five, categories of outcome: (1) Dead, (2) Vegetative State, (3) Lower
Severe Disability, (4) Upper Severe Disability, (5) Lower Moderate Disability, (6) Upper
Moderate Disability, (7) Lower Good Recovery, and (8) Upper Good Recovery (Nichol et al.,
2011). Structured interviews are provided to facilitate ratings patient outcome and the
assignment of an ordinal score of 1 to 8. The severely disabled category is indicative of ability to
follow commands yet cannot live independently, while a moderately disabled category indicates
the ability to live independently with reduced work capacity. Lastly, a good recovery category is
indicative of ability to return to work to full functional capacity (Jennett et al., 1981). Overall,
the scores are either favorable (Lower Moderate Disability, Upper Moderate Disability, Lower
Good Recovery, Upper Good Recovery) or unfavorable (Dead, Vegetative State, Lower Severe
Disability, Upper Severe Disability) outcomes. Thus, the Upper Good Recovery (GOS-E score
of 8) indicates return to pre-injury baseline with no residual effects of the TBI. In general, a
given score of 7 or more as (good recovery) is indicative of return to full functional status at
work and in daily activity (McMahon et al., 2014).
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Distinctively, the GOSE differentiates between specific aspects of functional disabilities
within mild-to-moderate, rather than mild-to-severe TBI and it is most commonly utilized postMTBI global functional outcomes measure (Levin, O'Donnell, & Grossman, 1979) and there is
an extensive literature demonstrating its reliability and validity (Nichol et al., 2011). The GOSE
is a reliable measure with added practical usefulness advantage of the ability to be administered
through structured phone-interview, with an interrater reliability that ranges from 0.85 to 0.89
(Pettigrew, Wilson, & Teasdale, 2003; Wilson et al., 1998), specifically shows a good reliability
in patients with TBI (Wilson, Pettigrew, & Teasdale, 2000). The criterion validity of the GOSE
demonstrated that it is better and more sensitive to change than the GOS (Levin et al., 2001;
Wilson et al., 1998). The GOSE has been shown to be associated with other functional outcome
measures: initial injury severity, the Disability Rating Scale, and self-reported measures of health
outcomes (Wilson et al., 2000)
Researchers identified limitations of the functional outcome measures including the
following: insensitivity to function outcomes, limited domains of functional assessments,
insufficient operational definitions, lack of evaluation for unconscious patients, and the inability
to incorporate categories of morbidity and mortality (Nichol et al., 2011; Shukla et al., 2011).
However, the GOSE has been valued by researchers as fulfilling all criteria for a reliable and
valid outcome scale, and is regarded in combination with neuropsychological tests as a near
comprehensive and inclusive outcome post-TBI (Shukla et al., 2011).
Cognitive Outcome
California verbal learning trial–II. The California Verbal Learning Test, Second
Edition (CVLT-II) Trials 1-5 Standard Score (Delis D. C., Kramer J. H., Kaplan E., & Ober B.
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A., 2000), is a verbal learning and memory task which consists of the following: five learning
trials, an interference trial, an immediate recall trial, and a post-20 min recall trial. The CVLT-II
Trials 1–5 Standard Score (CVLT-TSS) is normed for age and sex, and provides a global index
of verbal learning ability (Delis D. C. et al., 2000). It was used in this current study as one of the
measures for cognitive impairment; specifically, verbal learning at the six-month follow-up. It
measures both recall and recognition memory (Delis et al., 2000).
The CVLT-II consists of a word list task of 16 words that are randomly presented, each
of which belongs to one of four categories, including animals, vegetables, ways of traveling, and
furniture, and the participants are asked to recall them across a series of trials. The words were
selected after careful study of their frequency of use across multiple demographic variables
(Delis D. C. et al., 2000). The participants are instructed to recall them in any order and as many
as they can. There are a series of recall trials, followed by a 20-minute delay, at which point
more recall trials are given, in addition to a yes/no recognition component. Following another
delay of 10 minutes, a forced choice recognition component of 16 items is given (Delis D. C. et
al., 2000). The CVLT-II is known for higher reported consistency on between-norm sets
(Stallings, Boake, & Sherer, 1995). The forced-choice an item is useful for detecting
malingering, thereby helping to reduce false results. In addition to recall and recognition scores,
CVLT–II measures encoding strategies, learning rates, error types, and other process data (Delis
D. C. et al., 2000).
The recent revision of the CVLT led to improved psychometric properties (Delis D. C. et
al., 2000; Stallings et al., 1995). The new items provide more comprehensive and inclusive
results. Additionally, the second edition includes new options that provide administration
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flexibility when the Standard or Alternate Forms impractical. A Short Form can be used with
limited exam time is limited, less detailed test information needed, fatigued patients, and/or
severe memory or cognitive impairments. The Short Form consists of nine words in three
categories and is administered in only 15 minutes with two delay periods of 15 minutes.
Additionally, an alternate form can be utilized when re-testing to prevents falsely inflated scores.
The Standard and Alternate Forms can be administered in 30 minutes, with an additional 30minute delay (Delis D. C. et al., 2000).
When comparing CVLT-II Trials 1-5 Free Recall results to the norms, researchers
provide normative data from large samples of 285 outpatients in a mixed neurologic sample with
low executive functioning (M=34.86, SD= 16.66), medium executive functioning (M= 43.10
SD=17.26), and high executive functioning (M= 45.02, SD=22.72) (Hill, Alosco, Bauer, &
Tremont, 2012).
Wechsler Adult Intelligence Scale IV (WAIS IV). The Wechsler Adult Intelligence
Scale Processing Speed Index (WAIS IV-PSI; consists of Digit Symbol Coding and Symbol
Search subtests) (Wechsler, 2008). WAIS-IV PSI is a test of nonverbal processing speed with
additional contribution from working memory (Kennedy, Clement, & Curtiss, 2003;
Lichtenberger & Kaufman, 2013; Wechsler, 2008) comprised of two nonverbal tasks (Digit
Symbol Coding and Symbol Search subtests of the WAIS IV) which involves both visual
attention and motor speed (Wechsler, 2008). Briefly, it measures the amount of time it takes to
process a set amount of information, or vice versa. It is considered one of the most clinically
culturally, racially, and ethnically sensitive cognitive measures to neurological conditions, and is
known for its usability across different literacy levels (Lichtenberger & Kaufman, 2013;
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Wechsler, 2008). The Wechsler Adult Intelligence Scale is known to have an extensive
normative data and excellent psychometric properties (Wechsler, 2008). Researchers
investigated the extent to which working memory, motor speed and perceptual processing speed
influence WAIS-III-PSI scores in a sample of 68 TBI outpatients of varying severity. In
hierarchical multiple regression analyses, findings confirmed that the WAIS-III PSI scores of
TBI patients reflect perceptual processing speed, with an additional component attributable to
working memory (Kennedy et al., 2003). The composite score which is used in this study refers
to a scale that ranged from 50 to 150 to resemble a certain percentile (0.1st to 99.9th percentile)
of performance across different age groups. For example, the 25 th percentile represented a score
of ∼90, the 50th percentile represented a score of 100, and the 75th percentile represented a score
of ∼110 (Wechsler, 2008). However, previous research with TBI patients revealed that it mainly
reflects cognitive impairment in perceptual processing speed with a minimal attribution to
working memory and slight contribution from motor speed (Kennedy et al., 2003). In this
secondary data analysis, the WAIS-PSI was used to measure one of the cognitive outcomes—
specifically, nonverbal processing speed at the six-month follow-up post-MTBI. When
comparing WAIS-IV Processing Speed Index Composite Score results to the norms, researchers
provide normative data for a clinical sample that scored lowest and highest on WAIS-IV
Processing Speed Index: The means that the lowest scores included autistic disorders (M=75.1),
traumatic brain injury (M=80.5), major depressive disorder (M=95.8), ADHD (M=94),
intellectually gifted (M=112.4), and probable Alzheimer’s dementia-mild (M=76.6). The highest
score included mathematics disorders (M=93.2), borderline intellectual functioning (M=80.9),
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and reading disorder (M=94.5). WAIS-IV Processing Speed Index score between the range of 90
and 109 are considered average (Wechsler, 2008).
Trail-Making Test and B (TMT). In general, The TMT measures attention, speed, and
mental flexibility (Reitan, 1958). The TMT consists of two parts, A and B, and takes about 5

minutes to be completed, as it measures the number of seconds needed for the patient to
complete the tasks (Reitan, 1958). These tests are used to measure neuro-cognitive performance,
where TMT-A assesses visual processing, and TMT-B assesses mental flexibility and processing
speed (Reitan, 1958). In this secondary data analysis, the difference score between the TMT-B
and TMT-A—TMT B-A—was used to measure one of the cognitive outcomes; specifically,
mental flexibility at the six-month follow-up. TMT B-A represents a purer index of executive
control and mental flexibility separate from visual processing and motor speed (Sanchez-Cubillo
et al., 2009). The lower the score, the higher and more improved the performance will be
concluded.
On both components A and B, patients are instructed to complete the task quickly and
accurately (Reitan & Wolfson, 2004). The TMT is known for its sensitivity to cognitive
impairment post-TBI, and it is also used extensively for its good reliability with demographically
adjusted normative data available for a wide age range (Tombaugh, 2004). Normative data for
the TMT A and B are presented for 911 community-dwelling individuals aged 18-89 years.
Researchers found that the performance on the TMT decreased with increasing age and lower
levels of education. Based on these results, the norms were stratified for both age (11 groups)
and education (2 levels). These current norms represent a more comprehensive set of norms than
previously available and will increase the ability of neuropsychologists to determine more
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precisely the degree to which scores on the TMT reflect impaired performance for varying ages
and education (Tombaugh, 2004).
For comparing TMT B-A results to the norms, with the notion that the lower score
correlates with better performance, researchers provide normative data from large samples of
patients with traumatic brain injury (TBI) (n=90; M=102.1, SD=80.1), and healthy controls as
well (n=223; M=36.4, SD=35) (Perianez et al., 2007). More specifically, the groups are the
following: the young group 16–24 (M= 24.99, SD=23), middle-aged 25–54/education 0-12
years (M= 38.46, SD=27.1), middle aged 25–54/education 13+ (M=27.69, SD= 15.52), and the
elderly group 55–88 (M=56.58, SD= 38; Perianez et al, 2007). Statistical properties of the
demographic and TMT variables for each normative group of patients with TBI were the
following: education: 0–11 years M=135.24, SD= 106.5, education: 12+ years M=81.95, SD= 58
(Perianez et al., 2007).
Behavioral Symptoms
Post-Traumatic Stress Disease (PTSD). PTSD will be measured using the PTSD
Checklist–Civilian Version (PCL-C). The PCL is a standardized self-reported rating scale for
PTSD, comprising 20 items that correspond to the key symptoms of PTSD. Two versions of the
PCL exist: (1) PCL-M is specific to PTSD caused by military experiences, and (2) PCL-C is
applied generally to any traumatic event and asks about symptoms in relation to generic
“stressful experiences” and can be used with any population. The PCL is self-administered and
patients indicate how much they have been bothered by a symptom over the past month/week
using a 5-point Likert scale, ranging from (1 Not at All – 5 Extremely) (Weathers et al., 2013).
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It was administered at the six-month follow-up, as the PCL can be easily modified to fit specific
time frames or events (Kaloupek et al., 2010).
As for the PCL-C psychometric properties, a good test-retest reliability was reported after
one week using computerized PCL-C total scores with a civilian community population with
slightly lower reliability found using mixed administration (computer vs. paper administration)
(Campbell et al., 1999). Researchers reported average PCL- C scores for the computerized
administration with only 1.5 points difference. For validity, internal consistency was reported in
14 studies investigating psychometric properties in a variety of samples (e.g., military samples,
patients with severe mental illness, patients with HIV, women with substance use disorders,
women treated for breast cancer, patients with recent limb loss, female undergraduates, and
community adults), and these studies reported total score values above .75 (Wilkins, Lang, &
Norman, 2011). The PTSD Checklist Civilian Version (PCL-C) is a widely used selfadministered screening tool for identification of patients who need further evaluation for PTSD
(Kaloupek et al., 2010).
Brief Symptoms Inventory-18 items (BSI-18). The BSI-18 is a screening tool to assess
the level of psychological distress after TBI (Meachen, Hanks, Millis, & Rapport, 2008). The
BSI-18 a short form of the Symptom Checklist-90-R and consists of three subscales
(somatization, depression, and anxiety) as well as a Global Severity Index. Each subscale
contains six questions that rate the level of distress over the past seven days using a 4-point
Likert-scale, ranging from “not at all” to “extremely often” (Meachen et al., 2008). The overall
reliability of the GSI is high, with a kappa of 0.89 and a retest reliability kappa of approximately
0.66 (Meachen et al., 2008). In tests of validity, the BSI correlates significantly with other
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validated psychosocial and functional tests in TBI patients (Meachen et al., 2008). The BSI-18 is
commonly used as a measure of psychological distress post TBI, and is known for its
comprehensive psychometric characteristics (Derogatis, 2000; Meachen et al., 2008).
Post-concussion symptoms. Post-concussion symptoms will be measured using the
Rivermead Post-Concussion Symptoms Questionnaire (RPQ) (King, Crawford, Wenden, Moss,
& Wade, 1995). The RPQ consists of 16 items and patients are asked to rate the degree of
experienced symptoms for the last 24 hours compared to symptoms prior to head injury. Items
include symptoms such as headaches, dizziness, nausea, noise sensitivity, sleep disturbance,
fatigue, irritability, depression, frustration, poor memory, poor concentration, taking longer to
think, blurred vision, light sensitivity, double vision, and restlessness. It is a 5-point Likert scale
that ranges from 0 to 4, ranging from “not experienced at all” to “ a severe problem.” The total
RPQ score is the sum of all of the 16 symptom items. Possible total scores range from 0 (no
change in symptoms since the injury) to 64 (most severe problems symptoms) (King et al.,
1995). RPQ has demonstrated validity and reliability in studies using classical test theory (King
et al., 1995). A well-established internal consistency of 0.71 was reported in MTBI patients
(Lannsjo, Borg, Bjorklund, Af Geijerstam, & Lundgren-Nilsson, 2011). The test is divided into
the RPQ-3 and the RPQ-13, with the RPQ-3 items assessing headaches, nausea and/or vomiting,
and dizziness that are considered to be early concussion symptoms (headaches, dizziness, and
nausea/vomiting) typically experienced as short term outcomes post MTBI. The RPQ-13 items
assess cognitive, mood, sleep, and other psychological symptoms (i.e., hyperacusis, sleep
disturbances, fatigue, irritability, depressed mood, frustration, forgetfulness, poor concentration,
requiring longer times to think, blurred vision, light sensitivity, double vision, and restlessness)
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(Eyres, Carey, Gilworth, Neumann, & Tennant, 2005; King et al., 1995). The separate scores for
analysis method is known for good test-retest reliability and construct validity. The RPQ-13 is
considered as a long-term outcome post-MTBI (Eyres et al., 2005; Potter, Leigh, Wade, &
Fleminger, 2006; Sveen, Bautz-Holter, Sandvik, Alvsaker, & Roe, 2010), thus used in this
secondary data analysis. It is widely known for its psychometric characteristics and capability of
detecting clinical changes in patients post MTBI.
Quality of Life Outcome:
Satisfaction With Life Scale (SWLS). The Satisfaction with Life Scale (SWLS) was
developed as a measure of the judgmental component of subjective well-being (SWB) (Diener,
Emmons, Larsen, & Griffin, 1985). The SWLS is a series of five statements that assess current
patient life satisfaction. Patients rank each question from 1 (“strongly disagree”) to 7 (“strongly
agree”) (Diener et al., 1985). The total score ranges from a maximum very high score between
30–35 indicating “highly satisfied,” high score 25–29, “slightly below average in life
satisfaction” score between 15–19, “dissatisfied’ score between 10–14, and “extremely
dissatisfied” score between 5–9 (Diener et al., 1985). In this secondary analysis, we used the
SWLS as the aqality of life outcome measure.
The average score for economically developed nations ranges between 20–24, indicating
general satisfaction, but with desire for improvement in certain aspects of life (Diener et al.,
1985). A cut-off value of 19 or below was used to indicate significant dissatisfaction. The SWLS
is considered to have good reliability and validity and is believed to be an accurate measure of
subjective wellbeing (Diener et al., 1985; Pavot, Diener, Colvin, & Sandvik, 1991). As for
reliability, initial and subsequent studies have examined the internal consistency of the SWLS
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and alpha coefficients have continually exceeded .80 (Pavot et al., 1991) also in the Diener and
colleagues examined a two-month test-retest correlation coefficients for 76 students and it was
reported at .82. Interestingly, the SWLS is known for sensitivity to differences and consistency
between different populations with expected different qualities of life, such as psychiatric
patients and male prison inmates, as well as different life directions and major life-events
changes, and in patients receiving psychotherapy (Diener et al., 1985; Pavot et al., 1991).
When comparing SWLS results to the norms, the reported mean of for TBI patients (n =
95, six months to five years after inpatient rehabilitation; mean age = 32.4 years) was 19
(SD=7.6), and time post-injury was significantly associated with higher SWLS total score
(Corrigan, Smith-Knapp, & Granger, 1998). Undergraduates at the University of Illinois who
were enrolled in psychology classes (n = 176) had a mean score of 23.5 (SD= 6.43) (Diener et
al., 1985). In a Turkish sample cross-sectional assessment of the SWLS, university students (n =
547) had a mean of 21.91 (SD= 6.18), correctional officers (n = 166) had a mean of 15.68
(SD=6.97), and elderly adults (n=123) had a mean age = 68.18 (5.10) years. In the elderly
population, 2 reported their health as “very poor,” 10 as “poor,” 51 as “average,” 46 as “well,”
and 14 as “very well,” with a mean of 23.82 (SD=7.44) (Durak, Senol-Durak, & Gencoz, 2010).
Additional Variables
Covariates. This study controlled for the following confounding variables: health
history, pre-injury functional status, and a history of behavioral symptoms (i.e., history of
depression, anxiety, and sleep disturbance).
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Data Analysis
Statistical Analysis
The independent variables to be evaluated for this study include genetic variants (i.e.,
SNPs), and symptoms cluster of behavioral symptoms (i.e., fatigue, depression and sleep).
Dependent variables will include functional outcomes (i.e., Glasgow Outcome Scale Extended
(GOSE)), cognitive out-come (i.e., nonverbal processing speed assessed by Wechsler Adult
Intelligence Scale-IV (WAIS-IV), mental flexibility assessed by the difference score between the
Trial Making Test (TMT) B and TMT A (TMT B-A). The main independent variables in this
study will be verbal learning assessed by California Verbal Learning Test-II (CVLT-II), and
quality of life outcomes assessed by the Satisfaction with Life Scale (SWLS). In addition, this
study will control for the following confounding variables through a history of behavioral
symptoms: history of depression, anxiety, and sleep disturbance. These variables are clearly and
explicitly linked to the framework and aims of the study.
Preliminary analysis will assess variable distribution, residuals for normality, linearity,
homoscedasticity, homogeneity, and multicollinearity. Data transformations to correct for nonnormal distribution will be completed as needed. Descriptive statistics will summarize the
sample’s general health histories, injury type, severity, and demographics. Analysis will be
performed using the SPSS Grad Pack Mac Version 20 (SPSS, 2011). First, the assumption of
normality and homogeneity of variances and outliers will be assessed for all outcome measures.
Normality will be assessed by examining histogram plots and z scores, while homogeneity of
variances will be assessed by Levene's test. All variables will be checked for skewness and
kurtosis. If results indicate that all outcome variables are normally distributed, no
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transformations will be necessary.
For the first aim, Latent Class Analysis (LCA) will be used to identify profiles of MTBI
patients based on the intensity of behavioral symptom, using items derived from the Rivermead
Post-Concussion Questionnaire that was administered at six-months follow-up. These assess
presence and intensity of depressive mood, fatigue, and poor sleep, and are to be completed by
participants in the TRACK-TBI study.
LCA analysis will be conducted using Mplus 7.4 (Muthén & Muthén, 1998-2011) for
running the LCA. The analysis was performed by fitting a two-class model, and gradually
increasing the number of classes one at a time for model comparison, setting a random starting
value arbitrarily from 500 to 100. Several criteria were used to guide the decision on the number
of classes in mixture modeling, including the Akaike Information Criterion (AIC), the Bayesian
Information Criterion (BIC) (Schwarz, 1978), the sample-size-adjusted aBIC, the Vuong-LoMendell-Rubin (VLMR) test (requested using TECH 11 in Mplus), and the bootstrapped
parametric likelihood ratio test (LRT; requested using TECH 14 in Mplus). Both tests compared
the model of the currently chosen number of classes (K) to a model of K−1 classes. For AIC,
BIC, and aBIC, lower observed values indicate better model fit. In case of entropy, values closer
to 1.00 suggest better fit. In addition, a nonsignificant p value for the BLMR LR test indicates
that the model with the K-1 class is preferred to the model with K classes. The final classes were
determined by small AIC, BIC, and aBIC values comparing each class (K) with each of the K-1
classes, as well as nonsignificant BLMR LR and strong entropy values.
For the second aim, analysis of variance (ANOVA) and analysis of covariance (ANCOVA)
were conducted to determine (after identifying the latent class solution that best fit the data) the
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differences among the predicted classes and outcome variables (functional, cognitive, and quality
of life) at six-months follow-up. The extent to which membership in an identified cluster predicts
functional, cognitive, and quality of life outcomes at six-months post-MTBI was explored. We
will assess the association between predicted classes and the three main outcomes: Functional
outcomes assessed by Glasgow Outcome Scale Extended (GOSE), cognitive outcome and
nonverbal processing speed assessed by Wechsler Adult Intelligence Scale-IV (WAIS-IV;
Coding Subset Total Raw Score, Symbol Search Subset), mental flexibility assessed by the
difference score between the Trial Making Test (TMT) B and TMT A (TMT B-A), verbal
learning assessed by the California Verbal Learning Test-II (CVLT-II), and quality of life
outcomes assessed by the Satisfaction with Life Scale (SWLS).
For the third exploratory aim, an Analysis of Covariance (ANCOVA) was performed to
explore the extent to which SNPs predict risk for more intense behavioural symptoms
(somatisation, anxiety, depression, PTSD, and post-concussive syndrome) at six months postMTB. We assessed the association between SNPs genotype and three main measures: (1) BSI-18
(the BSI-18 is a brief screen of psychological distress with a Global Severity Index (GSI), and
three clinical subscales: BSI-somatisation, BSI-anxiety, and BSI-depression); (2) PTSD-PCL (3
subscales; hyper-vigilance, avoidance, Re-experiencing); and (3) the Rivermead Post Concussion
Symptoms Questionnaire 13 (RPQ-13). For all follow-up posthoc tests, the Hochberg’s GT2 was
used to correct for the unequal sample size (Field, 2009).
The outcomes of this study will build a foundation upon which to establish clinically based
strategies to identify MTBI patients at risk for protracted recovery and to identify those who may
require earlier and more intense intervention.
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Ethical Considerations
Protection of Human Subjects
The TRACK-TBI pilot study is an example of Multi-Dimensional Data Sharing, where
multicenter patients’ data and protected health information (PHI) are collected under informed
consent into a central, custom-designed storehouse (QuesGen Systems, Inc., Burlingame, CA).
In order to protect the privacy of patient enrolled in the study, each patient is assigned a globally
unique identifier (Sorani et al., 2015). The permission for access ranged from ‘no-PHI’, to ‘local
PHI only’, to ‘full-access’. For the purpose of this secondary data analysis, a completed and
approved research collaboration proposal was submitted to the TRACK TBI executive
committee, which was reviewed and accepted. Then, the Data Use Agreement between the
Regents of the University of California, on behalf of its San Francisco campus (“UCSF”) and
Loyola University of Chicago was acknowledged and signed by the data user’s research team
members who will access and/or analyze data. Access to TRACK-TBI and access to clinical data
is provided to the data user for the purpose of collaboration in TBI research and will be used only
as described in research proposal agreed upon by the TRACK-TBI executive committee and is
data access was effective as of March, 18, 2016.
Additionally, an approval form from the Loyola University Medical Center (LUMC)
institutional review boards (IRB) for conducting this secondary data analysis study was obtained.
Federally sponsored studies are subject to strict guidelines for evaluation and before undertaking
any study; researchers need to submit their research plans to the IRB, and must also go through a
formal human subjects training and certification process that can be completed online (Polit &
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Beck, 2008). The duty of the IRB is to ensure that the proposed plans meet the federal
requirements for ethical research (Polit & Beck, 2008).
This is a no-benefit project; however, there are several anticipated benefits to MTBI
populations in the future. It is hoped that results from this study will help in identifying MTBI
patients who are at risk of fatigue, depression, cognitive impairment, and poor sleep at discharge
and as early as possible. Findings may stimulate the development and implementation of programs
for early interventions with these trauma patients to prevent these symptoms and to promote better
quality of life.
Study Limitations
Overall secondary data analysis has been a widespread method in promoting the
proficiency of the health research initiative; however, there are some advantages and
disadvantages of analyzing existing secondary data (Cheng & Phillips, 2014). The major
disadvantage is that the available data were not collected to address the particular research
question or to test the particular hypothesis (Cheng & Phillips, 2014). However, overall the
purpose of the analysis is to follow the TRACK-TBI initiative to improve long-term outcomes of
TBI patients in general. Therefore, though a limitation of this study, it is not uncommon that
valuable confounding variables were not available for the analysis (Cheng & Phillips, 2014).
First, the threat from confounding variables is one of the most important threats the
investigator needs to account for. The confounding variables, as described earlier, will be
controlled for.
Second, another threat to internal validity was the missing data. Third, selection bias,
since the sample was a convenient and nonrandom sample. Convenience sampling is known as
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one of the weakest sampling techniques and available subjects might be atypical of the
population of interest with regard to critical variables. Selection bias is the most problematic and
frequently occurring threat to internal validity of studies not using an experimental design (Polit
& Beck, 2008). Fourth, the threat of history refers to the occurrence of external events that take
place concurrently with the independent variable that can affect the dependent variable (Polit &
Beck, 2008). A case in point is when something happens to the patient between follow-up points
or even before enrollment that causes depression, fatigue, or poor sleep; for example, events
such as death in the family or loss of job. Preinjury stress has been hypothesized to play a role in
long-term maintenance of symptoms (van Veldhoven et al., 2011). For example, using the Life
Events Scale could have assessed major life events. In fact, there is support for this notion,
where research shows that incidence of stressful life events was a significant predictor of
anxiety, depression, and mental health in MTBI patients. Thus, the experience of stressful events
prior to the injury may predispose those with MTBI to suffer from lingering poor long-term
outcomes. Assessment of stressful life events during acute stages post-MTBI is essential (van
Veldhoven et al., 2011). Since this is a secondary data analysis, the researcher was limited and
might not be able to overcome some of the threat.
Lastly, the threat to instrumentation is a minor threat in the use of self- report
questionnaires as the measure for symptoms. There were no measures for each behavioral
symptom (i.e., anxiety, depression, fatigue, poor sleep); they were either subscales from BSIGSI (i.e., BSI-Depression, BSI-anxiety, BSI- Somatization), or for the cluster analysis, the items
that address these factors were taken from the Rivermead Post-Concussion Questionnaire that
was administered at the six-month follow-up.
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Generalizability is identified as a threat to external validity. According to Polit and Beck
(2008), generalizability is the criterion used in quantitative research to assess the extent to which
the findings can be applied to other groups and setting. The population is a sample of MTBI
patients with a range of ethnic diversity. Despite the study limitations, this study may not be
generalizable to all MTBI patients. However, it could provide information that will help MTBI
patients in the future by advancing the ability of clinicians to predict those who are at greater risk
for more intense and/or prolonged depressive symptoms, fatigue, poor sleep, cognitive
impairment, and anxiety.
Another threat to external validity is the relatively small size. The TRACK-TBI pilot
phase consisted of three centers and collected data on 599 patients (only 340 MTBI patients;
with only 201 eligible for the study due to missing data). With regard to generalizability of the
current findings, the results are not generalizable beyond the institutions where data was
collected and cannot be generalizable to all MTBI patients.
However, despite these limitations, ultimately, the knowledge acquired can be used to
develop and implement improved risk assessment protocols for behavioral symptoms and to
target prevention programs to those most vulnerable, and it can be tested in future intervention
studies accordingly.
Conclusion
Overall, secondary data analysis has been a widespread method in promoting the
proficiency of the health research initiative; however there are some advantages and
disadvantages of analyzing existing secondary data (Cheng & Phillips, 2014). The most valuable
advantage of the secondary data analysis involves the novel ideas about possible creative
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research approaches when looking at the bigger picture of the readily available collected data
rather than collecting primary data (Cheng & Phillips, 2014). This would inspire innovative
usage of collected variables—for example, the use of symptom clusters analysis as a predictive
tool for profiling subgroups enduring behavioral symptoms post-MTBI. Thus, this approach can
bridge the gap between research and bedside nursing by addressing symptoms (as a cluster),
which is the most common reason that individuals seek healthcare (Dodd et al., 2001). This
paradigm shift might help better manage symptoms, ultimately reducing symptom burden (Aktas
et al., 2010).
The second innovative aspect are the chosen frameworks (the psycho-neuro-immunology
(PNI) framework, the Theory of Unpleasant Symptoms (TOUS), and the genetics field) that
guide this investigation. These frameworks can potentially lead to remarkable advancement in
the knowledge regarding improvement of quality of life and cognitive and functional recovery
post-MTBI and will provide insight into the role of psycho-neuro-immunological processes in
MTBI patients. Overall, the innovative conceptualized framework creatively addresses the depth
of the interaction between symptoms experienced and their impact on recovery outcome, and
explains the variations seen in MTBI patients.
The availability of the Track-TBI Pilot database, which provided a real-life data with a
very un-accessible population and helped in accomplishing this secondary study, will eventually
aid in identifying new treatment modalities to improve outcome of MTBI patients that can tested
in future intervention studies (Cheng & Phillips, 2014).
This secondary data analysis represents a fortunate example of clinical research
collaboration. Van Horn and Ball (date?) write that although it will not be “a pain-free process,
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with increased data availability, scientists from multiple fields can enjoy greater opportunity for
novel discoveries about the brain in health and disease.” Sorani et al. (2015) add that “The ability
to integrate clinical, genetic, imaging, and other types of biomedical data will be of tremendous
value in ongoing efforts to discover and develop biomarkers and drugs to address unmet medical
needs.”

CHAPTER FOUR
RESULTS
This chapter describes the findings from the study in the following manner. First, the
descriptive characteristics of the sample and all study variables are summarized. Second, the
results of the study aims are delineated. As previously stated, there were three aims to this study.
The first aim was to identify different profiles of MTBI patients based on the intensity of
depressive mood, fatigue, and poor sleep. The second aim was to determine whether there are
differences in cognitive and functional outcomes at six months post-MTBI among the identified
behavioral cluster profiles. The third aim was to explore differences in the intensity of behavioral
symptoms at six months post-MTBI based on SNP genotype.
Data Analysis: Aim 1
Results Summary of Sample Characteristics/Demographic Statistics
Data for 340 MTBI patients extracted from the TRACK-TBI pilot database. Of the
340 MTBI patients, 202 patients were included in the Latent Class Analysis (LCA) due to
missing data. The sample characteristics of the 202 patients are described below and in Table 4.
The majority of the sample were males (67.3%), white (99.5%) and single (50.5%), with a mean
age of 45±18 years. Nearly half (44.6%) of the sample worked full time (35 hours or more per
week) and had either a High school diploma (34.7%) or Bachelor’s degree (25.7%). Nearly 20%
of the sample had a previous TBI (With and Without Hospital Admission). Past history of
anxiety, depression and sleep disorder was reported by 14.4%, 20.8%, and 5.9% of the sample,
118
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respectively. Use of tobacco, alcohol, and drugs was reported by 31.7%, 51.5%, and 18.8% of
the sample, respectively.
Upon arrival to the ED, the majority of patients (77.7%) had a GCS of 15 and 71%
reported LOC with varied duration (i.e., 11.4% <1 minute,35.1% 1-29 minutes, 5% 30-59
minutes, and 20.3% unknown LOC duration). While the majority (62.4%) reported no Post
Traumatic Amnesia (PTA), of those reporting PTA the duration was: 5.9% <1 minute, 23.8% 129 minutes, 6.9% 30-59 minutes, 7.9% 1-24 hours, and 17.3% unknown PTA duration. Data on
injury severity, using the Injury Severity Score (ISS), was available for 88.1% of the sample.
The ISS rates traumatic injury based on worst injury of 6 body systems, and ranges from 1 to75;
1-9 Minor, 10-15 Moderate, 16- 24 Moderate/Severe, and ISS > 25 Severe/Critical (Baker,
O'Neill, Haddon, & Long, 1974). The majority (56.9%) of the sample had ISS scores ≥ 16,
placing them in the moderate to severe range. Nearly all injuries (99.5%) were closed head
injuries; roughly half (47.5%) were motor vehicle accidents (MVA). Accidental falls accounted
for 36.6% of the injuries and 0.5% were due to explosive injury. Please refer to Table 5.
Descriptive statistics for key study outcome variables. Fatigue, sleep disturbance and
depression were assessed by the items from the Rivermead Post-Concussive Questionnaire
(RPQ). The items were measured on a Likert scale in which respondents rated items from a
minimum score of 0 (not experienced at all) to a maximum score of 4 (severe problem). Means
and standard deviations are shown in Table 1 (all variables were normally distributed), see Table
1
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Table 1. Descriptive Statistics
N

Mean

Std.
Deviation

Statistic Statistic Statistic
202
1.27
1.233
202
1.00
1.333

Skewness

Kurtosis

Std.
Statistic Error
.475
.171
.984
.171

Std.
Statistic Error
-.972
.341
-.413
.341

RPQ Fatigue
RPQ Sleep
Disturbance
RPQ Feeling
202
.75
1.050
1.162
.171
.280
.341
Depressed or
Tearful
Note: RPQ = Rivermead post-concussive symptoms questionnaire (each question ranges from 0not experienced to 4-severe problem). STD = Standard
Aim 1 Data Analysis and Results
Latent Class Analysis of Behavioral Symptoms at six-month post MTBI
Latent Class Analysis (LCA) was performed to identify profiles of MTBI patients based
on the intensity of depressive symptoms, fatigue, and poor sleep. The items that address these
factors were taken from the Rivermead Post-Concussion Questionnaire that was administered at
the six-month follow-up. Mplus 7.4 (Muthén & Muthén, 1998-2011) was used to conduct the
LCA. The analysis was performed by fitting a two-class model, and gradually increasing the
number of classes one at a time for model comparison, setting a random starting value arbitrarily
from 500 to 100. A range of random start values was used to confirm that the true minimum was
reached.
Several criteria were used to guide the decision on the number of classes in mixture
modeling, including the Akaike Information Criterion (AIC), the Bayesian Information Criterion
(BIC (Schwarz, 1978), the sample-size-adjusted aBIC, the Vuong-Lo-Mendell-Rubin (VLMR)
test (requested using TECH 11 in Mplus) and the bootstrapped parametric likelihood ratio test
(LRT; requested using TECH 14 in Mplus). Both tests compared the model of the currently
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chosen number of classes (K) to a model of K−1 classes. For AIC, BIC, and aBIC, lower
observed values indicate better model fit. In case of entropy, values closer to 1.00 suggest a
better fit. In addition, a nonsignificant p value for the BLMR LR test indicates that the model
with the K-1 class is preferred to the model with K classes. The final classes were determined by
small AIC, BIC, and aBIC values comparing each class (K) with each K-1 classes, as well as
nonsignificant BLMR LR and strong entropy values.
The four-class model suggested the best fit to the data with the lowest observed AIC, BIC
and the sample-size-adjusted BIC. Entropy value was the highest also for the four-class model.
Also, when the number of latent classes was increased from four to five classes, the p value of
the VLMR test was not statistically significant (p= .5754), indicating that the addition of a fifth
class did not significantly improve the fit of the model. However, BLMR LR remained
significant for the five-class model (see Table 2).
Research suggests that BLMR LR is in general a more accurate indicator of the classes
than the VLMR test (Nylund, Asparouhov, & Muthén, 2007). For this reason, the discrepancy
between these two indices was further investigated by examining which model has most
conceptual as well as empirical value. The examination of the three-, four-, and five-class
solutions revealed that the four-class solution had the clearest interpretation. The three-class
solution largely combined Classes 3 and 4, which masked the important distinction in the levels
of depression between these two classes, whereas the five-class solution essentially divided Class
1 into two subclasses that differed in what appeared to be substantively unimportant ways. The
decision was made to disregard the BLMR LR test and retain the four-class model as the final
model.
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The means of the three variables used to generate the latent classes are shown in Table 3.
The first column shows the overall means for the full sample, and subsequent columns show the
means for the four latent classes. Class 1 was the largest class, constituting 67.7% of the cases,
and was characterized by low endorsement of depression, fatigue, and sleep disturbance. Class 4
accounted for 15.9% and had the highest ratings of depression, fatigue, and sleep disturbance.
Class 3 (9.5%) was characterized by low depression and high fatigue, whereas Class 2 (7%) was
characterized by low fatigue and high depression; both classes had the same ratings of sleep
disturbance. The difference between latent class on demographic and injury-related
characteristics are addressed in the following section (AIM 2).
Table 2. Information Criteria and Entropy for Different Class Solutions
Model

AIC

BIC

aBIC

Entropy

VLMR

BLMR LR

2 class

1545.078

1578.210

1546.528

0.945

>.001

>.001

3 class

1518.639

1565.024

1520.669

0.943

.1534

>.001

4 class

1454.946

1514.584

1446.556

0.951

>.03

>.001

5 class

1443.224

1516.115

1459.413

0.932

0.5754

>.001

Table 3. Means and Standard Errors of the Fatigue, Depression and Sleep Disturbance by Latent
Class Membership
Variable

Full Sample

Class 1

Class 2

Class 3

Class 4

Mean

1.27

0.165

0.431

1.953

2.538

SE

.087

0.034

0.142

Fatigue

Table 3 (cont.)

0.166

0.127
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Depression
Mean

0.75

0.184

2.569

0.605

2.536

SE

.074

0.039

0.221

0.162

0.122

Mean

1.00

0.394

1.373

1.062

1.837

SE

.094

0.065

0.318

0.202

0.238

Sleep
Disturbance

Figure 1. Mplus profile plot based on estimated means.
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Figure 1. The means of the three variables used to generate the latent classes are shown in Table
X. Class 1 was the largest class, constituting 67.7% of the cases, and was characterized by low
endorsement of depression, fatigue, and sleep disturbance. Class 4 accounted for 15.9% and had
the highest ratings of depression, fatigue, and sleep disturbance. Class 3 (9.5%) was
characterized by low depression and high fatigue, whereas Class 2 (7%) was characterized by
low fatigue and high depression; both classes had the same ratings of sleep disturbance. The
items that address these factors were taken from the Rivermead Post-Concussion Questionnaire
that was administered at six-months follow-up. (RPQ-13 questions; RPQ Fatigue: Tiring More
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Easily, RPQ Sleep Disturbance, RPQ Feeling Depressed or Tearful). It is a 5-point Likert scale
that ranges from 0 to 4, ranging from ‘‘not experienced at all’’ to ‘‘a severe problem’’.
Data Analysis: Aim 2
Sample Exclusion and Inclusion Criteria
Six hundred TBI patients were enrolled in the TRACK-TBI Pilot study (See Figure X for
enrollment diagram); however, 68 cases were excluded because of Glasgow Coma Scale < 13
upon arrival to the ED, 17 cases were excluded because of reported LOC > 30 minutes, 13 cases
were excluded because of reported PTA > 24 hours, 76 cases were excluded because their injury
was a result of assault by others or a result of domestic violence. Additionally, 31 cases were
excluded because of serious psychiatric disorders that would interfere with outcome measures.
Of the sample that met the inclusion criteria (n=340), 139 MTBI patients had missing data and
uncompleted biological data as shown in Figure 2. The final sample consisted of 201 patients
(see Figure 2).
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Figure 2: Enrollment flow diagram

Inclusion criteria were both males and females (ages >18years) who suffered external
force trauma to the head, an emergency department arrival GCS score between 13 and 15 (mild)
and who have completed the three- and six-month follow-up. Concussion/MTBI patients who
suffered minor injuries, who were alert, oriented, and who could read, write and speak English
were included. Mechanisms of injury included were motor vehicle accident, motorcycle/bicycle
accident, pedestrian struck by vehicle, struck by/against object, falls, and other accidental causes
of injury.
Sample Characteristics/Demographic Statistics
The sample characteristics by LCA class as describe in Aim 1 are presented below (see
Table 4). The demographic and health characteristics of the individuals grouped into the four
Classes were similar; however, there were some minor trending differences and other significant
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differences (i.e., employment status and GCS score). Among the trending differences were those
in social behaviors and history of behavioral symptoms (i.e., anxiety, depression, sleep
disturbance), and causes of injury.
For social behaviors, Class 4 (high symptoms) reported more alcohol consumption
(65.6%) compared to other Classes; yet, it is not clear if this was a pre-existing behavior or if it
developed in association with the post-MTBI symptoms. We attempted to conduct a chi-square
test of independence between LCA groups and social behaviors; however, all expected cell
frequencies were below five, and therefore we did not have an adequate sample size to run the
chi-square test of independence.
As for history of behavioral symptoms (i.e., anxiety, depression, sleep disturbance),
Class1 had the least reported history of behavioral symptoms—anxiety (9.5%), depression
(15.4%), and sleep disorder (3.6%). A comparison of the history of behavioral symptoms (i.e.,
anxiety, depression, poor sleep) between Class 2 and Class 3 revealed that Class 2 reported a
lower percentage of history of behavioral symptoms (i.e., anxiety (21.4%), depression (28.5%),
sleep disorder (7.1%)); whereas Class 3 reported a higher percentage of history of behavioral
symptoms prior to MTBI (i.e., anxiety (26.3%), depression (36.8%), sleep disorder (15.8%)).
These findings suggest that history of behavioral symptoms does not necessarily predict the
intensity of symptoms post-TBI. Along the same lines, another interesting finding is that only
9.4% of those in Class 4 reported some history of a sleep disorder, while a low percentage
reported history of anxiety (25%) and history of depression (31.3%). Although it is valuable to
asses for history of behavioral symptoms that could relate to susceptibility of poor long-term
outcome recovery, no such relationship was found in this sample. We attempted to conduct a chisquare test of independence between LCA groups and social behaviors; however, all expected
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cell frequencies were below five, and therefore, we did not have an adequate sample size to run
the chi-square test of independence.
With respect to the causes of injury, the majority of patients in Class 2 were involved in
accidental falls (43%), while the remainder presented with a mix of MVA, accidental fall, or
other injury. However, the present findings revealed that the symptom cluster intensity postMTBI was not associated with severity of injury, as the ISS Score was ≥ 16 for similar across
Classes (i.e., 56 % for Class 1, 43% for Class 2, 58 % for Class 3, and 65.6% for Class 4). A
chi-square test of independence was conducted, there were no statistically significant differences
between the LCA groups and causes of injury.
Lastly, the findings revealed few significant demographic differences across LCA
groups; that is, differences were observed in employment status and arrival GCS score. A chisquare test of independence was conducted between LCA groups and Employment status. All
expected cell frequencies were greater than five. There were statistically significant differences
between LCA groups and Employment status χ2(21) = 38.364, p < .012. The association was
moderately strong (Cohen, 1988), Cramer's V = .254. Additionally, a chi-square test of
independence was conducted between LCA groups and arrival GCS score. All expected cell
frequencies were greater than five. There were statistically significant differences between LCA
groups and arrival GCS χ2(6) = 14.094, p < .029. The association was small (Cohen, 1988):
Cramer's V = .188.
Overall, the findings revealed no major demographic differences across LCA groups; that
is, no differences were observed in age, gender, and marital status. An ANOVA was conducted
between LCA groups and age; however, there were no statistically significant differences. A
chi-square test of independence was conducted between LCA groups, and gender and marital
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status; however, there were no statistically significant differences. Also, the findings revealed no
major injury-related characteristics differences across LCA groups. A chi-square test of
independence was conducted between LCA groups and injury-related characteristics; however,
there were no statistically significant differences.
Descriptive Statistics of Outcome Variables
For Aim II, differences in the functional and cognitive abilities as well as the quality of
life factors were investigated as a function of the class membership that was identified in Aim 1.
The functional outcomes were assessed by the Glasgow Outcome Scale Extended (GOSE);
Cognitive outcomes were assessed by the Trial Making Test (Part B-Part A Difference and Part
B/Part A ratio), California Verbal Learning Test-II (CVLT-II; Trials 1-5 Free Recall), Wechsler
Adult Intelligence Scale-IV (WAIS-IV; Coding Subset Total Raw Score, Symbol Search
Subset). Quality of life outcomes were assessed by the Satisfaction with Life Scale (SWLS). For
means and standard deviations of main outcome variables, see Table 6. All variables were
normally distributed; see Table 6 for Skewness and Kurtosis values.
For functional outcomes, MTBI patients had a GOSE mean of 6.96 (SD= 1.108) for
functional level. More specifically, low symptoms (M=7.37, SD=.933) performed better than all
other groups: high depression/low fatigue symptoms group (M=6.29, SD=1.204), low
depression/high fatigue symptoms group (M=6.11, SD=.875), as well as high symptoms group
(M=6.03, SD=.897).
When comparing satisfaction with life results to the norms, overall MTBI patients
(M=22. 30, SD=7.645) reported greater level of satisfaction when compared to TBI patients
(Corrigan et al., 1998) and university students, but a lower level of satisfaction when compared
to elderly adults (Durak et al., 2010) and undergraduate students (Diener et al., 1985). More
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specifically, the low symptoms group (M=25.22, SD=6.590) reported greater level of satisfaction
when compared to TBI patients (Corrigan et al., 1998), undergraduate students (Diener et al.,
1985), university students, correctional officers and elderly adults (Durak et al., 2010). While
both high depression/low fatigue (M=18.71, SD=5.717) symptoms and low depression/high
fatigue symptoms group (M=16.89, SD=7.203) had lower level of satisfactions when compared
to all above mentioned groups they had a greater level of satisfaction than correctional officers
(Durak et al., 2010). Also, high symptoms group (M=14.81, SD=4.967) had the lowest level of
satisfaction when compared to TBI patients (Corrigan et al, 1998), undergraduate students
(Diener et al., 1985), university students and correctional officers (Durak et al, 2010).
When comparing non-verbal learning results, MTBI patients (M=102.55, SD=15.543)
performed better in WAIS-IV Processing Speed Index Composite Score when compared to all
the lowest and highest index except for the intellectually gifted (Wechsler, 2008). More
specifically, three classes—low symptoms group (M= 105.211, SD=14.773), low
depression/high fatigue symptoms group (M= 99.611, SD=14.034), and high symptoms group
(M= 97.143, SD=16.788)—performed better than all the highest and lowest score index clinical
population except for the intellectually gifted (Wechsler, 2008). Meanwhile, the high
depression/low fatigue symptoms group (M= 93.154, SD=16.201) performed better than some of
the highest and lowest except for major depressive disorder, ADHD, intellectually gifted, and
reading disorder (Wechsler, 2008).
When comparing mental flexibility results, overall TMT B-A performance was poorer in
MTBI patients (M=49.070, SD=45.40) as compared to healthy control (young group 16 to 24
and middle aged 25-54) (Perianez et al., 2007), but better than TBI patients and elderly healthy
controls (55–80 years old) (Perianez et al., 2007). For LCA groups, the low symptoms group
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(M=42.58, SD=35.26) and both high depression/low fatigue symptoms group (M=61.96,
SD=46.31) symptoms and low depression/high fatigue symptoms group (M=56.58, SD=36.61)
symptoms, as well as high symptoms group (M=66.54, SD=75.84) performed better than TBI
patients and elderly healthy controls but worse when compared with young and middle healthy
controls (Perianez et al., 2007).
When comparing verbal learning (CVLT-II Trials 1-5 Free Recall) results to the norms,
researchers provide normative data from large samples of 285 outpatients in a mixed neurologic
sample with low executive functioning (M=34.86, SD= 16.66), medium executive functioning
(M= 43.10 SD=17.26), and high executive functioning (M= 45.02, SD=22.72) (Hill et al., 2012).
In our sample, overall MTBI patients (M=49.08, SD=12.770) performed better in CVLT-II
Trials 1-5 Free Recall when compared to all levels of executive functioning. More specifically,
low symptoms group (M= 49.64, SD= 12.736), both high depression/low fatigue symptoms
group (M= 49.54, SD= 15.125) and low depression/high fatigue symptoms group (M= 47.83,
SD= 13.840), as well as high symptoms group (M= 47.22, SD= 11.430) had better scores when
compared to all levels executive functioning.

Table 4. Sample Characteristics for Aim 2

Male
Ethnicity
Hispanic or Latino
Non-Hispanic or Non-Latino
Race
Asian
Black
White
American Indian or Alaska Native
Native Hawaiian or Other Pacific
Islander
Other
Employment
Working full time with 35 hours or more
per week and at least minimum wage
Working 20-34 hours per week at least
minimum wage
Working less than 20 hours per week and
at least minimum wage
Special employment (sheltered workshop,
supportive employment, job coach)
Temporary or odd jobs and less
than minimum wage jobs
Not in paid workforce
Unemployed

class 1
n = 136
N
%
95
70%

class 2
n = 14
N
%
8 57%

class 3
n = 19
N
%
10
53%

class 4
n = 32
N
%
69%
22

13
123

10%
90%

1
13

7%
93%

3
16

16%
84%

10
21

31%
66%

8
5
114
0

6%
4%
84%
0%

1
0
12
0

7%
0%
85.7
0%

0
0
18
1

0%
0%
95%
5%

3
2
25
0

9%
6%
78%
0%

5

4%

0

0%

0

0%

3

2%

1

7%

0

0%

1
1

2

14%

3

16%

16

50%

2

14%

4

21%

2

6%

0

0%

2

11%

1

3%

0

0%

1

5%

0

0%

0%
21%
16%

1
5
7

3%
16%
22%

69

51%

12

9%

5

4%

0

0%

2
26
18

14%
19%
13%

0
4
4

0%
29%
29%

0
4
3

3%
3%
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Table 4 (cont.)
Education Highest Level
High school diploma
Associate degree
GED
Bachelor’s degree
Master’s degree
Doctoral degree
Marital Status
Divorced
Married or living together
Separated
Single
Widowed
Unknown

42
12
4
39
16
6

31%
9%
3%
29%
12%
4%

7
1
2
1
0
0

50%
7%
14%
7%
0%
0%

9
0
0
4
1
1

47%
0%
0%
21%
5%
5%

12
2
2
8
2
1

38%
6%
6%
25%
6%
3%

4
54
1
71
2
3

3%
40%
1%
52.2%
1%
2%

3
2
0
9
0
0

21%
14%
0%
64%
0%
0%

2
7
0
9
1
0

11%
37%
0%
47%
5%
0%

5
9
0
13
3
0

16%
28%
0%
41%
9%
0%

Note. GED = general education development
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Table 5. Sample Characteristics for Study Aim 2: Injury-Related Characteristics
class 1
class 2
n = 136
n = 14
N
%
N
%
Arrival GCS
13
2
1.5%
0
0.0%
14
21
15.7%
1
7.1%
15
111
82.8%
13
92.9%
84
61.7%
9
64.2%
LOC
LOC Duration
<1 minute
15
11.0%
2
14.3%
1-29 minutes
46
33.8%
5
36.0%
30-59 minutes,
6
4.4%
0
0.0%
Unknown
26
19.0%
3
21.0%
76
55.8%
6
43.0%
PTA
PTA Duration
<1 minute
12
8.8%
0
0.0%
1-29 minutes
30
22.0%
3
21.0%
30-59 minutes
11
8.0%
0
0.0%
1-24 hours
11
8.0%
1
7.0%
Reported injury severity
120
88.0%
11
79.0%
Poly-trauma with any two body regions,
7
5.1%
1
7.0%
Poly-trauma with Head or neck Injury
7
5.1%
1
7.0%
ISS Score ≤ 16
43
31.6%
5
36.0%
ISS Score ≥ 16.
77
56.0%
6
43.0%
Closed head injuries
135
99.3%
14
100.0%
previous TBI
24
17.6%
2
14.3%

class 3
n = 19
N
%

cclass 4
n = 32
N
%

1
4
14
13

5.2%
21.0%
74.0%
68.0%

0
13
19
23

0.0%
40.6%
59.4%
72.0%

2
7
2
3
10

0.9%
36.8%
10.5%
16.0%
53.0%

4
13
2
8
20

13.0%
41.0%
6.2%
28.0%
63.0%

0
5
1
0
17
2
2
6
11
19
3

0.0%
26.3%
5.3%
0.0%
89.0%
10.5%
10.5%
31.5%
58.0%
100.0%
15.8%

0
10
2
4
29
4
3
8
21
32
11

0.0%
31.0%
6.2%
12.5%
90.6%
13.8%
10.3%
27.6%
65.6%
100.0%
34.4%
133

Table 5 (cont.)
MVA
54
40.0%
4
28.5%
9
47.0%
14
Accidental Fall
46
34.0%
6
43.0%
9
47.0%
13
Cutting and piercing Object
1
0.7%
0
0.0%
0
0.0%
0
Firearm accident by explosive material
1
0.7%
0
0.0%
0
0.0%
0
Striking Accidents
5
3.6%
0
0.0%
0
0.0%
1
Struck accidentally by falling object
2
1.4%
0
0.0%
0
0.0%
0
Other environmental or accidental causes
0
0.0%
1
7.1%
0
0.0%
0
Other vehicle accident
10
7.3%
2
14.3%
0
0.0%
4
Motor vehicle accident but not traffic
4
2.9%
0
0.0%
0
0.0%
0
related
Unknown
14
10.2%
1
7.0%
1
5.2%
0
Note, GCS=Glasgow Coma Scale, PTA= Post Traumatic Amnesia, LOC= Loss of Consciousness, MVA= Motor vehicle
accident, ISS= Injury Severity Score.
Table 6. Descriptive for Main Study Outcome Variables
N
Range
Mean
GOSE
201
5
6.96
SWLS
199
28
22.30
TMT Part B-Part A\
181
328.5
49.070
CVLT-II Trials 1-5 Free Recall
177
63
49.08
WAIS-IV-PSI Composite Score 182
91
102.55

Std. Dev.
1.108
7.645
45.40
12.770
15.543

Skewness Std. Error Kurtosis
.172
-1.034
.341
.172
-.241
.343
.181
2.971
.359
.183
-.275
.363
.180
.179
.358

45.1%
40.6%
0.0%
0.0%
3.1%
0.0%
0.0%
12.5%
0.0%
0.0%

Std. Error
.749
-1.045
12.252
-.303
.407

Note. GOSE= Glasgow Outcome Scale Extended, WAIS-IV PSI= Wechsler Adult Intelligence Scale-IV Processing Speed Index,
TMT = Trial Making Test (TMT) CVLT-II trials 1– 5= California Verbal Learning Test-II (five learning trials, an interference trial, an
immediate recall trial, and a post-20 min recall trial); SWLS= Satisfaction with Life Scale.
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Aim 2: Data Analysis and Results
Statistical strategy. First, the assumption of normality and homogeneity of variances and
outliers was assessed for all outcome measures. Normality was assessed by examining
histogram plots and z scores. Homogeneity of variance was assessed by Levene's test. All
variables were checked for skewness and kurtosis (see Table 6). Results indicated that all
outcome variables were normally distributed and no transformations were necessary.
The second aim of this study was to determine (after identifying the latent class solution
that best fit the data) the differences among the predicted classes and outcome variables
(functional, cognitive, and quality of life) at six-months follow-up. Functional outcomes were
assessed by Glasgow Outcome Scale Extended (GOSE), cognitive outcome and nonverbal
processing speed were assessed by Wechsler Adult Intelligence Scale-IV (WAIS-IV; Coding
Subset Total Raw Score, Symbol Search Subset), mental flexibility was assessed by the
difference score between the Trial Making Test (TMT) B and TMT A (TMT B-A), verbal
learning was assessed by the California Verbal Learning Test-II (CVLT-II trials 1–5; five
learning trials, an interference trial, an immediate recall trial, and a post-20 min recall trial); and
quality of life outcomes assessed by the Satisfaction with Life Scale (SWLS). An analysis of
variance (ANOVA) and analysis of covariance (ANCOVA) were conducted to address this aim.
For all follow-up post hoc tests the Hochberg’s GT2 was used to correct for the unequal sample
size (Field, 2009).
Functional outcome and LCA groups. A one-way ANOVA was conducted to
investigate differences in the main functional outcome (Glasgow Outcome Scale Extended
(GOSE) among the four LCA Groups: low symptoms (n = 136), high depression/low fatigue (n
= 14), low depression\ high fatigue (n = 19), and high symptoms (n = 32)). Since the subgroup
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sizes were unequal, the Hochberg’s GT2 posthoc test which explicitly allows for unequal sample
sizes was used (Field, 2009).
Results revealed significant group differences in the level of functional outcome as
assessed by GOSE at six months post-injury, (F (3,197) = 26.40, p < .05, partial η2 = .287). The
assumption of homogeneity of variances was met, as assessed by Levene's test for equality of
variances (p = .813). The follow-up Hochberg’s GT2 post-hoc test revealed that group
differences in GOSE were significant between low symptoms (M=7.37, SD=.933) and high
depression/low fatigue symptoms (M=6.29, SD=1.204) (95% CI .38 to 1.79, p = .0003), as well
between low symptoms and low depression/high fatigue (M=6.11, SD=.875) symptoms (95% CI
.65 to 1.88, p< .05), and between low and high (M=6.03, SD=.897) symptoms (95% CI .84 to
1.83, p< .05). This indicates that those with low symptoms (M=7.37, SD=.933) had significantly
greater levels of functional outcomes and good recovery as compared to high depression/low
fatigue (M=6.29, SD=1.204) symptoms and, with low symptoms, had significantly greater levels
as compared low depression/high fatigue symptoms, and high symptoms. See Tables 7 and 8.
Table 7. Tests of ____________ Between-Subjects Effects

Source
Corrected Model
Intercept
LCAclass
Error
Total
Corrected Total

Type III Sum of
Squares
70.449a
4088.928
70.449
175.233
9983.000
245.682

df
3
1
3
197
201
200

Mean Square
23.483
4088.928
23.483
.890

F
26.400
4596.844
26.400

Sig.
.000
.000
.000

a. R Squared = .287 (Adjusted R Squared = .276)
b. Computed using alpha = .05

Note. The Glasgow Outcome Scale Extended provides eight categories of outcome, ranges from
(1) Dead to (8) Upper Good Recovery.
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Table 8. LCA Class
Dependent Variable: Glasgow Outcome Scale Extended (6 Month)
95% Confidence Interval
LCAclass
Mean
Std. Deviation Lower Bound
Upper Bound
low symptoms
7.368
.933
7.208
7.527
high depression/low fatigue 6.286
1.204
5.789
6.783
low depression/high fatigue 6.105
.875
5.679
6.532
high symptoms
6.031
.897
5.702
6.360
Note. The Glasgow Outcome Scale Extended provides eight categories of outcome, ranges from
(1) Dead to (8) Upper Good Recovery.
Figure 3. Glasgow Outcome Scale Extended (6-month).

Note. Patients (n=201) were classified into 4 groups: low symptoms (n = 136), high
depression/low fatigue (n = 14), low depression\ high fatigue (n = 19), and high symptoms (n =
32), The follow-up Hochberg’s GT2 post-hoc test revealed that group differences in GOSE were
significant between low symptoms (M=7.37, SD=.933) and high depression/low fatigue
symptoms (M=6.29, SD=1.204) (95% CI .38 to 1.79, p = .0003), as well between low symptoms
and low depression/high fatigue (M=6.11, SD=.875) symptoms (95% CI .65 to 1.88, p< .05), and
between low and high (M=6.03, SD=.897) symptoms (95% CI .84 to 1.83, p< .05). The Glasgow
Outcome Scale Extended provides eight categories of outcome, ranges from (1) Dead to (8)
Upper Good Recovery.
Satisfaction with life and LCA groups. A one-way ANOVA was conducted to
investigate differences in the main quality of life outcome measure assessed by the Satisfaction
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with Life Scale (SWLS) among patients (n=201) in the four LCA groups: low symptoms (n =
134), high depression/low fatigue (n = 14), low depression\high fatigue (n = 19), and high
symptoms (n = 32). Since the subgroup sizes were unequal, the Hochberg’s GT2 post hoc test,
which explicitly allows for unequal sample sizes was used (Field, 2009).
Results revealed significant group differences in the level of Satisfaction with Life at sixmonths follow-up, (F (3, 195) = 30.239, p < .0005, partial η2 = .318). The assumption of
homogeneity of variances was met, (p = .270). The follow-up Hochberg’s GT2 post hoc test
revealed that group differences in Satisfaction with Life were significant between low (M=25.22,
SD=6.590) and high depression/low fatigue (M=18.71, SD=5.717) symptoms (95% CI 1.76 to
11.26, p = .002), as well as the between low symptoms and low depression/high fatigue
(M=16.89, SD=7.203) symptoms (95% CI 4.18 to 12.47, p< .05), and between low and high
(M=14.81, SD=4.967) symptoms (95% CI 7.08 to 13.74, p< .05). This indicates that those with
low symptoms (M=25.22, SD=6.590) had significantly greater levels of satisfaction with life as
compared to high depression/low fatigue symptoms (M=18.71, SD=5.717) and low
depression/high fatigue symptoms (M=16.89, SD=7.203); both groups are considered slightly
below average in life satisfaction. Also, low symptoms (M=25.22, SD=6.590) had a significantly
greater level of satisfaction with life as compared to high symptoms (M=14.81, SD=4.967),
which are considered dissatisfied according to the SWLS scoring (see Tables 9 and 10).
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Table 9. Tests of Between-Subjects Effects
Dependent Variable: SWLS Total Score (6 Month)
Type III Sum of
Source
Squares
df
a
Corrected Model
3674.702
3
Intercept
35154.680
1
LCA class
3674.702
3
Error
7898.805
195
Total
110503.000
199
Corrected Total
11573.508
198

Mean Square
1224.901
35154.680
1224.901
40.507

F
30.239
867.873
30.239

Sig.
.000
.000
.000

a. R Squared = .318 (Adjusted R Squared = .307)

Note. SWLS- Satisfaction with Life scale. The SWLS is a series of five statements ranges from 1
(‘‘strongly disagree’’) to 7 (‘‘strongly agree’’). The total score ranges from a maximum very
high score between 30 – 35 indicating ‘‘highly satisfied’’, high score 25- 29, “slightly below
average in life satisfaction” score between 15 – 19, “dissatisfied’ score between 10 – 14, and
“extremely dissatisfied” score between 5 – 9
Table 10. Descriptive Statistics: SWLS
Dependent Variable: SWLS Total Score (6 Month)
Std.
LCA class
Mean
Deviation
low symptoms
25.224
6.590
high depression/low fatigue 18.714
5.717
low depression/high fatigue 16.895
7.203
high symptoms
14.813
4.967

95% Confidence Interval
Lower Bound
Upper Bound
24.140
26.308
15.360
22.069
14.015
19.774
12.594
17.031
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Figure 4. Satisfaction with Life Scale.

Note. Patients (n=201) were classified into 4 groups: Low symptoms (n = 134), high
depression/low fatigue (n = 14), low depression\ high fatigue (n = 19), and high symptoms (n =
32). The follow-up Hochberg’s GT2 post-hoc test revealed that group differences in Satisfaction
with Life were significant between low (M=25.22, SD=6.590) and high depression/low fatigue
(M=18.71, SD=5.717) symptoms (95% CI 1.76 to 11.26, p = .002), as well as the between low
symptoms and low depression/high fatigue (M=16.89, SD=7.203) symptoms (95% CI 4.18 to
12.47, p< .05), and between low and high (M=14.81, SD=4.967) symptoms (95% CI 7.08 to
13.74, p< .05). Note. SWLS- Satisfaction with Life scale. The SWLS is a series of five
statements ranges from 1 (‘‘strongly disagree’’) to 7 (‘‘strongly agree’’). The total score ranges
from a maximum very high score between 30 – 35 indicating ‘‘highly satisfied’’, high score 2529, “slightly below average in life satisfaction” score between 15 – 19, “dissatisfied’ score
between 10 – 14, and “extremely dissatisfied” score between 5 – 9
Cognitive abilities and LCA groups. A one-way ANOVA was conducted to investigate
differences in cognitive abilities among patients (n=201) who are classified into four LCA
groups: low symptoms (n = 136), high depression/low fatigue (n = 14), low depression/high
fatigue (n = 19), and high symptoms (n = 32). Cognitive measures evaluated were: nonverbal
processing speed assessed by Wechsler Adult Intelligence Scale-IV (WAIS-IV; Coding Subset
Total Raw Score, Symbol Search Subset); mental flexibility assessed by the difference score
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between the TMT B and TMTA (TMT B-A); and verbal learning assessed by California Verbal
Learning Test-II (CVLT-II trials 1– 5; five learning trials, an interference trial, an immediate
recall trial, and a post-20 min recall trial). Since the subgroup sizes were unequal, the
Hochberg’s GT2 post hoc test, which explicitly allow for unequal sample sizes, was used (Field,
2009).
Nonverbal processing speed. Results revealed significant group differences in the level
of nonverbal processing speed as assessed by WAIS-IV Processing Speed Index Composite
Score at the six-month follow-up, F (3, 178) = 4.360, p =.005, partial η2 = .068. The assumption
of homogeneity of variances was met (p = .905). The Hochberg’s GT2 post hoc test revealed
significant group differences in nonverbal processing speed between low (M= 105.21, SD=
14.733) and high depression/low fatigue (M= 93.15, SD= 16.201) symptoms (95% CI .33 to
23.97, p = .041). This indicated that those with low symptoms (M= 105.21, SD= 14.733) had
significantly greater level of nonverbal processing speed corresponding to the 50 th percentile of
performance across age groups as compared to high depression/low fatigue (M= 93.15, SD=
16.201) symptoms corresponding to 25th percentile of performance across age groups. There are
no group differences in nonverbal processing speed between individuals with low
depression/high fatigue symptoms and those with high symptoms (see Tables 11 and 12).
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Table 11. Tests of Between-Subjects Effects
Dependent Variable: Wechsler Adult Intelligence Scale-IV\Processing Speed
Index Composite Score (6 Month)
Type III Sum
Source
of Squares
df
Mean Square F
Sig.
a
Corrected Model 2993.048
3
997.683
4.360
.005
Intercept
885415.856 1
885415.856 3869.302 .000
LCA class
2993.048
3
997.683
4.360
.005
Error
40731.903
178
228.831
Total
1957913.000 182
Corrected Total
43724.951
181
a. R Squared = .068 (Adjusted R Squared = .053)

Note. The Wechsler Adult Intelligence Scale-IV-Processing Speed Index Composite Score
ranges from 50 to 150 to resemble a certain percentile (0.1st to 99.9th percentile) of performance
across different age groups. For example, the 25th percentile represent score of ∼90, the 50th
represent a score of 100, and 75th percentiles represent a score of ∼110.
Table 12. Descriptive statistics: Wechsler Adult Intelligence Scale-IV Processing Speed Index
Composite Score
LCA class
Dependent Variable: Wechsler Adult Intelligence Scale-IV Processing Speed Index Composite Score (6
Month)

LCA class
low symptoms
high depression/low fatigue
low depression/high fatigue
high symptoms

Mean
105.211
93.154
99.611
97.143

Std.
Deviation
14.773
16.201
14.034
16.788

95% Confidence Interval
Lower Bound
Upper Bound
102.520
107.903
84.874
101.433
92.575
106.647
91.501
102.784

Mental flexibility. TMT-A assesses visual processing, and TMT-B assesses mental
flexibility and processing speed, and therefore the difference between TMT-B and TMT-A
provides an index of executive control and mental flexibility separate from visual processing and
motor speed (Sanchez-Cubillo et al., 2009; Tombaugh, 2004). Results revealed significant group
differences in the level of Mental Flexibility at six-months follow-up, (F (3, 177) = 2.806, p <
.041, partial η2 = .045). The assumption of homogeneity of variances was violated, (p = .002).
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The follow-up Games-Howell post hoc procedure, was chosen to correct for the unequal
variances. Results revealed that the differences between these LCA groups were not statistically
significant, Welch's F (3, 31.968) = 1.997, p = .134.
In an exploratory analysis, results revealed that mental flexibility was positively
correlated with age (r (181) = .405, p < .01) and negatively with number of years of education
completed (r (168) = -.270, p < .01); thus these variables were controlled for in the subsequent
ANOVA. However, there were no statistical significant group differences in the level of mental
flexibility as assessed by TMT B-A between LCA Groups at six-months follow- (F (3, 94) =
1.163, p < .328, partial η2 = .036).
Table 13. Tests of Between-Subjects Effects
Dependent Variable: TMT\Part B-Part A (6 Month)
Type III Sum of
Source
Squares
df
a
Corrected Model
16848.534
3
Intercept
293793.302
1
LCA class
16848.534
3
Error
354262.502
177
Total
806940.471
181
Corrected Total
371111.036
180

Mean Square
5616.178
293793.302
5616.178
2001.483

F
2.806
146.788
2.806

Sig.
.041
.000
.041

a. R Squared = .045 (Adjusted R Squared = .029)

Note. The Trail-Making Test (TMT), the difference score between the Trial B and Trial A (TMT
B-A) A lower is a two-part timed test (TMT-A and TMT-B), and both scores are measured in
number of seconds needed for the patient to complete the task. In this test, a lower score
suggests improved performance.
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Figure 5. Wechsler Adult Intelligence Scale-IV processing speed index composite score .

Note. Patients (n=201) were classified into 4 groups: Low symptoms (n = 136), high
depression/low fatigue (n = 14), low depression\ high fatigue (n = 19), and high symptoms (n =
32). The follow-up Games-Howell post-hoc procedure, was chosen to correct for the unequal
variances. Results revealed that the differences between these LCA groups were not statistically
significant, Welch's F (3, 31.968) = 1.997, p = .134. In this test, a lower score suggests improved
performance, and results were trending toward indicating that the Low symptoms group appears
to have more improved performance compared to other groups; however, results revealed that
the differences between these LCA groups were not statistically significant. Note. The TrailMaking Test (TMT), the difference score between the Trial B and Trial A (TMT B-A) A lower is
a two-part timed test (TMT-A and TMT-B), and both scores are measured in number of seconds
needed for the patient to complete the task. In this test, a lower score suggests improved
performance.
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Verbal learning. Results of the ANOVA revealed no significant differences in the level
of verbal learning as assessed by (i.e., CVLT-II trials 1– 5; five learning trials, an interference
trial, an immediate recall trial, and a post-20 min recall trial) among LCA Groups.
In an exploratory analysis, results revealed that verbal learning was positively correlated
with injury severity as assessed by ISS (r (153) = .215, p < .01), thus this variable was controlled
for in the subsequent ANOVA; however, there were no statistical significant group differences in
the level of Verbal Learning as assessed by (i.e., CVLT-II trials 1– 5) between LCA Groups at
six-months follow-up (F (3, 48) = .180, p < .910, partial η2 = .004).
Summary of Aim 2
First, there was a significant difference among predicted LCA Groups and functional
outcomes. Results revealed significant group differences in the level of functional outcomes as
assessed by GOSE, indicating that those with low symptoms had significantly greater levels of
functional outcomes and good recovery as compared to those reporting high depression/low
fatigue symptoms. Also, those with low symptoms had significantly greater levels of functional
outcomes and good recovery as compared to individuals who reported low depression/high
fatigue symptoms, and high symptoms.
Second, there were significant differences among predicted LCA Groups and quality of
life. Results revealed significant group differences in the level of Satisfaction with Life,
indicating that those reporting low symptoms had significantly greater levels of satisfaction with
life as compared to individuals reporting high depression/low fatigue symptoms and low
depression/high fatigue symptoms; the reported life satisfaction scores reported are considered
slightly below average. Also, individuals with low symptoms had a significantly greater level of
satisfaction with life as compared to individuals who reported high symptoms; the life
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satisfaction scores of that group is considered “dissatisfied with their life” according to the
SWLS scoring.
Third, for cognitive outcomes, there were significant differences among LCA Groups
and the level of nonverbal processing speed as assessed at the six-month follow-up, indicating
that those with low symptoms had levels of nonverbal processing speed/that processing speed
corresponded to the 50th percentile of performance across age groups, which were significantly
greater as compared to individuals reporting high depression/low fatigue symptoms, whose
processing speed corresponded to the 25th percentile of performance across age groups. There
were no group differences in nonverbal processing speed between individuals with low
depression/high fatigue symptoms and those with high symptoms. Additionally, there was a
significant difference between predicted LCA Groups and the level of mental flexibility as
assessed by the difference between TMT-B and TMT-A at the six-month follow-up. In this test,
a lower score suggests improved performance, and results were trending toward indicating that
the low symptoms group appears to have more improved performance compared to other groups.
However, there were no group differences among the predicted LCA Group and the level of
mental flexibility. Lastly, there was no significant relationship between predicted LCA Groups
and verbal learning as assessed by CVLT-II trials 1– 5.
Data Analysis: Aim 3—Exploratory Aim
Sample Exclusion and Inclusion Criteria
Of the sample that met the inclusion criteria (n=340), 187 MTBI patients had missing
data and uncompleted biological data (i.e., genetic) as shown in Figure 6. The final sample
consisted of 153 patients (see Figure 6).
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Figure 6: Enrollment flow diagram.

Inclusion criteria were the following: males and females (ages >18years) who suffered external
force trauma to the head, an emergency department arrival GCS score between 13 and 15 (mild)
and completion of three- and six-month follow-ups. In addition, only those concussion/MTBI
patients who suffered minor injuries, and who were alert, oriented, and were able to read, write
and speak English were eligible. Mechanisms of injury included; motor vehicle accident,
motorcycle/bicycle accident, pedestrian struck by vehicle, struck by/against object, falls, and
other accidental causes of injury.
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Sample Characteristics/Demographic Statistics
The majority of the sample was male (66%) and single (52.9%), with a mean age of 18 to
84 years (M = 44.18, SD = 17.93). Most were working full time (46.4%) with 35 hours or more
per week and at least minimum wage. Eighteen percent had a history of anxiety, 24% had a
history of depression, 7% had some history of sleep disorders. Nearly 23% had a previous TBI
(with & without hospital admission). Tobacco use was reported by 31.4% patient, and alcohol
use was reported by 51.6%, while drug use was reported by 19% patients (see Table 14).
Injury-related characteristics. Upon arrival to the ED, the majority had a GCS of 15
(77.1%). For reference, a GCS score of 8 or less indicates severe injury, GCS of 9-12 moderate
injury, and a GCS score of 13-15 indicate minor injury. As with mild TBI, 13-15 GCS is one of
the criteria for MTBI and is indicative of minor injury. Additionally, the majority of the sample
(76.5%) reported LOC of varied duration; of these 13% had LOC of less than 1 minute, 37.9%
had LOC between 1-29 minutes, 5.2% between 30-59 minutes, and 20.3% participants had
unknown LOC duration. PTA was reported by 61.4% patients with varied duration; of these
0.6% patients had PTA for less than1 minute, 26.7% had PTA between 1-29 minutes, 5.8% had
PTA between 30-59 minutes, 8.4% had PTA between 1-24 hours, and 16.3% had unknown PTA
duration. Injury severity scores (ISS) was reported for 87.6% patients. Fourteen suffered polytrauma involving two body regions, and 13 suffered poly-trauma with head or neck injury. The
majority had an ISS Score ≥ 16 (53.5%). All injuries were closed head injuries. The majority of
patients were involved in a MVA and accidental falls (see Table 15).
Descriptive Statistics for Main Study Outcome Variables
The three main measures were the following: Brief Symptom Inventory 18 (the BSI-18 is
a brief screen of psychologic distress with a Global Severity Index (GSI) and three clinical
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subscales: BSI-somatization, BSI-anxiety, and BSI-depression), PTSD-PCL (3 subscales—
hypervigilance, avoidance, re-experiencing), and the Rivermead Post Concussion Symptoms
Questionnaire 13 (RPQ-13). Table 16? lists mean and standard deviations for main study
outcome variables. All variables were normally distributed.
Table 14. Sample Characteristics for Study Aim 3

Characteristic
Male
Ethnicity
Hispanic or Latino
Non-Hispanic or Latino
Race
Asian
Black
White
American Indian or Alaska Native
Native Hawaiian or other Pacific Islander
Other
Employment
Working full time with 35 hours or more per week and at least
minimum wage
Working 20-34 hours per week at least minimum wage
Working less than 20 hours per week and at least minimum wage
Special employment (sheltered workshop, supportive employment,
job coach)
Temporary or odd jobs and less than minimum wage jobs
Not in paid workforce (including child, retired, student, homemaker,
disabled pre-injury)
Unemployed
Unable to obtain information
Education Highest Level
None, not currently in school
None, but currently in diploma or degree-oriented program

Actual Sample
Analyzed
MTBI n = 153
N
%
101 66.0%
129 84.3%
23 15.0%
10 6.5%
7 4.6%
126 82.4%
1 0.7%
5 3.3%
3 2.0%
71 46.4%
16 10.5%
4 2.6%
1

0.7%

2

1.3%

29 19.0%
25 16.3%
3 2.0%
5
2

3.3%
1.3%
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Table 14 (cont.)
Vocational training (no high school diploma or GED)
Table 14 (cont.)
Vocational training (post high school)
GED, 53 (34.6%) High school diploma
Bachelor’s degree
Master’s degree
Doctoral degree
Unable to obtain information
Unknown
Marital Status
Divorced
Married or living together or common law
Separated
Single
Widowed
Unknown

1

0.7%

6
8
39
15
5
2
4

3.9%
5.2%
25.5%
9.8%
3.3%
1.3%
2.6%

12
50
3
81
5
2

7.8%
32.7 %
2.0%
52.9%
3.3%
1.3%

Table 15. Sample Characteristics for Study Aim 3: Injury-Related Characteristics

Characteristic
Arrival GCS
13
14
15
LOC
LOC Duration
<1 minute
1-29 minutes
30-59 minutes,
Unknown
PTA

Actual Sample Analyzed
MTBI n = 153
N
%
2 1.3%
31 20.3%
118 77.6%
117 76.9%
20
58
8
31
94

13.1%
38.8%
5.2%
20.3%
61.8%
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Table 15 (cont.)
PTA Duration
<1 minute
6 3.9%
1-29 minutes
41 26.9%
30-59 minutes
9 5.9%
1-24 hours
13 8.5%
Unknown
25 16.4%
Reported injury severity
134 88.1%
Poly-trauma with any two body regions,
14 9.2%
Poly-trauma with Head or neck Injury
13 8.5%
ISS Score ≤ 16
52 34.2%
ISS Score ≥ 16.
82 53.9%
Closed head injuries
151 99.3%
MVA
61 39.9%
Accidental Fall
61 39.9%
Firearm accident by explosive material
1 0.7%
Striking Accidents
3 2.0%
Struck accidentally by falling object
1 0.7%
Other environmental or accidental causes
1 0.7%
Other vehicle accident,
11 7.2%
Motor vehicle accident but not traffic-related
2
1.3%
Unknown
12 7.8%
LOC= Loss of Consciousness, PTA= Post Traumatic Amnesia, ISS= Injury severity
score.
Table 16. Descriptive Statistics
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60

11.18

Std.
Deviation Skewness
Std.
Statistic Error
11.291
1.356
.196

153

20

3.75

4.493

1.274

.196

.947

.390

153

18

3.66

4.005

1.311

.196

1.297

.390

153

22

3.77

4.201

1.456

.196

2.232

.390

N

BSI-GSI (6
Month)
BSI-Depression
(6 Month)
BSI-Somatization
(6 Month)
BSI-Anxiety (6
Month)

Range

Mean

Kurtosis
Std.
Statistic Error
2.037
.390
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Table 16 (cont.)
PTSD -Reexperiencing (6
Month)
PTSD Hypervigilance (6
Month)
PTSD Avoidance (6
Month)
PTSD PCL-C
Total Score (6
Month)
RPQ-13 Score (6
Month)

152

20

8.41

4.319

1.504

.197

1.894

.391

152

20

9.71

4.632

1.049

.197

.271

.391

152

24

12.78

5.755

1.125

.197

.660

.391

152

60

30.89

13.615

1.178

.197

.801

.391

152

49

11.70

11.356

.942

.197

.267

.391

Aim 3 Data Analysis and Results
Statistical strategy. First, the assumption of normality and homogeneity of variances
and outliers was assessed for all outcome measures. Normality was assessed by examining
histogram plots and z scores, homogeneity of variances was assessed by Levene's test. All
variables were checked for skewness and kurtosis (see Tables 16). Results indicated that all
outcome variables were normally distributed and no transformations were necessary.
Differences in behavioral symptoms (somatization, anxiety, depression, PTSD, and post
concussive syndrome) among the SNPs genotype (rs1800497 (ANKK1), rs1799971 (OPRM1),
rs279836 (GABRA2), rs279845 (GABRA2), rs279871 (GABRA2), and rs4680 (COMT)) were
determined. Behavioural symptoms were assessed by three main measures: (1) BSI-18 (the BSI18 is a brief screen of psychological distress with a Global Severity Index (GSI), and three
clinical subscales: BSI-somatisation, BSI-anxiety, and BSI-depression); (2) PTSD-PCL (3
subscales; hyper-vigilance, avoidance, Re-experiencing); and (3) the Rivermead Post
Concussion Symptoms Questionnaire 13 (RPQ-13). An analysis of variance (ANOVA) and
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analysis of covariance (ANCOVA), were conducted to address this aim. For all follow-up post
hoc tests the Hochberg’s GT2 was used to correct for the unequal sample size (Field, 2009).
To identify potential covariates, an independent sample t-test statistical test was
conducted between medical history of depression, anxiety, and poor sleep, ethnicity, and
outcome variables (i.e., Somatization, Anxiety, Depression, PTSD, and Post-Concussive
Syndrome) to determines statistically significant differences between the means. Those variables
that were significantly different were included as covariates in the subsequent ANOVAs (Table
17a, 17b, and 17c). Somatization was associated with history of depression (t (151) = 4.423, p <
.01) and Ethnicity (t (150) = 3.114, p < .01); thus these variables were controlled for in the
subsequent ANOVA. Also, anxiety was associated with history of anxiety (t (151) = 4.572, p <
.01), Ethnicity (t (150) = 2.760, p < .01). These variables were controlled for in the subsequent
ANOVA. Refer to Tables 17, 18, and 19.

Table 17. Independent Sample T-Test Analysis Between Medical History of Depression and Outcome Variables
Levene's Test
for Equality of
Variances
t-test for Equality of Means

Brief Symptom
Inventory 18- GSI (6
Month)

Equal
variances
assumed
Equal
variances
not
assumed
Brief Symptom
Equal
Inventory 18variances
Depression (6 Month) assumed
Equal
variances
not
assumed
Brief Symptom
Equal
Inventory 18variances
Somatization (6 Month) assumed
Equal
variances
not
assumed

F
3.970

7.562

1.567

Sig.
.048

.007

.213

Mean
Difference
8.492

Std. Error
Difference
2.024

95% Confidence
Interval of the
Difference
Lower Upper
4.493 12.492

3.584 48.975 .001

8.492

2.369

3.731 13.253

3.351 151

.001

2.752

.821

1.129 4.374

2.841 48.559 .007

2.752

.968

.805

4.423 151

.000

3.158

.714

1.747 4.568

3.959 51.771 .000

3.158

.798

1.557 4.758

t
df
4.195 151

Sig. (2tailed)
.000

4.698
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Table 17 (cont.)
Brief Symptom
Inventory 18-Anxiety
(6 Month)

Equal
variances
assumed
Equal
variances
not
assumed
PTSD ChecklistEqual
Civilian-Domain Score variances
Reexperiencing (6
assumed
Month)
Equal
variances
not
assumed
PTSD ChecklistEqual
Civilian-Domain Score variances
Hypervigilance (6
assumed
Month)
Equal
variances
not
assumed
PTSD ChecklistEqual
Civilian-Domain Score variances
Avoidance (6 Month)
assumed
Equal
variances
not assumed

5.547

2.879

.434

.144

.020

.092

.511

.705

3.365 151

.001

2.583

.768

1.067 4.100

2.840 48.308 .007

2.583

.910

.755

3.439 150

.001

2.712

.789

1.154 4.270

3.168 53.862 .003

2.712

.856

.995

4.428

2.008 150

.046

1.740

.867

.027

3.453

2.123 67.165 .037

1.740

.820

.104

3.376

1.796 150

.075

1.939

1.080

-.195

4.072

1.781 60.112 .080

1.939

1.088

-.238

4.116

4.412
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Table 17 (cont.)
PCL-C Total Score (6 Month) Equal
variances
assumed

.195

.660

Equal
variances not
assumed

RPQ-13 Score (6 Month)

Equal
3.856
variances
assumed
Equal
variances not
assumed
RPQ-3 Score (6 Month)
Equal
5.762
variances
assumed
Equal
variances not
assumed
SWLS Total Score (6 Month) Equal
.184
variances
assumed
Equal
variances not
assumed
Equal
.688
GOSE Score (6 Month)
variances
assumed
Equal
variances not
assumed

.051

.018

.669

.408

2.527 150

.013 6.391 2.529

1.394

11.387

2.521 60.653 .014 6.391 2.535

1.321

11.460

3.316 150

.001 6.893 2.079

2.786

11.000

3.020 53.042 .004 6.893 2.283

2.315

11.471

2.653 150

.009 1.136 .428

.290

1.983

2.287 49.553 .026 1.136 .497

.138

2.134

150
4.704

.000 1.378
6.481

-9.203 -3.759

59.707 .000 1.359
4.770
6.481

-9.199 -3.763

.019 -.504 .212

-.924

-.084

54.832 .031 -.504 .227
2.216

-.959

-.048

151
2.371
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Table 18. Intendent Sample T-Test Analysis Between Medical History of Anxiety and Outcome Variables
Levene's Test for
Equality of
Variances
t-test for Equality of Means

F
2.423

Brief Symptom Inventory Equal
18- GSI (6 Month)
variances
assumed
Equal
variances not
assumed
Brief Symptom Inventory Equal
2.124
18- Depression (6 Month) variances
assumed
Equal
variances not
assumed
Brief Symptom Inventory Equal
1.762
18-Somatization (6
variances
Month)
assumed
Equal
variances not
assumed

Sig.
.122

.147

.186

t
df
4.372 151

Sig. (2- Mean
tailed) Difference
.000
9.897

Std. Error
Difference
2.263

95% Confidence
Interval of the
Difference
Lower
Upper
5.425
14.369

3.536 31.965 .001

9.897

2.799

4.195

15.599

3.298 151

.001

3.045

.923

1.221

4.869

2.747 32.590 .010

3.045

1.108

.789

5.301

3.703 151

.000

3.021

.816

1.409

4.633

3.109 32.770 .004

3.021

.972

1.044

4.999
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Table 18 (cont.)
Brief Symptom Inventory Equal
18- (6 Month)
variances
assumed
Equal
variances not
assumed
PTSD Checklist-Civilian- Equal
Domain Score
variances
Reexperiencing (6
assumed
Month)
Equal
variances not
assumed
PTSD Checklist-Civilian- Equal
Domain Score
variances
Hypervigilance (6
assumed
Month)
Equal
variances not
assumed
PTSD Checklist-Civilian- Equal
Domain Score Avoidance variances
(6 Month)
assumed
Equal
variances not
assumed

8.627

2.054

.005

.025

.004

.154

.945

.875

4.572 151

.000

3.831

.838

2.175

5.486

3.489 30.884 .001

3.831

1.098

1.591

6.070

3.626 150

.000

3.197

.882

1.455

4.939

3.268 34.603 .002

3.197

.978

1.210

5.184

2.171 150

.031

2.108

.971

.190

4.027

2.193 38.472 .034

2.108

.961

.163

4.054

2.128 150

.035

2.569

1.207

.184

4.954

2.200 39.454 .034

2.569

1.168

.207

4.930
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Table 18 (cont.)
PCL-C Total Score (6
Month)

Equal
variances
assumed
Equal
variances not
assumed
RPQ-13 Score (6 Month) Equal
variances
assumed
Equal
variances not
assumed
RPQ-3 Score (6 Month) Equal
variances
assumed
Equal
variances not
assumed
SWLS Total Score (6
Equal
Month)
variances
assumed
Equal
variances not
assumed

.014

1.267

15.806

2.047

.906

.262

.000

.155

2.786 150

.006

7.874

2.827

2.289

13.460

2.814 38.483 .008

7.874

2.798

2.212

13.536

3.507 150

.001

8.151

2.325

3.558

12.745

3.170 34.687 .003

8.151

2.572

2.929

13.374

3.157 150

.002

1.504

.477

.563

2.446

2.406 30.884 .022

1.504

.625

.229

2.780

150
3.682

.000

-5.789

1.572

-8.895

-2.683

43.026 .000
4.087

-5.789

1.417

-8.646

-2.932
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Table 18 (cont.)
GOSE Score (numerical) Equal
.089
(6 Month)
variances
assumed
Equal
variances not
assumed

.766

151
1.906

.059

-.458

.240

-.932

.017

37.361 .069
1.875

-.458

.244

-.952

.037
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Table 19. Independent Sample T-Test Analysis Between Ethnicity, and Outcome Variables
Levene's Test for
Equality of
Variances

Brief Symptom
Inventory 18GSI (6 Month)
Brief Symptom
Inventory 18Depression (6
Month)
Brief Symptom
Inventory 18Somatization (6
Month)
Brief Symptom
Inventory
18\Raw Score
Anxiety (6
Month)

Equal variances
assumed
Equal variances
not assumed
Equal variances
assumed
Equal variances
not assumed
Equal variances
assumed
Equal variances
not assumed
Equal variances
assumed
Equal variances
not assumed

F
5.913

11.715

2.470

3.396

Sig.
.016

.001

.118

.067

t-test for Equality of Means

T
df
3.273 150

Sig. (2tailed)
.001

95% Confidence
Interval of the
Mean
Std. Error Difference
Difference Difference Lower
Upper
8.129
2.483
3.222
13.035

2.692 26.642 .012

8.129

3.020

1.929

14.328

3.114 150

.002

3.084

.990

1.127

5.041

2.488 26.249 .020

3.084

1.240

.538

5.631

2.792 150

.006

2.480

.888

.725

4.236

2.397 27.294 .024

2.480

1.035

.358

4.602

2.760 150

.006

2.564

.929

.729

4.400

2.353 27.184 .026

2.564

1.090

.329

4.799
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Table 19 (cont.)
PTSD ChecklistCivilian-Domain
Score
Reexperiencing
PTSD ChecklistCivilian-Domain
Score
Hypervigilance
PTSD ChecklistCivilian-Domain
Score Avoidance
(6 Month)
PCL-C Total
Score (6 Month)

Equal variances
assumed
Equal variances
not assumed
Equal variances
assumed
Equal variances
not assumed
Equal variances
assumed
Equal variances
not assumed
Equal variances
assumed
Equal variances
not assumed
RPQ-13 Score (6 Equal variances
Month)
assumed
Equal variances
not assumed
RPQ-3 Score (6 Equal variances
Month)
assumed
Equal variances
not assumed

1.842

.310

4.368

1.848

2.259

.935

.177

.578

.038

.176

.135

.335

2.638 149

.009

2.530

.959

.635

4.424

2.341 27.894 .027

2.530

1.080

.316

4.743

2.905 149

.004

2.935

1.010

.939

4.931

2.810 29.636 .009

2.935

1.045

.801

5.070

2.866 149

.005

3.646

1.272

1.132

6.160

2.370 26.751 .025

3.646

1.539

.488

6.805

3.050 149

.003

9.111

2.987

3.208

15.014

2.740 28.115 .011

9.111

3.325

2.301

15.921

3.126 149

.002

7.748

2.479

2.850

12.645

2.781 27.936 .010

7.748

2.786

2.040

13.455

1.170 149

.244

.612

.523

-.422

1.646

1.095 28.920 .283

.612

.559

-.531

1.756
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Table 19 (cont.)
SWLS Total
Score (6 Month)

GOSE Score
(numerical) (6
Month)

Equal variances
assumed
Equal variances
not assumed
Equal variances
assumed
Equal variances
not assumed

.320

.118

.572

.732

1.214
1.135
1.135
1.281

149

.227

-2.122

1.747

-5.574

1.331

28.883 .266

-2.122

1.870

-5.946

1.703

150

.258

-.294

.259

-.805

.217

34.123 .209

-.294

.229

-.759

.172
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Exploratory analysis of SNP rs1800497 ANKK1 on outcome measures. There were
marginal differences at α = 0.05 between SNP rs1800497ANKK1 and outcome variables
included: BSI18 Global Severity Index (GSI), BSI-somatisation, BSI-anxiety, and BSIdepression, PTSD- hyper-vigilance, PTSD-avoidance, PTSD-Re-experiencing, and RPQ-13
total score, which warrant further exploration. To identify potential covariates, independent
sample t-test analysis was conducted between medical history of depression, medical history of
depression anxiety, ethnicity, and outcome variables. Those variables that were significantly
correlated (p < .01) were included as covariates in the subsequent ANOVAs.
Then, Analysis of Covariance (ANCOVA) was conducted to investigate differences
between patients who were classified into 3 groups: A1/A1 (n = 10), A1/A2 (n = 56), A2/A2 (n
= 86), with respect to distress, posttraumatic symptoms, and post concussive symptoms. The
outcome variables included: BSI18 Global Severity Index (GSI), BSI-somatisation, BSI-anxiety,
and BSI-depression, PTSD- hyper-vigilance, PTSD-avoidance, PTSD-re-experiencing, and
RPQ-13 total score. Since the subgroup sizes are greatly unequal, the Hochberg’s GT2 post hoc
test explicitly allows for unequal sample sizes (Field, 2009).
Somatisation and SNP rs1800497ANKK1. Results revealed that somatization was
associated with history of depression (t (151) = 4.423, p < .01) and ethnicity (t (150) = 3.114, p <
.01), thus these variables were controlled for in the subsequent ANOVA. Significant group
differences in the level of somatisation were found, (F (2,146) = 3.859, p < .023, partial η2 =
.050). The assumption of homogeneity of variances was met, as assessed by Levene's test for
equality of variances (p = .177). The follow-up Hochberg’s GT2 post hoc test revealed that
group differences in somatization were significant between A1/A1 (M=7.416, SD=1.188) and
A1/A2 (M=4.366, SD= .571) genotypes (95 % CI .03 to 6.09, p = .047). However, no
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differences were observed between A1/A1 and A2/A2 (M=5.651, SD=.537) genotypes, and
A2/A2 and A1/A2 genotypes. Please refer to Tables 20 and 21.
Table 20. Tests of Between-Subjects Effects
Dependent Variable: Brief Symptom Inventory 18 Somatization (6 Month)
Type III
Sum of
Mean
Source
Squares
df
Square
F
Sig.
a
Corrected Model
471.845
4
117.961
8.851
.000
Intercept
1557.248
1
1557.248
116.849 .000
SNP1800497ANKK1 102.863
2
51.432
3.859
.023
Ethnicity
102.176
1
102.176
7.667
.006
MHPSYCDEP
268.709
1
268.709
20.163
.000
Error
1945.745
146
13.327
Total
4487.000
151
Corrected Total
2417.589
150

Partial Eta
Squared
.195
.445
.050
.050
.121

a. R Squared = .195 (Adjusted R Squared = .173)

Note. Brief Symptom Inventory 18- somatization subscale consists of 6 question (each question
ranges from 0 “not at all” to 4 “extremely”), total score for somatization subscale ranges from 0
to 18, a higher score is indicative of higher level of somatization.
:
Table 21. Descriptive statistics: Brief Symptom Inventory 18-Somatization
Dependent Variable: Brief Symptom Inventory 18-Somatization (6 Month)
95% Confidence Interval
SNP rs1800497
Std.
(ANKK1)
Mean
Error Lower Bound Upper Bound
A1/A1 (n = 10)
7.416
1.188 5.068
9.763
A1/A2 (n = 56)
4.366
.571
3.237
5.495
A2/A2 (n = 86)
5.651
.537
4.589
6.712
Note. Brief Symptom Inventory 18- somatization subscale consists of 6 question (each question
ranges from 0 “not at all” to 4 “extremely”), total score for somatization subscale ranges from 0
to 18, a higher score is indicative of higher level of somatization.
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Figure 7. Brief symptom inventory 18- Somatization.

Note. Patients were classified into 3 groups: A1/A1 (n = 10), A1/A2 (n = 56), A2/A2 (n = 86).
The follow-up Hochberg’s GT2 post-hoc test revealed that group differences in somatization
were significant between A1/A1 (M=7.416, SD=1.188) and A1/A2 (M=4.366, SD= .571)
genotypes (95 % CI .03 to 6.09, p = .047). However, no differences were observed between
A1/A1 and A2/A2 (M=5.651, SD=.537) genotypes, and A2/A2 and A1/A2 genotypes. Note.
Brief Symptom Inventory 18- somatization subscale consists of 6 question (each question ranges
from 0 “not at all” to 4 “extremely”), total score for somatization subscale ranges from 0 to 18, a
higher score is indicative of higher level of somatization.
Anxiety and SNP rs1800497ANKK1. Results revealed that also, anxiety was associated
with history of anxiety (t (151) = 4.572, p < .01), and ethnicity (t (150) = 2.760, p < .01); these
variables were controlled for in the subsequent ANOVA. Significant group differences in the
level of anxiety were found, (F (2,145) = 5.060, p < .008, partial η2 = .065). The assumption of
homogeneity of variances was met, as assessed by Levene's test for equality of variances (p =
.269). The follow-up Hochberg’s GT2 post-hoc test revealed that group differences in anxiety
were significant between A1/A1 (M=7.982, SD= 1.264) and A1/A2 (M= 4.266, SD= .604)
genotypes (95 % CI .27 to 6.67, p = .029); however, no differences were observed between
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A1/A1 and A2/A2 (M=5.824, SD=.572) genotypes and A2/A2 and A1/A2 genotypes. Please
refer to Tables 22 and 23.
Table 22. Tests of Between-Subjects Effects
Dependent Variable: Brief Symptom Inventory 18- Anxiety (6 Month)
Type III Sum
Source
of Squares
df
Mean Square F
Corrected Model
588.101a
4
147.025
10.386
Intercept
1736.771
1
1736.771
122.685
SNP1800497ANKK1
143.633
2
71.816
5.073
MHPSYCANX
345.789
1
345.789
24.426
Ethnicity
117.038
1
117.038
8.268
Error
2066.826
146 14.156
Total
4769.000
151
Corrected Total
2654.927
150
a.

Sig.
.000
.000
.007
.000
.005

Partial Eta
Squared
.222
.457
.065
.143
.054

R Squared = .222 (Adjusted R Squared = .200)

Note. Brief Symptom Inventory 18- Anxiety subscale consists of 6 question (each question
ranges from 0 “not at all” to 4 “extremely”), total score for anxiety subscale ranges from 0 to
18, a higher score is indicative of higher level of anxiety.
Table 23. Descriptive Statistics: Brief Symptom Inventory 18-Anxiety
Dependent Variable: Brief Symptom Inventory 18-Anxiety (6 Month)
95% Confidence Interval
Biomarker Data\SNP\SNP
Calls\rs1800497 (ANKK1)
Mean
Std. Error
Lower Bound
Upper Bound
A1/A1 (n = 10)
7.982
1.264
5.485
10.480
A1/A2 (n = 56)
4.266
.604
3.072
5.459
A2/A2 (n = 86)
5.824
.572
4.693
6.955
Note. Brief Symptom Inventory 18- Anxiety subscale consists of 6 question (each question
ranges from 0 “not at all” to 4 “extremely”), total score for anxiety subscale ranges from 0 to 18,
a higher score is indicative of higher level of anxiety.
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Figure 8. Brief symptom inventory 18- Anxiety.

Note. Patients were classified into 3 groups: A1/A1 (n = 10), A1/A2 (n = 56), A2/A2 (n = 86).
The follow-up Hochberg’s GT2 post-hoc test revealed that group differences in anxiety were
significant between A1/A1 (M=7.982, SD= 1.264) and A1/A2 (M= 4.266, SD= .604) genotypes
(95 % CI .27 to 6.67, p = .029); however, no differences were observed between A1/A1 and
A2/A2 (M=5.824, SD=.572) genotypes and A2/A2 and A1/A2 genotypes. Note. Brief Symptom
Inventory 18- Anxiety subscale consists of 6 question (each question ranges from 0 “not at all” to
4 “extremely”), total score for anxiety subscale ranges from 0 to 18, a higher score is indicative
of higher level of anxiety.
Post-concussive syndrome and SNP rs1800497ANKK1. Results of the ANOVA revealed
no significant differences in the level of post-concussive syndrome (i.e., as assessed by RPQ-13)
between the SNP rs1800497ANKK1 genotypes (F (2,148) = .642, p < .537).
PTSD symptoms and SNP rs1800497ANKK1. The ANOVA was performed to assess
the differences between SNP rs1800497ANKK1 genotype groups, with respect to PTSD-PCL
(hypervigilance, avoidance, re-experiencing). The ANOVA was done for each outcome variable.
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Results revealed no significant SNP rs1800497ANKK1 genotype group differences for any of
the PTSD-PCL subscales (i.e., hypervigilance, avoidance, re-experiencing)
Exploratory analysis of SNP1799971 OPRM1 on outcome measures. A one-way
Analysis of variance (ANOVA) was conducted to investigate differences between patients who
were classified into 3 groups: A/A (n = 111), A/G (n = 39), G/G (n = 2) with respect to distress,
posttraumatic symptoms and post concussive symptoms. The outcome variables included:
BSI18 Global Severity Index (GSI), BSI-somatization, BSI-anxiety, and BSI-depression, PTSDhypervigilance, PTSD-avoidance, PTSD-Re-experiencing, and RPQ-13 total score. The
assumption of homogeneity of variances was met, as assessed by Levene's test for equality of
variances for all outcome measures. No differences in any outcome measures were observed
among SNP1799971 OPRM1 Genotype groups.
Exploratory analysis of SNP rs279836 (GABRA2) on outcome measures. A one-way
analysis of variance (ANOVA) was conducted to investigate differences between patients
(n=151) who were classified into 3 groups: A/A (n = 30), A/T (n = 70), T/T (n = 51) with respect
to distress, posttraumatic symptoms and post-concussive symptoms. The outcome variables
included: BSI18 Global Severity Index (GSI), BSI-somatisation, BSI-anxiety, and BSIdepression, PTSD- hyper-vigilance, PTSD-avoidance, PTSD-Re-experiencing, and RPQ-13 total
score. The assumption of homogeneity of variances was violated, as assessed by Levene's test for
equality of variances for all outcome measures. No differences in any outcome measures were
found among SNP rs279836 GABRA2 Genotype groups.
Exploratory analysis of rs279845 (GABRA2) on outcome measures. A one-way
analysis of variance (ANOVA) was conducted to investigate differences in distress,
posttraumatic symptoms and post-concussive symptoms among patients (n=151) who were
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classified into 3 groups: A/A (n = 29), A/T (n = 73), T/T (n = 49). The outcome variables were
assessed using: BSI18 Global Severity Index (GSI), BSI-somatisation, BSI-anxiety, and BSIdepression, PTSD- hyper-vigilance, PTSD-avoidance, PTSD-Re-experiencing, and RPQ-13 total
score. Results revealed no differences in these behavioural outcome measures between SNP
rs279845 GABRA2 Genotype groups.
Exploratory analysis of rs279871 (GABRA2) on outcome measures. A one-way
Analysis of variance (ANOVA) was conducted to investigate differences between patients
(n=152) who were classified into 3 groups: C/C (n = 29), C/T (n = 70), T/T (n = 53), with
respect to distress, posttraumatic symptoms and post concussive symptoms. The outcome
variables included: BSI18 Global Severity Index (GSI), BSI-somatisation, BSI-anxiety, and BSIdepression, PTSD- hyper-vigilance, PTSD-avoidance, PTSD-Re-experiencing, and RPQ-13 total
score. No differences in any outcome measures among SNP rs279871 GABRA2 Genotype
groups were found.
Exploratory analysis of rs4680 (COMT) on outcome measures. A one-way Analysis
of variance (ANOVA) was conducted to investigate differences between patients (n=153) who
were classified into 3 groups: Met/Met (n = 40), Met/Val (n = 74), Val/Val (n = 39), with respect
to distress, posttraumatic symptoms and post concussive symptoms. The outcome variables were
assessed using the following measures: BSI18 Global Severity Index (GSI), BSI-somatisation,
BSI-anxiety, and BSI-depression, PTSD- hyper-vigilance, PTSD-avoidance, PTSD-Reexperiencing, and RPQ-13 total score. No differences in any outcome variables were found
among the SNP rs4680 (COMT) Genotype groups.
Additional exploratory analysis. Additional exploratory analysis was conducted to
further explore group differences among SNP rs1800497 (ANKK1) genotypes and the level of
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fatigue, depression, and sleep disturbance. The three RPQ-13 questions used for Aim 1 (LCA)
that addressed fatigue, depression, and sleep were used to measure the dependent variables. To
identify potential covariates, an independent sample t-test statistical test was conducted between
medical history of depression, anxiety, ethnicity, and outcome variables (i.e., RPQ-13 questions;
RPQ Fatigue: Tiring More Easily, RPQ Sleep Disturbance, RPQ Feeling Depressed or Tearful)
to determine statistically significant differences between the means. Those variables that were
significantly different were included as covariates in the subsequent ANOVAs (See Tables 24,
25, and 26). For all follow-up post hoc tests the Hochberg’s GT2 was used to correct for the
unequal sample size (Field, 2009).

Table 24. Independent Sample T-Test Analysis Between Medical History of Anxiety and Outcome Variables (RPQ-13 questions;
RPQ Fatigue: Tiring More Easily, RPQ Sleep Disturbance, RPQ Feeling Depressed or Tearful)
Levene's Test for
Equality of
Variances
t-test for Equality of Means

F
1.668

RPQ Fatigue, Tiring
Equal
More Easily
variances
(numerical) (6 Month) assumed
Equal
variances not
assumed
RPQ Feeling
Equal
4.101
Depressed or Tearful variances
(numerical) (6 Month) assumed
Equal
variances not
assumed
RPQ Sleep
Equal
2.370
Disturbance
variances
(numerical) (6 Month) assumed
Equal
variances not
assumed

Sig.
.198

.045

.126

t
df
3.943 150

Sig. (2- Mean
tailed) Difference
.000
.962

Std. Error
Difference
.244

95% Confidence
Interval of the
Difference
Lower
Upper
.480
1.444

3.448 33.787 .002

.962

.279

.395

1.529

3.601 150

.000

.809

.225

.365

1.254

3.145 33.754 .003

.809

.257

.286

1.333

1.799 150

.074

.508

.283

-.050

1.067

1.633 34.809 .112

.508

.311

-.124

1.141
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Table 25. Independent Sample T-Test Analysis Between Medical History of Depression and Outcome Variables (RPQ-13 Questions;
RPQ Fatigue: Tiring More Easily, RPQ Sleep Disturbance, RPQ Feeling Depressed or Tearful)
Levene's Test for
Equality of
Variances
t-test for Equality of Means

F
2.254

RPQ Fatigue, Tiring
Equal
More Easily
variances
(numerical) (6 Month) assumed
Equal
variances not
assumed
RPQ Feeling
Equal
3.618
Depressed or Tearful variances
(numerical) (6 Month) assumed
Equal
variances not
assumed
RPQ Sleep
Equal
2.684
Disturbance
variances
(numerical) (6 Month) assumed
Equal
variances not
assumed

Sig.
.135

.059

.103

t
df
2.985 150

Sig. (2- Mean
tailed) Difference
.003
.662

Std. Error
Difference
.222

95% Confidence
Interval of the
Difference
Lower
Upper
.224
1.100

2.723 53.168 .009

.662

.243

.174

1.150

3.530 150

.001

.708

.201

.312

1.104

3.179 52.261 .002

.708

.223

.261

1.155

1.560 150

.121

.394

.252

-.105

.893

1.457 54.876 .151

.394

.270

-.148

.936
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Table 26. Independent Sample T-Test Analysis Between Ethnicity and Outcome Variables (RPQ-13 questions; RPQ Fatigue: Tiring
More Easily, RPQ Sleep Disturbance, RPQ Feeling Depressed or Tearful)
Levene's Test for
Equality of
Variances

RPQ Fatigue,
Tiring More
Easily
(numerical) (6
Month)
RPQ Feeling
Depressed or
Tearful
(numerical) (6
Month)
RPQ Sleep
Disturbance
(numerical) (6
Month)

Equal variances
assumed
Equal variances
not assumed

F
.959

Equal variances
assumed
Equal variances
not assumed

5.839

Equal variances
assumed
Equal variances
not assumed

6.502

Sig.
.329

.017

.012

t-test for Equality of Means

t
df
1.624 149

Sig. (2tailed)
.107

95% Confidence
Interval of the
Mean
Std. Error Difference
Difference Difference Lower
Upper
.441
.272
-.096
.978

1.518 28.898 .140

.441

.291

-.153

1.036

3.050 149

.003

.739

.242

.260

1.219

2.573 27.052 .016

.739

.287

.150

1.329

2.108 149

.037

.636

.301

.040

1.231

1.786 27.117 .085

.636

.356

-.094

1.366
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Fatigue and SNP rs1800497ANKK1. Results revealed that fatigue was associated with
history of anxiety (t (150) = 3.943, p < .01); thus, this variable was controlled for in the
subsequent ANOVA. Significant group differences in the level of fatigue were found, (F (2,147)
= 3.057, p = .050 partial η2 = .040). The assumption of homogeneity of variances was violated,
as assessed by Levene's test for equality of variances (p = .008). The follow-up Hochberg’s GT2
post-hoc test revealed that there were no differences in fatigue between A1/A1 (M=2.200, SD=
.366) and A1/A2 (M= 1.354, SD= .166) genotypes. Also, no differences in fatigue were
observed between A1/A1 and A2/A2 (M=1.709, SD=.150) genotypes and A2/A2 and A1/A2
genotypes (see Table 27 and Figure 9).
Table 27. Descriptive Statistics: RPQ Fatigue, Tiring More Easily
Dependent Variable: RPQ Fatigue, Tiring More Easily (6 Month)
95% Confidence Interval
SNP \rs1800497 (ANKK1)
Mean
Std. Error
Lower Bound
Upper Bound
A1/A1
2.200
.366
1.476
2.923
A1/A2
1.354
.166
1.027
1.682
A2/A2
1.709
.150
1.412
2.006
Note. RPQ = Rivermead post-concussive symptoms questioner (each questions ranges from 0not experienced to 4-severe problem).
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Figure 9. RPQ-Fatigue, tiring more easily.

Note. Patients were classified into 3 groups: A1/A1 (n = 10), A1/A2 (n = 55), A2/A2 (n = 86).
The follow-up Hochberg’s GT2 post-hoc test revealed that there were no differences in fatigue
between A1/A1 (M=2.200, SD= .366), A1/A2 (M= 1.354, SD= .166) genotypes, no differences
were observed between A1/A1 and A2/A2 (M=1.709, SD=.150) genotypes and A2/A2 and
A1/A2 genotypes (See Table x, and Figure X). Note: RPQ = Rivermead post-concussive
symptoms questioner (each question ranges from 0- not experienced to 4-severe problem).
Depression, sleep disturbance and SNP rs1800497ANKK1.No significant differences in
levels of depression and sleep disturbance were found among SNP rs1800497ANKK1 genotype
groups.
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Summary of Exploratory Aim
The results of this aim indicated that there are no differences in behavioural symptoms
outcomes on the three main measures—BSI-GSI, BSI-somatisation, BSI-anxiety, and BSIdepression, PTSD-PCL (hyper-vigilance, avoidance, re-experiencing), and RPQ-13—among the
five SNP genotypes—(rs279836 (GABRA2), rs279845 (GABRA2), rs279871 (GABRA2),
SNP1799971 (OPRM1), and rs4680 (COMT)). However, differences were found for patients
with different SNP rs1800497 ANKK1 genotype and their level of BSI-somatisation and BSIanxiety.
First there was a significant difference in somatisation among SNP rs1800497 ANKK1
genotype groups while controlling for history of depression and ethnicity. Results revealed
significant group differences in the level of somatisation, (F (2,146) = 3.859, p < .023, partial η2
= .050), indicating that those with A1/A1 (M=7.416, SD=1.188) had significantly greater levels
of somatisation as compared to A1/A2 (M=4.366, SD= .571) genotype. However, no differences
were observed between A1/A1 and A2/A2 (M=5.651, SD= .537) genotypes, and A2/A2 and
A1/A2 genotypes.
Second, there was a significant difference in anxiety among SNP rs1800497 ANKK1
genotype groups while controlling for history of anxiety and ethnicity. Results revealed
significant group differences in the level of anxiety (F (2,145) = 5.060, p < .008, partial η2 =
.065). Specifically, those with A1/A1 (M=7.982, SD= 1.264) reported significantly greater
levels of anxiety than patients with A1/A2 (M= 4.266, SD= .604) genotype. However, no
differences were observed between A1/A1 and A2/A2 genotypes and A2/A2 and A1/A2
genotypes.
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In conclusion, it is important to note that although the differences observed were
significant, there was very little difference among the means, which warrants replication with a
larger sample. Also, perhaps a larger sample size may produce different findings regarding
differences between groups with different six types of SNPs genotype (rs1800497 (ANKK1),
rs1799971 (OPRM1), rs279836 (GABRA2), rs279845 (GABRA2), rs279871 (GABRA2), and
rs4680 (COMT).
Schematic of the Variables
The primary aim of this investigation was to use latent class cluster analysis to identify
behavioral symptom clusters in MTBI patients; and to then determine whether there were
differences in quality of life, and in cognitive and functional outcomes among the symptom
groups. An exploratory aim assessed whether there were differences in the intensity of
behavioral symptoms among SNP genotypes (see Figure 10).
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Figure 10. Diagram of the final study variables.
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Note. Aim 1: to identify different profiles of MTBI patients based on the intensity of
depressive mood, fatigue, and poor sleep. Aim 2: to determine whether there are differences
in cognitive and functional outcomes at six months post-MTBI among the identified
behavioral cluster profiles. Aim 3: to explore differences in the intensity of behavioral
symptoms at six months post-MTBI based on SNP genotype.

CHAPTER FIVE
DISCUSSION
This chapter summarizes and integrates results for each research question, aim and
hypothesis; derives conclusions and provide explanations for findings; integrates findings with
extant literature and discusses areas of convergence and divergence; discusses how findings
address knowledge gaps; identifies and discusses realistic implications of the findings for
nursing; addresses strengths and limitations of the study; and identifies directions for further
study.
Overview of Findings
For Aim 1, Latent Class Analysis (LCA) was performed to identify profiles of MTBI
patients based on the intensity of depressive symptoms, fatigue, and poor sleep. The
measurements for these variables were derived from the Rivermead Post-Concussion
Questionnaire, which was administered six months post-MTBI. Mplus 7.4 (Muthén & Muthén,
1998-2011) was used to conduct the LCA. The means of the three variables (depressive
symptoms, fatigue, and poor sleep) were used to generate the latent classes. Results for Aim 1
revealed four predicted LCA Groups with different symptom intensity that were classified into
four groups (Class 1—low symptoms, Class 2—high depression/low fatigue, Class 3—low
depression/high fatigue, and Class 4—high symptoms). Class 1 was the largest class,
constituting 67.7 % of the sample, and was characterized by low endorsement of depression,
fatigue, and sleep disturbance. Class 4 accounted for 15.9% of the sample and had the highest
ratings of depression, fatigue, and sleep disturbance. Class 3 consisted of low depression and
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high fatigue and accounted for 9.5 % of the sample, whereas Class 2 was characterized by low
fatigue and high depression and accounted for 7 % of the sample; both Class 2 and 3 had the
same ratings of sleep disturbance.
After identifying the LCA groups, the second aim of this study was to determine whether
there were differences among outcome variables (functional, cognitive, and quality with life)
among the predicted LCA groups. An analysis of variance (ANOVA) and analysis of covariance
were conducted to address this aim. The results for Aim 2 indicated that there were group
differences in functional and quality of life outcomes among the four predicted LCA Groups.
First, findings revealed significant group differences in the level of functional outcomes as
assessed by GOSE, indicating that those with low symptoms had significantly greater levels of
functional outcomes and good recovery as compared to those reporting high depression/low
fatigue symptoms, low depression/high fatigue symptoms, and high symptoms. Second, results
revealed significant group differences in the level of Satisfaction with Life, indicating that those
reporting low symptoms had significantly greater levels of satisfaction with life as compared to
individuals reporting high depression/low fatigue symptoms and low depression/high fatigue
symptoms; the reported life satisfaction scores reported are considered slightly below average.
Also, individuals with low symptoms had a significantly greater level of satisfaction with life as
compared to individuals who reported high symptoms; the life satisfaction scores of that group is
considered “dissatisfied with their life” according to the SWLS scoring. Third, group
differences were found in both nonverbal processing speed and mental flexibility; findings
revealed that those with low symptoms had levels of nonverbal processing speed, which
corresponded to the 50th percentile of performance across age groups. This level was
significantly greater as compared to individuals reporting high depression/low fatigue symptoms,
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whose processing speed corresponded to the 25th percentile of performance across age groups.
Additionally, there was a significant difference between predicted LCA Groups and the level of
mental flexibility as assessed by the difference between TMT-B and TMT-A at the six-month
follow-up. In this test, a lower score suggests improved performance. Results revealed a trend,
such that the low symptoms group had better performance (approaching significance) compared
to other groups. No differences in verbal learning were found among the LCA groups.
For the third exploratory aim, differences in intensity of behaviour symptoms
(Somatisation, Anxiety, Depression, PTSD, and Post-Concussive Syndrome) among SNP
genotypes (rs1800497 (ANKK1,) rs1799971 (OPRM1), SNPs genotype (rs1800497 (ANKK1),
rs1799971 (OPRM1), rs279836 (GABRA2), rs279845 (GABRA2), rs279871 (GABRA2), and
rs4680 (COMT)) was explored. An analysis of variance (ANOVA) and analysis of covariance
(ANCOVA) were conducted to address this aim. The results for Aim 3, revealed no differences
in intensity of behavioural symptoms at six months post-MTBI for the five different SNP
genotypes (rs279836 (GABRA2), rs279845 (GABRA2), rs279871 (GABRA2), SNP1799971
(OPRM1), and rs4680 (COMT)). However, group differences in the level of BSI-somatisation
and BSI-anxiety were found for patients with different SNP rs1800497 ANKK1 genotypes. Yet,
it is important to note that although the differences were statistically significant, the magnitude
of these differences was small, and warrants replication with a larger sample. Also, it is likely
that a larger sample size would reveal significant differences for other functional outcomes,
especially cognitive function (i.e., non-verbal processing speed and mental flexibility). As well,
a larger sample may also yield significant differences in functional outcomes among the six
types of SNPs genotype (rs1800497 (ANKK1), rs1799971 (OPRM1), rs279836 (GABRA2),
rs279845 (GABRA2), rs279871 (GABRA2), and rs4680 (COMT).
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Relevance to Guiding Frameworks/Theories
This study was guided by a psychoneuroimmunology (PNI) framework. The field of PNI
posits bidirectional networks that underlie the manifestation of behaviour; in this case
inflammatory-related behaviour. The type and extent of such interaction and a given behavioural
phenotype is also influenced by an individual’s genetic make-up; and these behavioural
phenotypes may influence cognitive and functional outcomes post-MTBI. Thus, consistent with
this concept, this investigation explored genetic variants as a potential mechanism to explain
individual differences in cognitive and functional outcomes post-MTBI. Understanding these
physiological (genetic) factors may lead to tailored strategies to improve outcomes. Furthermore,
the Theory of Unpleasant Symptoms (TOUS) (Lenz et al., 1997) guided the symptom-clustering
analysis. The TOUS emphasizes the importance of consideration of symptom experiences as
clusters. Incorporating the experience of symptoms “as clusters” (adapted from TOUS) would
allow researchers to have a broader view of the symptom-related variables that contribute to the
symptoms clusters, as well the symptoms-related recovery outcomes (e.g., cognitive and
functional recovery).
The PNI framework guided the investigation of these relationships, and the results
revealed that co-occurring symptoms synergize to negatively impact cognitive and functional
recovery. Additionally, the findings revealed that genetic variants (i.e., SNP rs1800497
ANKK1) could predispose MTBI patients to more intense behavioural symptoms post-MTBI,
which is consistent with the embodiment of mind and body. That is, a unique genetic phenotype
may predispose an individual who suffers mild traumatic brain injury to exhibit more intense
psychological symptoms. This line of thought is consistent with this study’s finding that patients
with different SNP rs1800497 ANKK1 genotype had differences in their level of somatisation
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and anxiety. That is, those with A1/A1 had a significantly greater level of somatisation and
anxiety as compared to A1/A2 genotype. Thus, we could perhaps, speculate that different
genotypes could have a positive relationship with such psychological symptoms post MTBI.
These preliminary results offer compelling impetus for further exploration of genetic variants
linked to mental health outcomes in individuals who suffer MTBI. Such findings are innovative,
as they may lead to novel genotype-based biomarkers predictive of who is at risk for worse
outcomes as early as possible.
Discussion of Study Aims
Aim 1: Different Profiles of MTBI Patients and Intensity of Behavioral Symptoms
The first aim of this study was to identify different profiles of MTBI patients based on
the intensity of depressive mood, fatigue, and poor sleep. First, symptom clusters analysis was
used as a predictive tool for profiling subgroups with enduring behavioral symptoms post-MTBI.
Such an analysis can reveal symptom interrelationships (Aktas et al., 2010) and facilitate
exploring the influence of symptoms on each other (AIM 1) and on cognitive and functional
outcomes (AIM 2). It is well established from previous research that MTBI patients can suffer
from anxiety, fatigue, poor sleep, and depressive mood for weeks and months after injury
(Ayalon et al., 2007; Bay, 2009; Beaulieu-Bonneau & Morin, 2012; Beetar et al., 1996; Chaput
et al., 2009; Levin et al., 2005; Norrie et al., 2010; Ponsford et al., 2000; Rapoport et al., 2006).
However, few studies have identified behavioral symptom clusters in MTBI patients, and no
prior study has addressed the extent to which clusters of these symptoms influence functional
and cognitive outcomes over time.
The results for Aim 1 extend the existing literature regarding persistence of behavioral
symptoms post MTBI, in that most of previous studies have either evaluated individual
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symptoms or the co-occurrence of two symptoms. For example, it has been shown that MTBI
patients who experience sleep disturbance are also more likely to suffer depressive symptoms
(Auxemery, 2012; Bay & Donders, 2008; Bay, 2009; Beaulieu-Bonneau & Morin, 2012;
Chaput et al., 2009; Guskiewicz et al., 2007; Kristman et al., 2014; Levin et al., 2005; Mooney
& Speed, 2001; Ponsford et al., 2011; Rapoport et al., 2006). Prevalence of depression is 15%
in the first 3 months post-MTBI (Rapoport et al., 2003) and 18% up to a year after MTBI (Rao
et al., 2010). These prevalence rates are similar to what was observed in the present study, as
the present findings found that 25.3 % of the sample reported sleep disturbance (17.4 % mild,
6.5 % moderate, and 1.5% severe) at six-month post-MTBI. Also, the LCA results revealed that
7 % of cases had high depression symptoms/low fatigue symptoms (Class 2) and 15% of cases
had high levels of depressive symptoms along with other symptoms (Class 4). In addition;
however, the present results also demonstrate that high levels of sleep disturbance and fatigue
accompanied such high levels of depression.
Fatigue is a prominent symptom following TBI, with self-report prevalence rates ranging
from 43%–73% (Belmont et al., 2006). Fatigue can also endure as a predominant symptom
several years after the TBI (Cantor et al., 2008; Ouellet et al., 2004). In comparison, the present
findings reveal that 43.3 % of the sample (24.4 % mild, 14.9 % moderate, and 4% severe) report
fatigue at six-month post-MTBI; while the LCA revealed prevalence of high fatigue in 9.5% of
the cases (Class 3), and 15.9% of the cases reported high levels of fatigue symptoms along with
other symptoms (Class 4). Fatigue after TBI has the potential to impact activities of daily
functioning, occupational and leisure activities, and thus quality of life (Cantor et al., 2008;
Ouellet et al., 2004). Although cluster analysis has not been conducted, correlational studies
reveal several factors to be highly correlated with post-TBI fatigue; these include sleep
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disturbance, perceived stress, somatic symptoms, anxiety and depression (Bay & Xie, 2009;
Bushnik et al., 2008; Ponsford et al., 2000), which resonate with the clustering of symptoms (i.e.,
fatigue, depression, and sleep disturbance) in Class 4. Along the same line, a prospective
longitudinal study assessed fatigue and associated factors in patients at 6, 12, and 18-24 months
after TBI (Bushnik et al., 2008). Results of that study revealed self-reported fatigue improved
during the first year, as did pain, sleep quality, cognitive independence, and involvement in
productive activity. On the other hand, the subset of individuals who reported significant
increases in fatigue over the first two years demonstrated poorer outcomes in regard to cognition,
motor symptoms, and general functioning than those with decreased or stable fatigue (Bushnik et
al., 2008).
In comparison, our results revealed significant group differences in the level of
satisfaction with life. Those results showed that those who reported low symptoms had
significantly greater levels of functional outcomes and good recovery, and greater levels of
satisfaction with life as compared to individuals reporting high levels of fatigue. Further, those
reporting high fatigue symptoms reported a level of satisfaction considered slightly below
average. As for cognitive outcomes, there were significant group differences in the level of
mental flexibility and results were trending toward indicating that the low symptoms group
appears to have more improved performance compared to individuals reporting high fatigue
symptoms.
Although systematic and comparative studies of fatigue after MTBI are limited, severe
fatigue has been shown to be highly correlated with the experience of acute symptoms
(Stulemeijer et al., 2006). In a longitudinal prospective study, post-MTBI fatigue was prevalent
at one week (68%), at three months (38%), and at six months (34%) (Norrie et al., 2010).
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Interestingly, depression and earlier prevalence of fatigue were highly correlated with later
depression. Although fatigue was exacerbated by depression, it was not related to increased
anxiety (Norrie et al., 2010). Post TBI fatigue appears to be persistent after mild-to-moderate
TBI. For example, in those who were hospitalized and followed prospectively for symptom
persistence and disability outcome, fatigue was present in 57% and persisted in 42% of the
sample at one year (van der Naalt et al., 1999). Collectively, the findings of this secondary
analysis and that of others highlight the importance of addressing fatigue after MTBI to identify
biomarkers that can discern which MTBI patients are at risk for more severe symptoms. Such
identification will permit the implementation of interventions earlier for better quality of life.
Sleep disturbance is a common complaint following TBI, and it is more common with
MTBI (Beetar et al., 1996; Clinchot et al., 1998; Fichtenberg et al., 2000; Mahmood et al., 2004).
In recent reviews, 30–70% of TBI survivors reported sleep disturbances (Orff et al., 2009). Most
of the time the sleep disturbances are directly related to the TBI, enduring for months and/or
years after the injury, consequently hindering the recovery process and return to pre-injury
function (Orff et al., 2009). In comparison, the present findings are similar to the literature as the
findings revealed that sleep disturbance was prevalent in 32.2% of the sample (14.4 % mild, 10.9
% moderate, and 7% severe) at six-month post-MTBI; and the LCA revealed that 15.9% of the
cases had high levels of sleep disturbance (i.e., Class 4).
The above described how fatigue, depression, and sleep disturbance are relevant longterm outcomes in MTBI patients, in approximately 15% of MTBI survivors. MTBI research has
primarily focused on studying symptom(s) (single, parried or all symptoms) experienced 3, 6, 12
months or years post injury. As mentioned earlier, MTBI patients can suffer from depressive
mood, fatigue, and poor sleep for weeks and months after injury (Bay & Xie, 2009; Beaulieu187

Bonneau & Morin, 2012; Beetar et al., 1996; Chaput et al., 2009; Levin et al., 2005; Norrie et al.,
2010; Ponsford et al., 2000; Rapoport et al., 2006). Although there is ample research regarding
symptoms experienced post-MTBI, to date only six studies used cluster analysis to identify
symptom profiles related to recovery (Bailie et al., 2016; Goldstein et al., 2010; Hellstrom et al.,
2013; Hoffer et al., 2016; Snell et al., 2015; Velikonja et al., 2010). These studies attempted to
explain the cluster of behavioral symptoms posited to underlie cognitive and functional recovery
in MTBI survivors, which is a critical first step to improve risk assessment and to better manage
post-MTBI outcomes (Lingsma et al., 2014). In contrast, analysis of symptom clusters has been
a focus of research in oncology, in which a symptom cluster is defined as co-occurring
symptoms that share a common influence on an outcome (Fox & Lyon, 2007). That literature
provides overwhelming evidence that fatigue, depression, and insomnia commonly co-occur and
exacerbate each other in cancer patients (Donovan & Jacobsen, 2007). For example, pain,
fatigue, anxiety, insomnia, and depression are commonly co-occurring symptoms in breast
cancer (Fiorentino, Rissling, Liu, and Ancoli-Israel, 2011). These findings suggest potential for
practitioners to develop customized and comprehensive approaches that target not only one
symptom but multiple symptoms; thus, breaking the vicious cycle whereby individual symptoms
exacerbate each other.
Another closer look at the results of Aim 1 revealed that Class 3 (9.5%) was
characterized by low depression and high fatigue, whereas Class 2 (7%) was characterized by
low fatigue and high depression; both classes had the same ratings of low levels of sleep
disturbance. These results appear contradictory, given the strong relationship between fatigue
and depression across different healthcare settings and populations, from community samples to
those in specialist care (Afari & Buchwald, 2003; Ball et al., 2010; Skapinakis, Lewis, &
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Mavreas, 2003; Skapinakis, Lewis, & Meltzer, 2003). However, fatigue has long been a very
challenging and elusive concept to comprehend by researchers and health care providers. Results
are unclear, yet interesting, in that they do not co-occur in Class 2 and Class 3 (each are high
without the other being high). Yet, they co-occur in 15% of cases in Class 4. Nevertheless, there
are some factors, which may explain why fatigue and depression do not necessarily always cooccur. First, it is important to acknowledge that they are district concepts and independent of
each other despite sharing some similarities and connections. Beyond that acknowledgement,
there are several differences why fatigue and depression do not always co-occur:
(1)

There are symptom presentation differences (Leone, 2010); that is, feeling depressed and
tearful is different than feeling fatigued and tiring more easily (King et al., 1995). Also
depression is operationally defined as feeling blue, feeling no interest in things, feeling
lonely, feeling hopeless about future, feeling worthlessness, and/or having auicidal
thoughts (Meachen et al., 2008).

(2)

There are biological differences in the regulation of the hypothalamic–pituitary–adrenal
(HPA) axis associated with fatigue and depression. Interestingly, with chronic fatigue
syndrome a down-regulation of the HPA axis is observed, while with depression an upregulation of the HPA axis is observed (Parker, Wessely, & Cleare, 2001).

(3)

There are differences in epidemiology and etiology determinants. For example, one study
evaluated genetic and environmental antecedents of fatigue, anxiety, depression and
psychological distress in healthy adult twin pairs (n= 1004; 533 monozygotic and 471
dizygotic, age >50). Results distinctively reveled the etiological independence of
prolonged fatigue; both genetic and environmental determinants were independent for
other psychiatric symptoms. Multivariate genetic modeling revealed an independent
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genetic factor influenced anxiety and depression, while another independent genetic
factor solely influenced fatigue. Congruently, fatigue was linked to unique particular nonoverlapping independent environmental factors, incomparable to environmental factor
influencing psychological distress. Others note that despite some overlap, fatigue is
independent from psychiatric symptoms, specifically depressive symptoms (Hickie, Kirk,
& Martin, 1999).
On the other hand, there is growing evidence that supports the association between
depression and fatigue, where both may predict and influence each other over time, and this may
be partially explained by similar risk factors (Harvey, Wadsworth, Wessely, & Hotopf, 2008;
Huibers, Leone, van Amelsvoort, Kant, & Knottnerus, 2007; Skapinakis, Lewis, & Mavreas,
2004). This notion emphasizes the importance and necessity of prolonged measurement of long
term outcomes, as MTBI patients can suffer from depressive mood, fatigue, and poor sleep for
weeks and months after injury (Ayalon et al., 2007; Bay & Xie, 2009; Beaulieu-Bonneau &
Morin, 2012; Beetar et al., 1996; Chaput et al., 2009; Levin et al., 2005; Norrie et al., 2010;
Ponsford et al., 2000; Rapoport et al., 2006). If untreated, individuals who fall into Class 2 and
Class 3 may be predisposed to more severe, debilitating long-term outcomes; specifically, those
in Class 2 may be predisposed to depression, whereas those in Class 2 maybe be predisposed to
fatigue.
The demographic and health characteristics of the individuals grouped into the four
classes were similar; however, there were some minor trending differences and other significant
differences (i.e., employment status and GCS score). First, there were trending differences in
social behaviors, history of behavioral symptoms (i.e., anxiety, depression, sleep disturbance),
and causes of injury. For social behaviors, Class 4 (high symptoms) reported more alcohol
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consumption (65.6%) compared to other classes; yet, it is not clear if this was a pre-existing
behavior or if it developed in association with the post-MTBI symptoms. We attempted to
conduct a chi-square test of independence between LCA groups and social behaviors; however,
we did not have an adequate sample size to run the chi-square test of independence. As for
history of behavioral symptoms (i.e., anxiety, depression, and sleep disturbance), Class1 had the
least reported history of behavioral symptoms (anxiety (9.5%), depression (15.4%), and sleep
disorder (3.6). A comparison of the history of behavioral symptoms (i.e., anxiety, depression,
poor sleep) between Class 2 and Class 3 revealed that Class 2 reported a lower percentage of
history of behavioral symptoms (i.e., anxiety (21.4%), depression (28.5%), sleep disorder
(7.1%); whereas Class 3 reported a higher percentage of history of behavioral symptoms prior to
MTBI (i.e., anxiety (26.3%), depression (36.8%), sleep disorder (15.8%). These findings suggest
that history of behavioral symptoms does not necessarily predict the intensity of symptoms post
MTBI. Along the same lines, another interesting finding is that only 9.4% of those in Class 4
reported some history of a sleep disorder, while a low percentage reported history of anxiety
(25%) and history of depression (31.3%). Although it is valuable to assess for history of
behavioral symptoms that could relate to susceptibility of poor long-term outcome recovery, no
such relationship was found in this sample. We attempted to conduct a chi-square test of
independence between LCA groups and social behaviors; however, we did not have an adequate
sample size to run the chi-square test of independence.
Lastly, the findings revealed few significant demographic differences across LCA groups,
with the only differences observed being differences in employment status and arrival GCS
score. The difference found between LCA groups and employment status was moderately strong
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(Cohen, 1988). Also, there were statistically significant differences between LCA groups and
arrival GCS.
Overall, the findings revealed no major demographic differences across LCA groups; that
is, no differences were observed in age, gender, and marital status. It is possible that a larger
more heterogeneous sample could yield such differences. If so, this could lead to tailored
treatment of behavioral symptoms based on age, gender and marital status. This could also
provide descriptive insight into the nature of post-injury affective and behavioral symptoms,
which in turn could lead to establishing a more inclusive conceptualization of needs with
specifically, customized treatment modalities (Velikonja et al., 2010). Other studies were able to
delineate such differences between their predicted profile patterns and associated demographic
factors (Demakis et al., 2007; Velikonja et al., 2010; Warriner, Rourke, Velikonja, & Metham,
2003). For example, researchers found cluster membership was associated with education, age
and employment status, but not with neurological findings (e.g., lesion location) (Goldstein et al.,
2010). It is possible that relationships between demographic factors (i.e., age, gender, marital
status, education, and employment status) and symptom experience will be found in the
TRACK-TBI cohort study; thus emphasizing the importance of replicating this analysis with a
larger sample.
Taken together, the results demonstrate that LCA can be used to reliably and objectively
detect subtypes of behavioral symptom clusters post MTBI. These findings go beyond the prior
research, which primarily focused on single, paired or all symptoms experienced at 3, 6, 12
months or years post injury. Although there is ample literature describing symptoms experienced
post-MTBI, to date only six studies used cluster analysis to identify symptom profiles related to
recovery (Bailie et al., 2016; Goldstein et al., 2010; Hellstrom et al., 2013; Hoffer et al., 2016;
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Snell et al., 2015; Velikonja et al., 2010). The findings from the current study, therefore,
encourage further studies of the relationship between symptoms experience and evaluation of
inflammation-related behavioral symptom clusters as a potential predictor of cognitive and
functional recovery. Thus, there is a critical need to further develop prognostic models of MTBI
to identify those at greater risk for poorer cognitive and functional recovery and who will most
benefit from targeted therapy (McMahon et al., 2014). Explication of the cluster of behavioral
symptoms (i.e., depressive mood, fatigue, and poor sleep) posited to underlie cognitive and
functional recovery in MTBI survivors is a critical first step to improve risk assessment and to
better manage post-MTBI outcomes (Lingsma et al., 2014).
In addition, an important cluster that emerged from these findings is a group of individuals
who experience a cluster of high levels of depression, fatigue, and sleep disturbance. It is likely
that the co-occurrence of these distressing symptoms presents a vicious cycle, in which these
symptoms reinforce each other making them more difficult to manage. Understanding the
etiology of this symptom cluster and treatment of these symptoms as a whole may be more
effective. However, to accomplish this, mechanistic studies of the linkages among sleep, fatigue,
pain, and depression are needed to more fully understand the etiology of this symptom cluster, as
a common biological pathway may underlie this cluster. Such understanding can guide new
approaches to manage these symptoms as a group. For example, further understanding the
relationship among symptom clusters could lead to the development of algorithms and decision
trees for assessment and management. It is important that practitioners comprehensively assess
symptoms and make informed decisions as to which interventions could target single and
multiple symptoms to improve quality of life in the MTBI survivor.
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Aim 2: Latent Cluster Analysis Groups and Cognitive, Functional, and Quality of Life
Outcomes
The second aim of this study was to determine (after identifying the latent class that best
fit the data) if there were any differences among the predicted classes and outcome variables
(functional, cognitive, and quality with life) at the six-month follow-up. The extent to which
membership in an identified cluster predicts functional, cognitive, and quality of life outcomes at
six-months post -MTBI was explored. Specifically, we assessed the association between the
four predicted Classes (low symptoms, high depression/low fatigue, low depression\ high
fatigue, and high symptoms) and three outcomes (functional outcomes assessed by GOSE,
cognitive outcome: nonverbal processing speed assessed by WAIS-IV Processing Speed Index;
mental flexibility assessed TMT B-A, and verbal learning assessed by CVLT-II; and quality of
life outcomes assessed by SWLS. An analysis of variance (ANOVA) and analysis of covariance
were conducted to address this aim.
Depression, fatigue, and poor sleep have been independently associated with impeded
cognitive recovery from MTBI (Guskiewicz et al., 2007; Mooney & Speed, 2001; Orff et al.,
2009) and the resumption of pre-injury lifestyle and responsibilities (Patterson & Holahan, 2012;
Silver et al., 2009). This aim presents a novel approach since predictive power may be gained by
evaluating clusters of symptoms that co-occur and which may portend slower recovery.
Determining the existence of symptom clusters is vital in MTBI patients and will lead to further
crucial investigation into the mechanisms that underlie these clusters, which will advance the
knowledge regarding cognitive and functional outcomes. Although there is ample literature
about symptoms experienced post-MTBI, to date only six studies used cluster analysis to identify
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symptom profiles related to recovery (Bailie et al., 2016; Goldstein et al., 2010; Hellstrom et al.,
2013; Hoffer et al., 2016; Snell et al., 2015; Velikonja et al., 2010).
The results of Aim 2 identified group differences in functional outcomes between the
four LCA symptom cluster groups. Findings revealed that those with low symptoms had
significantly higher levels of functional outcomes and better recovery as compared to high
depression/low fatigue symptoms, low depression/high fatigue symptom, and between high
symptoms. Although, fatigue has been linked to poor recovery post-TBI a recent systematic
review concluded that the impact of fatigue on patient outcomes is unclear and more intensive
investigation is essential (Mollayeva et al., 2014). The prevalence and persistence of fatigue
after TBI has the potential to impact activities of daily functioning, occupational and leisure
activities, and thus quality of life (Cantor et al., 2008; Ouellet et al., 2004). Previous studies
highlight the importance of fatigue after MTBI and the need for further investigation and
identification of markers that could possibly identify MTBI patients who are at risk for more
severe symptoms in order to implement interventions earlier for better quality of life in MTBI
survivors. Thus, the result of this study revealed the potential importance of evaluating clusters
of symptoms as an approach to increases predictive power to identify trajectories of recover
(good versus poor).
The findings also revealed that six months post-MTBI, those with low symptoms had
significantly greater levels of satisfaction with life as compared to high depression/low fatigue
symptoms, and low depression/high fatigue symptoms (M=16.89, SD=7.203). [Note - both of
these groups reported slightly below average in life satisfaction based on SWLS scoring]. Also,
individuals with low symptoms also reported significantly greater levels of satisfaction with life
as compared to those reporting high symptoms (i.e., those considered dissatisfied according to
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the SWLS scoring). In fact, there is some support for this notion, as others have showed that
post- concussive symptoms associated with MTBI reduce psychological quality of life for
veterans who experienced deployment-related MTBI (Sofko, Currier, Hill, & Drescher, 2016).
In regard to cognitive outcomes, the results revealed that there were group differences in
cognitive outcomes between the four predicted LCA Groups with different symptom intensity.
Specifically, LCA group differences were found in both nonverbal processing speed and mental
flexibility (i.e., TMT B-A). This is congruent with previous research that demonstrate that MTBI
patients also have long-term cognitive impairments related to trauma-induced neurodegeneration, and these impairments include impairment of memory, changes in executive
cognitive function affecting the accomplishment of tasks involving complex cognition, impaired
attention and concentration, and struggles with speed of information processing (slowed)
(Binder, Rohling, & Larrabee, 1997; Patterson & Holahan, 2012; Silver et al., 2009).
Our results indicate that those with low symptoms had significantly greater levels of
nonverbal processing speed, corresponding to the 50th percentile of performance across age
groups, as compared to high depression/low fatigue symptoms, whose performance
corresponded to the 25th percentile of performance across age groups. Few identified
differences could explain the difference in nonverbal processing. There were trending
differences between LCA groups and education background and statistically significant
differences between LCA groups and employment status. For example, the majority of Class 1
(Low symptoms) were working full time and received at least minimum wage (50.7%); also the
majority had either a Bachelor’s degree (39 %) high school diploma (30.8%), or a master’s
degree (11.7%); while for Class 2 (high depression/low fatigue), the majority were not in the
paid workforce or unemployed (57%) and the majority had a high school diploma (50%). This
196

could partially explain the differences in nonverbal processing, perhaps a larger sample could
explain these differences better.
As mentioned earlier, there were minor trending differences between LCA groups and
history of depression, with 15.4% of Class 1 reporting a history of depression, while 28.5% of
Class 2 reported history of depression (this could also explain how Class 2 patients clustered in
the Class; high depression/low fatigue). Others have previously reported a relationship between
level of depression and performance on cognitive tests, with higher levels of depression
correlating with worse cognitive impairment and poor social functioning (Busch & Alpern,
1998). In particular, worse prognosis of depression was highly associated with impaired mental
flexibility and visio-motor tracking (Veiel, 1997). This suggests that subgroups of patients with
MTBI could be identified according to their symptom clusters to delineate those who are at risk
poor cognitive and functional outcomes.
Additionally, relevant to this study, Ramati et al. (2009) examined the association
between psychiatric morbidity and cognitive functioning in 86 electrical injury patients. They
found that patients with multiple psychiatric morbidities showed worse cognitive impairment
(verbal memory, executive functioning and attention) when compared to electrical injury patients
with one or no post-injury psychiatric morbidities. Again, this is consistent with the present
study results, as they reveal a relationship between psychological symptoms and cognitive and
functional recovery (Ramati et al., 2009). On the other hand, previous researchers have
established that MTBI patients with a decreased Glasgow Coma Scale score in the acute phase
exhibit significantly decreased and disturbed cerebral perfusion in the frontal and occipital grey
matter as seen on a normal non-contrast CT performed directly after admission. Moreover, these
observations correlated with severity of injury and cognitive impairment (Metting et al., 2009).
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Such relationships could not be determined in this study. This is likely because the majority had
a GCS of 15. Nevertheless, the above-mentioned differences between classes could relate to the
importance of considering the causes of injuries and cognitive recovery.
Although the present study revealed a significant difference among LCA Groups and the
level of Mental Flexibility, as assessed by the difference between TMT-B and TMT-A at sixmonths follow-up, unfortunately there were no group differences between the LCA Groups on
the post hoc test. Perhaps a larger sample size could delineate these differences in the future.
Also, there were no group differences in verbal learning. This again is likely due to the small
sample size. However, this finding is important when considered with other research in that only
10-20% of MTBI patients will experience persistent cognitive impairments beyond the acute
phase; such cognitive impairment significantly disrupts their capacity to resume many pre-injury
activities (Patterson & Holahan, 2012; Silver et al., 2009). Perhaps the small sample size could
explain these results and a larger sample size could more reflective of the symptom experience of
the miserable minority (who suffer from a plethora of persistent physical, emotional, and
cognitive symptoms) (R. Ruff, 2005). In general, the small sample size hindered finding
meaningful statistical or clinical differences in verbal learning and mental flexibility for the
“miserable minority.”
This study is unique and the first of its kind to link behavioral symptom clusters with
cognitive outcomes post-MTBI. In one of the few previous investigations Snell et al. (2015),
conducted a prospective observational study to examine associations between baseline
demographic, clinical, psychological variables, and six-months follow-up outcome. Using a twostep approach for cluster analysis, their findings reveled three clusters of psychological
adaptation (high 36.3%, medium 38.3%, and low 25.3%) related to injury outcomes (Snell et al.,
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2015). Furthermore, they found that the identified cluster-group membership was significantly
correlated with outcomes. This study supports the notion that groups could be identified early
post injury based on psychological factors, and that different group membership is correlated
with different recovery outcomes. Yet again, low adapters were only 25.3% of the whole sample,
representing a miserable minority. This is also comparable to the work by Bailie et al. (2016).
That study explored the taxonomy of combat-related MTBI (n=1341 military personnel) based
on symptom patterns within two years of evaluation. Cluster analysis revealed four subtypes
(primarily psychiatric PTSD group, a cognitive group, a mixed symptom group, and a good
recovery group). Once more, the largest cluster had an overall low symptom profile, which was
the "good recovery" group.
Overall, previous research was limited to identifying whether the long-term cognitive
impairments correlate with patho-physiological factors of the injury itself, or if these
impairments are a result of the influence of other psychological adverse outcomes such as
fatigue, sleep, and depression (Bigler, 2008; Wood, 2004). Historically, researchers attempted to
theorize and explain the development of long-term cognitive impairment post-TBI (Ryan &
Warden, 2003). In this secondary analysis, we identified different behavioral profiles of MTBI
patients based on the intensity of depressive mood, fatigue, and sleep quality, and determined
differences in quality of life (i.e., satisfaction with life), cognitive (i.e., non-verbal learning and
mental flexibility), and functional outcomes at six months post-MTBI among the identified
behavioral cluster profiles.
It is crucial to advance the knowledge of how symptom clusters can influence cognitive
and functional outcomes especially in this understudied MTBI population (as opposed to the TBI
population). The research on symptom clusters and their influence on cognitive and functional
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outcomes remain limited. Further research on such associations can provide insight as to who
might be at high risk for poor recover. Thus, it was imperative to attempt to identify subgroups
within the MTBI patients that may account for the differences in symptom experiences and
variation in cognitive and functional recovery outcomes over time.
The results revealed that those with low symptoms had significantly better cognitive and
functional and quality of life outcomes, concluding that the intensity of experienced symptom
clusters can influence long term outcomes negatively. Although there is ample literature about
symptoms experienced post-MTBI, to date only six studies used cluster analysis to identify
symptom profiles related to recovery (Bailie et al., 2016; Goldstein et al., 2010; Hellstrom et al.,
2013; Hoffer et al., 2016; Snell et al., 2015; Velikonja et al., 2010). Given this discussion and
our analysis, one might argue that simply inquiring about symptoms experienced post-MTBI by
healthcare professionals will improve long term outcomes and predict those who are more at risk
for poor recovery. Thus, the results of this study along with previous cluster analysis studies,
highlights the importance of evaluating symptom clusters to critically provide treatment or
prevention of long-term complications. Further, these findings highlight the need for unique
tailored treatment resources and programs (Bailie et al., 2016; Goldstein et al., 2010; Hellstrom
et al., 2013; Hoffer et al., 2016; Snell et al., 2015; Velikonja et al., 2010).
Aim 3: SNPs and Behavioural Symptoms
The third aim of this study was to explore whether the intensity of behavioral symptoms
differed with respect to SNPs (rs1800497 (ANKK1,) rs1799971 (OPRM1), SNPs genotype
(rs1800497 (ANKK1), rs1799971 (OPRM1), rs279836 (GABRA2), rs279845 (GABRA2),
rs279871 (GABRA2), and rs4680 (COMT)). We assessed the differences among SNPs
genotypes and three main measures: BSI18 (The BSI-18 is a brief screen of psychologic distress
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with a Global Severity Index (GSI), and 3 clinical subscales: BSI-somatization, BSI-anxiety, and
BSI-depression), PTSD-PCL (3 subscales; hypervigilance, avoidance, Re-experiencing), and
RPQ-13, and Rivermead Post Concussion Symptoms Questionnaire 13 (RPQ-13). An analysis of
variance (ANOVA) and analysis of covariance (ANCOVA) were conducted to address this aim.
Findings revealed no differences in the intensity of behavioral symptoms, as assessed by
three main measures (BSI-GSI, BSI-somatization, BSI-anxiety, and BSI-depression, PTSD-PCL
(hypervigilance, avoidance, Re-experiencing), and RPQ-13) at six months post-MTBI based on t
five types of SNPs genotype (rs279836 (GABRA2), rs279845 (GABRA2), rs279871
(GABRA2), SNP1799971 (OPRM1), and rs4680 (COMT)). However, differences were found
for patients with different SNP rs1800497 ANKK1 genotype and their level of BSI-somatization
and BSI-anxiety at six months post-MTBI. Specifically, findings revealed a significant
difference between SNP rs1800497 ANKK1 and somatization, while controlling for history of
depression and ethnicity. These findings showed that individuals with A1/A1 had significantly
greater levels of somatization as compared to A1/A2 genotype. However, no differences were
observed between A1/A1 and A2/A2 genotypes, and A2/A2 and A1/A2 genotypes.
Second, there was a significant difference between SNP rs1800497 ANKK1 and anxiety,
while controlling for history of anxiety and ethnicity. Individuals with A1/A1 reported
significantly greater levels of anxiety than patients with A1/A2 genotype. However, no
differences were observed between A1/A1 and A2/A2 genotypes and A2/A2 and A1/A2
genotypes.
Ample research has shown that anxiety symptoms are prevalent in the aftermath of a mild
TBI (Hiott & Labbate, 2002; Koponen et al., 2002; Ma et al., 2014; Mooney & Speed, 2001;
Moore et al., 2006; Rao & Lyketsos, 2002; Rao et al., 2010; R. Ruff, 2005; R. M. Ruff, 2011;
201

Stulemeijer et al., 2006; Woodcock & Morganti-Kossmann, 2013). Our results revealed that
ANKK1 might predispose individuals to experience persistent symptoms of anxiety and
somatization) after MTBI, which could impede cognitive recovery. These results are important
when considered in combination with other research. For example, McAllister et al. showed
rs1800497 (T allele) to be negatively associated with poorer performance on cognitive outcomes,
specifically poorer verbal learning, at one-month post mild to moderate TBI (McAllister et al.,
2005; McAllister et al., 2008). Subsequently, others examined the influence of the (C/T) SNP
rs1800497 on post-TBI outcome using data from two multicenter studies: Citicoline Brain Injury
Treatment trial and TRACK-TBI Pilot. Findings from that study showed that the ANKK1 T/T
genotype is related to poorer verbal learning performance at six-months post-TBI (Yue et al.,
2015). Identification of such associations between ANKK and cognitive outcome, will permit
earlier intervention for those at risk for behavioral symptoms clusters, since behavioral
symptoms could impede cognitive outcomes as seen in AIM 2.
Genetic association analyses suggest certain common single nucleotide polymorphisms
(SNPs) may negatively influence recovery from MTBI (Feng et al., 2015; Lanctot et al., 2010;
McAllister et al., 2005; McAllister et al., 2008; Pap et al., 2012; Roetker et al., 2012). Although
results from this study did not reveal group differences in behavioral symptoms among five
SNPs (rs1799971 (OPRM1), rs279836 (GABRA2), rs279845 (GABRA2), rs279871 (GABRA2),
and rs4680 (COMT)), we did observe differences in the levels of BSI-somatization and BSIanxiety at six months post-MTBI in those patients with different SNP rs1800497 ANKK1
genotype.
This study is unique and the first of few studies to link behavioral symptoms to SNPs
post-MTBI. If replicated in a larger sample, it may open up new approaches to identify and treat
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the “miserable minority.” Ruff et al. (2005) hypothesized that 10- 20 % of MTBI patients will
suffer long term symptoms, and defined this subgroup as the "miserable minority." New
approaches can aid in improving the quality of life of these miserable minority who continue to
experience high levels of behavioral symptoms long after MTBI. Also, perhaps the TRACKTBI cohort with a larger sample size may produce significant differences in symptoms among
groups that differ with respect to other SNPs genotypes (rs1800497 (ANKK1), rs1799971
(OPRM1), rs279836 (GABRA2), rs279845 (GABRA2), rs279871 (GABRA2), and rs4680
(COMT)). The lack of statistically significant findings may be attributed to the small sample size
and inadequate power to detect statistically significant findings. However, controlling for
possible correlated covariates added strength and importance to the analysis and produced
statistically significant differences among groups. As such, these findings highlight the
importance of considering other variables that could be cofounders for the miserable minority.
In conclusion, several SNPs have been proposed to be implicated in outcomes post MTBI
and TBI. Yet there is a need for replication or validation of those SNPs that may underlie
individual differences in behavioral symptoms post-MTBI. Only then can this evidence be
translated to the clinical setting. If genetic variants predict risk for more intense and enduring
behavioral symptoms clusters, this might eventually aid in predicting prognoses and responses to
treatment. Therefore, investigation of these biomarkers genetic variants (SNPs) may provide a
valuable means to predict persistent and lingering behavioral symptoms in MTBI patients. This
investigation is significant because it will fundamentally advance knowledge of behavioral
symptoms in the at risk subgroup of MTBI patients, as well as provide information as to the role
of genetic variants in the etiology of behavioral symptom clusters post-MTBI.

203

Summary of Major Findings
Results revealed that for a sizeable subgroup of MTBI patients, recovery is protracted,
and prediction of who will experience protracted functional and cognitive recovery was
explored. Findings from this secondary analysis study increased knowledge as to whether certain
behavioral symptoms clusters (i.e., depressive mood, fatigue, and poor sleep), differentiate
cognitive (i.e., mental flexibility and non-verbal learning) and functional recovery; and quality of
life. Additionally, the LCA identified 4 classes of symptom clusters profiles: Class 1 was the
largest class, constituting 67.7% of the cases, and was characterized by low endorsement of
depression, fatigue, and sleep disturbance. Class 4 accounted for 15.9% and had the highest
ratings of depression, fatigue, and sleep disturbance. Class 3 (9.5%) was characterized by low
depression and high fatigue, whereas Class 2 (7%) was characterized by low fatigue and high
depression; both class2 and 3 had the same ratings of sleep disturbance.
Based on LCA symptom clusters profiles (i.e., Class 1, 2, 3 and 4), significant
differences in functional outcomes, quality of life, and cognitive outcomes (nonverbal processing
speed and mental flexibility) were found at six-months post-MTBI. These differences were:


Individuals with low symptoms (Class 1) had significantly greater levels of functional
outcomes and good recovery as compared to those reporting high depression/low fatigue
symptoms, low depression/high fatigue symptoms, and high symptoms.

204

For both high depression/low fatigue symptoms and low depression/high fatigue
symptoms the reported life satisfaction scores are considered slightly below
average. Meanwhile, those with high symptoms the reported life satisfaction
scores of that group is considered “dissatisfied with their life” according to the
SWLS scoring.


For cognitive outcomes, individuals with low symptoms had levels of nonverbal
processing speed that corresponded to 50th percentile of performance across age
groups; this performance level was significantly greater as compared to
individuals reporting high depression/low fatigue symptoms, whose processing
speed corresponded to the 25th percentile of performance across age groups.
There were no group differences in nonverbal processing speed between
individuals with low depression/high fatigue symptoms and those with high
symptoms.



Results revealed significant group differences in the level of mental flexibility at
six-months follow-up. Those results showed a trend indicating that the low
symptoms group appears to have better performance compared to other groups.
Lastly, for the exploratory aim focused on genetic variants, results revealed that

the ANKK1 genotype might predispose individuals to experience persistent behavioral
symptoms (i.e., anxiety and somatization) after MTBI; such symptoms could further
impede cognitive recovery, as well as reduce quality of life.
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Study Strength and Limitations
A primary strength of this investigation is the chosen frameworks; namely, the PNI
framework and the Theory of Unpleasant Symptoms (TOUS). In combination, these frameworks
offered an integrated and holistic perspective to guide discovery, which can lead to remarkable
advancement in symptom science. It is clear that behavioral symptoms arise from complex
interactions among biological, psychological and social factors; consistent with a PNI
framework. Overall, the use of an integrated framework in combination with a theory of
symptom clusters creatively addresses the depth of the interaction among symptoms experienced,
their impact on recovery outcomes, and may explain individual variation in symptom intensity
and duration seen in MTBI patients.
This study acquired data from an existing database, which has both strengths and
limitations. Overall, secondary data analysis has been a widespread and useful method in health
promotion research. Nevertheless, there are clear advantages and disadvantages of analyzing
existing secondary data (Cheng & Phillips, 2014). One of the most valuable advantages of
secondary data analysis is the accessibility and ease of data collection; often from large data sets
than would be impractical to achieve with primary data collection. This can speed the
procurement of findings, saving time for the investigator, and stimulating more rapid translation
of findings to the targeted population (Cheng & Phillips, 2014). Secondary data analysis can
lead to unexpected findings and new insights, which can spur hypothesis generation to guide
future primary data collection. From a practical point of view, analyzing an existing data set
requires few resources and is cost effective. On the other hand, secondary data analysis has its
disadvantages. For example, an investigator may not be able to ask a specific question or test a
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specific hypothesis due to the nature and measures used to obtain the original data set. In
contrast, with primary data collection an investigator can design the study and choose the
measures to address a specific question. For the current study, measurement of fatigue,
depression, and sleep had to be obtained from several measures, which may not have adequately
captured the variables of interest. Also, there were no biomarkers of inflammation in the data
set, and these biomarkers were assumed to underlie the clustering of these symptoms.
Furthermore, the investigator does not have control of data quality or control of potential
confounders. However, given the nature, purpose, and oversight of the TRACK-TBI database,
the data collected could be assumed to be of good quality. Further, the overall the purpose of the
TRACK-TBI initiative is to improve long-term outcomes of TBI patients in general, and this
purpose is consistent with the objectives of the present study. Therefore, these limitations are
minimized. Lastly, the availability of the Track-TBI Pilot database provided real-life data from a
population that is difficult to access single handedly, and this allowed the accomplishment of the
objectives of this investigation.
There were limitations in this study based on threats to internal and external validity.
First, the threat from confounding variables is one of the most important threats the investigator
needs to account for. Therefore, this study did control for several confounding variables. For
example, to address Aim 3 potential, covariates were controlled (i.e., history of behavioral
symptoms), and this added strength and validity to the findings. However, it is likely that other
uncontrolled covariates may confound findings, especially as relates to those suffering more
intense and persistent behavioral symptoms post-MTBI (i.e., the “miserable minority”).
Another threat to internal validity was missing data. For this study, data were missing for
both the biological variables and the self-reported questionnaires. As a result, this decreased the
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sample size from n=340 to n= 201 for (AIM 1 AND Aim 2), and further reduced the N to 153 for
Aim 3. Also, there were missing data regarding injury severity and acute histories. For example,
duration of LOC and PTA associated with a MTBI has been shown to contribute to worse
behavioral avoidance and psychological well-being for veterans who experienced deploymentrelated MTBI (Sofko et al., 2016). Therefore, missing data regarding LOC and PTA duration is
very crucial. Since this is a secondary data analysis, the research did not have control over data
that was missing.
A third threat is selection bias. For this study, the sample was a convenient and
nonrandom sample and subject to selection bias. Convenience sampling is known as one of the
weakest sampling techniques, as available subjects might be atypical of the population of interest
with regard to critical variables. Selection bias is the most problematic and frequently occurring
threat to internal validity of studies not using an experimental design (Polit & Beck, 2008). For
example, because of the sampling techniques, the majority of the sample was white (84%) and
male (67%), which limits generalizability. Also, history of behavioral symptoms was not
controlled for during enrollment; however, it was accounted for in this analysei to address the
potential impact of this threat to validity; thus attenuating this limitation.
A fourth threat to validity is history. History refers to the occurrence of external events
that take place concurrently with the independent variable and which can affect the dependent
variable (Polit & Beck, 2008). A case in point is when something happens to the patient
between follow-up data collection or even before enrollment that influences depression, fatigue,
or poor sleep. Such events might be a death in the family or loss of a job. Pre-injury stress has
been hypothesized to play a role in long-term maintenance of symptoms (van Veldhoven et al.,
2011). A way to control for this would be to administer a Life Events Scale to assess occurrence
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of major life events. In fact, there is support for this notion, as research shows that incidence of
stressful life events to be a significant predictor of anxiety, depression, and mental health in
MTBI patients (van Veldhoven et al., 2011). Thus, the experience of stressful events prior to the
injury may predispose those with MTBI to suffer from poor long-term outcomes. Assessment of
stressful life events during acute stages post-MTBI is essential (van Veldhoven et al., 2011).
Again, since this is a secondary data analysis and the researcher was unable to overcome this
threat.
Lastly, the use of self-report questionnaires to measure symptoms is considered a minor
threat to validity. For this secondary analysis, there were no data available that used specific
validated measures for each behavioral symptom (i.e., anxiety, depression, fatigue, poor sleep).
Measures for these variables were obtained from either subscales of the BSI- GSI (i.e., BSIDepression, BSI-anxiety, BSI- Somatization), or the Rivermead Post-Concussion Questionnaire.
Use of validated instruments, containing more items, may have revealed more significant
differences in outcomes among symptom cluster groups. Again, this was a secondary analysis
and the researcher was limited by the measurements used in the original investigation. Perhaps,
replication of this study with more comprehensive and specific measures of behavioral
symptoms could produce more representative and valid results.
Generalizability is identified as a threat to external validity. According to Polit and Beck
(2008), generalizability is the criterion used in quantitative research to assess the extent to which
the findings can be applied to other groups and settings. The target population for this study is
MTBI patients with a range of ethnic diversity. Due to the study limitations, this study may not
be generalizable to the general population of MTBI patients. However, the findings could
provide information to generate hypotheses and guide future studies, which can advance the
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ability of clinicians to predict those who are at greater risk for worse cognitive/functional
outcomes. Another threat to external validity is the relatively small sample size. The TRACKTBI pilot phase recruited subjects from three centers, resulting in data collection from 599
patients (only 340 MTBI patients; with only 201 eligible for the study due to missing data).
With regard to this secondary data analysis, the results are not generalizable beyond the
institutions where data was collected and the demographics of the sample; hence, the findings
cannot be generalizable to all MTBI patients.
Nevertheless, despite these limitations, ultimately, the knowledge acquired can be used to
develop and implement improved risk assessment protocols and targeted interventions to those
most vulnerable for behavioral symptoms and poor outcomes.
Nursing Implications
One of the important contributions of the symptom clusters analysis is that in
addition to profiling subgroups, it also to a certain extent reveals symptom
interrelationships (Aktas et al., 2010). This conceptualization of symptom clusters is
visualized as a paradigm shift in symptom management research. The goal of symptom
cluster research is to address the reality of concurrent symptom experiences in different
populations and to lead to more promising research that will potentially generate
knowledge needed to rapidly improve symptom management. Thus, the findings from
this study can contribute to bridging the gap between research and bedside nursing by
addressing symptoms (as a cluster), which is the most common reason that individuals
seek healthcare (Larson et al., 1994). Furthermore, advancing knowledge of symptom
interrelationships within a cluster might lead to more efficient approaches that target
multiple symptoms as opposed to a single symptom approach. This may more effectively
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leverage scarce recourses and ultimately reduce the symptom burden (Aktas et al., 2010).
Consistent with this notion, a recent study demonstrated that military MTBI patients who
completed multidisciplinary treatment reported a reduction in both persistent postconcussive and PTSD symptoms (Janak et al., 2015). Thus, profiling subgroups of MTBI
patients has potential to improve clinical practice, inform clinical practice guidelines, and
ultimately provide patients with the most effective and innovative treatment modalities
(Barsevick et al., 2006; Dodd et al., 2001; Kim & Abraham, 2008).
Additionally, enhanced understanding of which clusters of symptoms relate to the
development of specific cognitive profiles of MTBI patients would allow for the
development of future rehabilitation programs that target specific cognitive deficits.
Furthermore, clinicians could identify patients at risk for poor cognitive and functional
outcomes based on post-MTBI symptoms experiences/presentations (perhaps symptom
clusters). Such identification may facilitate the tailoring of earlier interventions to better
serve this population and promote better quality of life.
Collectively, several implications can be derived from the findings of this study.
Nurses are the first line of contact with MTBI patients at their ER visits post-MTBI. In
most cases, it is the only time they are seeking medical help. Often a diagnosis of a
“mild” traumatic brain injury could be misleading. After discharge from the ER, they
may never return for a follow-up visit at a concussion clinic or even to their primary
physician. Although a few, but identifiable, number of MTBI patients will suffer from
lingering long-term symptoms, it is important for nurses to know and understand the
prevalence of symptom clusters in MTBI patients and their relationship with long-term
cognitive and functional outcomes. ER nurses need to be sensitive to long-term outcomes
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of MTBI and to teach these patients when to seek help prior to being discharged from the
ER. It is imperative that nurses are aware of the long-term cognitive and functional
outcome that are disabling and hinder MTBI patients from retuning to life before the
injury. In follow-up concussion clinics, it may be necessary to include self-reported
measures of depression, fatigue, and sleep quality along with the usually addressed
questions about physical symptoms (such as headache). For those who report these
symptoms, a follow-up teaching session is necessary to address the relationship between
symptom clusters and cognitive and functional outcomes. Health care providers may
want to consider earlier screening for history of behavioral symptoms that could be
aggravated by the injury.
Also, involved family members or supportive people of MTBI patients should be
educated on the risks of symptom clusters. MTBI patients will most probably need help
in recognizing these symptom clusters and guidance to see medical help accordingly. If
the family and support system of the MTBI patients are educated about symptom clusters,
and cognitive and functional outcomes, they may be more likely to support and even
recognize the need for MTBI patients to seek medical treatment. MTBI patients’ need to
be reassured by nurses (the first line of help) that symptom clusters are common and
there is treatment designed to help them deal with these symptoms. In order to bridge the
gap between research and nursing practice, it should a high priority for nurses to provide
sympathetic and compassionate care for these patients, while emphasizing that although
some can experience these symptoms clusters, early treatment can lead to better recovery.
One interesting contribution of this study is the consideration of predictive
biomarkers that can predict risk of symptom clusters and long-term outcomes. Evaluation
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of genetic markers may lead to new ways to prevent, predict, and treat behavioral
symptoms, and directly or indirectly improve long-term cognitive and functional
outcomes. Specifically, the preliminary findings of this study suggest that those with SNP
rs1800497 ANKK1 who had the A1/A1 allele had significantly greater levels of
somatization as compared to A1/A2 genotype. Additionally, those with A1/A1 reported
significantly greater levels of anxiety than patients with A1/A2 genotype. Confirming
these genetic findings in larger studies can lead to genetic risk profiling for such
symptoms. Somatization is a very elusive concept, which has been defined in many ways
(De Gucht & Fischler, 2002). For example, somatization has been defined as “the
tendency to experience and communicate somatic distress and symptoms unaccounted for
by pathological findings, to attribute them to physical illness, and to seek medical help
for them” (Lipowski, 1988). Furthermore, some researchers distinguish between
presenting and functional somatization, with presenting somatization defined as “the
predominantly or exclusively somatic presentation of psychiatric disorder, most
commonly depression and anxiety,” (Kirmayer & Robbins, 1991); and functional
somatization defined as “high levels of medically unexplained symptom reporting in
multiple physiological systems” (Kirmayer & Robbins, 1991). This added distinction
draws attention to hidden psychiatric morbidity, especially anxiety and depressive
disorders (De Gucht & Fischler, 2002).
Shifting the paradigm to view symptoms as clusters will potentially assist in
identifying common underlying mechanisms, which can then lead to single approaches to
treat multiple symptoms. For example, this may lead to new discoveries that target
biological processes related to inflammation (which may underlie behavioral symptom
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clusters and cognitive impairment) and/or targeting symptoms at the genetics-epigenetic
level. Using predictive parameters can help ED personnel identify MTBI patients who are
at higher risk before discharging them from the ED; allowing the opportunity to make
appropriate referrals and prevent prolonged suffering from debilitating symptoms. This is
a clinically relevant and important area for research, as early identification and providing
more knowledge about risk factors for MTBI behavioral symptoms soon after the injury
can help initiate preemptive treatment; thus, promoting optimal quality of life in the long
run.
Implications for Cytokines-Brain Signaling
It is well established that one of the causative factors implicated in cognitive impairment
following MTBI is neuro-inflammation, which is likely related to dysregulation of proinflammatory cytokines (Huang & Sheng, 2010; McAfoose & Baune, 2009; J. A. Smith et al.,
2012). For example, ample evidence shows that when the microglia are activated post-injury,
they release pro-inflammatory cytokines (e.g., IL-1, IL-6, and TNF-α), which, in turn, alter
neuro-cognitive function. Thus, it is possible that cytokine dysregulation could orchestrate the
long-term development and pathogenesis of neuropsychiatric disorders (McAfoose & Baune,
2009). Emerging research suggests that enhancing the environment may improve cognition by
restoring cytokine balance, as discussed below.
Interventions to reduce long-term consequences of MTBI. Environmental
enhancement (EE) refers to conditions that provide increased social, cognitive, and physical
stimulation. Such enhancement could help decrease the negative long-term consequences of
MTBI subsequent to neuro-inflammation. EE may also decrease the alterations in brain energy
metabolism linked to cognitive impairment. EE has been shown to be correlated with decreased
214

levels of the pro-inflammatory cytokines IL-1β and TNF-α and enhanced levels of the antiinflammatory cytokine IL-10 after MTBI (Briones et al., 2013). Also, there is evidence that EE
alleviated MTBI-induced cognitive impairment in rodent models (Briones et al., 2013). Thus,
these findings demonstrate the potential of EE to attenuate the persistent neuro-inflammatory
state, which occurs after MTBI (Briones et al., 2013).
Behavioral therapies implications. Behavioral therapies could be exploited to alleviate
stress and other adverse environmental factors that may potentially lead to epigenetic
modification within the brain and restoration of brain function. For example, exercise can result
in weight loss and help provide resistance to stress-induced chromatin remodeling within the
brain. It has been shown that rats that were exposed to greater physical activity prior to stress
exposure exhibited resistance to stress-induced chromatin remodeling within the dentate gyrus
(Bilang-Bleuel et al., 2005). These findings demonstrate that stress-related learning results in
hippocampal chromatin remodeling, which may facilitate behavioral adaptation to environmental
changes. This presents an opportunity for the exploration of other behavioral life-style changes
that could aid in the prevention or restoration of epigenetic modification (Mathews & Janusek,
2011) and may offer potential to prevent and/or restore cognitive function after MTBI.
Recently, Yehuda et al. (2013) examined the association between methylation of the GR
and FKBP5 genes, downstream neuroendocrine measures, cortisol, and NPY, and before and
after prolonged exposure to psychotherapy in combat veterans with PTSD (N=8). The purpose
was to determine if cytosine methylation in promoter regions of the glucocorticoid-related
NR3C1 and FKBP51 genes would predict or correlate with treatment (prolonged exposure
psychotherapy) outcome in these patients. These results denote that specific genes can be
correlated with prognosis and symptom state. Although these preliminary results require
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replication and validation, they support research indicating that some glucocorticoid-related
genes are subject to environmental regulation throughout lifespan, and also that psychotherapy
treatment may alter epigenetic state through environmental regulation. This is the first
longitudinal study of an epigenetic alteration in association with behavioral treatment outcomes.
This study represents an important initial step in establishing relevant molecular markers for
PTSD therapies (Yehuda et al., 2013), and perhaps injury-related traumatic events that results in
MTBI and risk for PTSD post-injury (Yehuda et al., 2013).
Several symptoms (e.g., pain, sleep disruption, and fatigue) can result from the persistent
release of cytokines as a response to inflammation; thus specific treatments aimed to block
cytokine production may have a direct effect on symptoms relief. Furthermore, the model of
cytokine-induced depression provides valuable insight into the relationship between cytokines
and depression (Dantzer, 2009). Clinicians may explore the implications of sickness behavior
related to depression and specific disease-related symptoms. For example, nurses could benefit
from increased awareness and understanding of the relationship between pro-inflammatory
cytokines and sickness behaviors. Enhanced knowledge in this arena will aid nurses in assessing
and identifying vulnerable patients at risk for these sickness behavior symptoms.
Future Research
Collectively, the results from this study provide compelling impetus for further
exploration of behavioral symptom clusters post-MTBI using genetic and PNI paradigms.
Findings that suggest symptom clusters participate directly or indirectly in the symptomatology
of functional cognitive impairment in trauma patients is fascinating and worth further
investigation. Future investigation of genetic variants could provide information for the
prediction of symptoms as early as possible in MTBI patients; specifically, somatization and
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anxiety. As such, this study enhanced the knowledge regarding relationships among genetic
variants, symptom clusters, and functional outcomes post MTBI. Yet, given that many of the
findings in the current study were trending toward significance, a larger study is needed to
determine if there are additional statistically significant differences in cognitive outcomes,
specifically, verbal learning. A well-powered study may reveal significant findings regarding
differences among groups based on the six different SNP genotypes evaluated in this study (i.e.,
rs1800497 (ANKK1), rs1799971 (OPRM1), rs279836 (GABRA2), rs279845 (GABRA2),
rs279871 (GABRA2), and rs4680 (COMT). Additionally, future studies could benefit from use
of additional and more comprehensive symptom measurement instruments and a longitudinal
design which evaluates patients beyond six months. As well, the addition of reliable measures
for each symptom (fatigue, depression, and poor sleep) could yield more favorable results.
Second, it has been long emphasized that longitudinal research regarding post-discharge
cognitive impairment in MTBI patients is needed, as it is possible that persistent intense
behavioral symptoms sustain cognitive and functional outcomes in the absence of long-term
structural damage (Bernstein, 1999). These studies will help inform the development of the most
appropriate treatment approaches for MTBI patients with persistent intense symptoms and poor
cognitive and functional outcomes.
Following the aims of the TRACK-TBI initiative, this current secondary analysis
identified symptom clusters that account for variability in cognitive and functional outcomes
post-MTBI. The above-mentioned clinical implications are suggestive of the need for more
future prospective studies of symptom management designed to identify components of specific
collaborative multidisciplinary innovative-therapeutic interventions that contribute to symptom
reduction and improvement of cognitive and functional outcomes. Future research would then
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call for further investigation of the prevalence of cognitive impairments after the reduction or
elimination of symptoms. Also, the results can open the venue for more research in specific
areas; studies of genetic, epigenetic, neurobiological and inflammatory mechanisms underlying
MTBI; as well as intervention studies that incorporate PNI (mind-body) framework.
Future Genetic Studies
There is increasing knowledge of gene-to-brain communication and the complex ways in
which genes regulate brain function and behavior. Yet, there is a need to increase such evidence
in human paradigms for translation to clinical practice. Results from this study revealed that the
symptom experience negatively affects MTBI patients. Further, results suggest specific preexisting genetic variants (i.e., ANKK) predispose certain individuals to more persistent
behavioral symptoms post-injury (i.e., anxiety and somatization). Determining the extent to
which genetic variants contribute to the symptomatology of more intense behavioral symptoms
in MTBI patients can result in novel biomarkers to predict behavioral symptoms as early as
possible. The identification of these genetic variants may shed light on viable targets to predict
distinct sets of behavioral symptoms. Such knowledge may eventually help in genetic-targeted
intervention tailored for greater treatment response and tolerability, and improvement of
resiliency against developing inflammatory cytokine-associated behavioral symptoms.
Future Epigenetic Studies
Environmental exposures have been shown to affect the activity of the methylation
machinery, leading to behavioral and mental pathologies. Future epigenetic studies can provide
key insight into the impact of environment-gene interaction on behavior and vulnerability to
poor health over the human lifespan (Mathews & Janusek, 2011). Since evidence shows that
epigenetic modifications are reversible; the supportive evidence addressed earlier opens a
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window for a variety of novel epigenetic-based interventions that could be implemented at
periods of biological vulnerability (i.e., post-trauma) to prevent the harmful effects of stress and
reduce incidences of intense behavioral symptoms post MTBI.
Individuals who suffer traumatic brain injury are at risk for post-traumatic stress disorder
(PTSD). Recently, traumatic events have been found to induce epigenetic modifications for
genes that encode immuno-regulatory proteins in individuals with PTSD (Segman et al., 2005).
Evidence reveals that for PTSD patients, the experience of a traumatic event triggers downstream
alterations in immune function by decreasing methylation of immune-related genes (Uddin et al.,
2010). These findings demonstrate the capacity of a traumatic event to trigger long-lasting
epigenetic-induced alterations (i.e., DNA methylation) in immune function, possibly through
brain-immune interactions (Uddin et al., 2010). Although currently there is little evaluation of
stress-related epigenetic modification in trauma survivors, the findings in individuals with PTSD
provide preliminary evidence suggesting this possibility (Uddin et al., 2010). Investigation of
these biomarkers (DNA methylation and pro-inflammatory cytokines) may provide valuable
information for understanding the link between behavioral symptoms and cognitive/functional
outcomes in MTBI patients. Such understanding is a critical first step that will improve risk
assessment and ultimately lead to prevention and/or better management of trauma-associated
behavioral symptoms. Moreover, future studies that enhance the knowledge regarding the role of
epigenetic modification (i.e., DNA methylation) has potential to lead to predicting at discharge,
which MTBI patients are at risk for prolonged behavioral symptoms. These studies can guide
the future development of personalized epigenetic-based approaches to identify and treat trauma
patients to promote quality of life, and reduce symptom intensity and duration.
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Future Neurobiological Mechanisms and Pro-Inflammatory Cytokines Studies
The results from this secondary analysis study have increased knowledge of the
importance of body-to-brain communication, but there is a need to further increase such
evidence in human paradigms for translation to clinical practice. Furthermore, the
neurobiological mechanisms underlying the behavioral effects of pro-inflammatory cytokines
have not been investigated in a manner that correlates to a given behavioral effect of a cytokine
on a well-defined area of the brain. For this reason, micro-pharmacology experiments that target
inflammatory mediators in specific brain areas must be implemented to define cause-effect
relationships (Dantzer et al., 2008). The identification of the intracellular association between
inflammation and behavioral symptoms (i.e., depression) will provide valuable targets for the
development of new antidepressant drugs, if the activation of brain pro-inflammatory cytokine
signaling is proven to represent the final common pathway for the various conditions that lead to
depression (Dantzer et al., 2008).
With respect to MTBI, low-grade systemic inflammation might contribute to the
development of psychological long-term morbidities in patients with MTBI. Yet, studies focused
on the systemic inflammation following MTBI are limited. Findings from animal models of
MTBI do show that systemic inflammatory processes are activated post-MTBI; specifically
circulating IL-6 levels are increased in rodent models of MTBI (Holmin et al., 1997; Shohami et
al., 1994; S. H. Yang et al., 2013). Similarly, Yang et al. (2013) found serum cytokines
interleukin-6 and keratinocyte-derived chemokine to be significantly increased within 90 minutes
after MTBI in a murine model. In a rat model of closed head injury, Shohami et al. (1994) found
elevated levels of IL-6 following injury, and suggested that rapid production of IL-6 following
closed head injury is a local inflammatory response of brain tissue to the primary insult.
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Yet, it still remains unknown whether the systemic inflammatory process could be used
as predictive markers for psychological outcomes after MTBI. Thus, it presents a fruitful area of
research, in view of the fact that it is well established that systemic inflammatory processes
activate the neuroendocrine HPA axis (Murray et al., 2013) and were found to result in chronic
stress linked to anxiety and depression (Mustafa, 2013). Also, systemic inflammation results in
an increase in indoleamine 2, 3-dioxy-genase (IDO) expression (Yamada et al., 2009), which
leads to an overproduction of kynurenic and quinolinic acids, and subsequent reduction of
serotonin within the brain. Lower serotonin is established to result in depression and other
psychological and behavioral problems (Capuron & Miller, 2011; Haroon et al., 2012; A. H.
Miller et al., 2009). Therefore, investigation of acute circulating inflammatory marker responses
is a fruitful area which may provide insight into the role of psycho-neuro-immunological
processes in MTBI patients. Additionally, standardization of appropriate markers of
inflammation and a systematic approach for investigation of the risk factors will improve
outcomes and quality of life. Furthermore, it is possible to develop clinical trials aimed at
blocking cytokine production or action, attenuating the production of second messengers or
deactivating glial cells and halting excessive quantities of pro-inflammatory cytokines. More
research is needed in this area to enhance its innovative potential and avoid the duplication of
efforts likely to occur because of the diversity of pathological conditions that lead to non-specific
clinical signs of sickness behavior (Dantzer & Kelley, 2007).
Taken together, future studies are warranted to illuminate the precise effects of certain
cytokines and explore targets for interventions and therapies in the MTBI population. For
example, targeting of inflammatory pathways for depression treatments post-MTBI can provide
valuable starting points for the identification of vulnerable subgroups of depressed patients who
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may be most appropriate for immune-targeted therapies. Such studies can lead to the
development of feasible and effective interventions to identify patients at risk for sickness
behaviors; thus, preventing or decreasing the negative effects of cytokine-induced inflammatory
responses, which reduce quality of life post-MTBI.
Intervention Studies
Findings from this secondary data analysis revealed that somatization and anxiety were
common symptoms after MTBI. Further, a significant relationship between SNP rs1800497
ANKK1 and anxiety and somatization was revealed; suggesting that this genetic variant
predisposed these individuals to these particular behavioral symptoms. Therefore, perhaps
screening MTBI patients for genetic variants linked to risk of these symptoms could lead to early
targeting of treatment and improvement in recovery.
Also, since symptom clusters predicted poor function and cognitive recovery, future
intervention studies may want to use EE to treat depression, stress, and anxiety at the same time.
The successful treatment of those symptom clusters may improve cognitive and functional
outcomes and subsequently quality of life for those most affected (i.e., the “miserable minority”).
Also, the consideration of controlling for previous history of behavioral symptoms and prior
stressful life events could yield better results. Early implementation of treatment modalities for
the “miserable minority” could improve or even prevent long-term cognitive impairment. Future
studies are needed to evaluate novel interventions that target symptom clusters, so that such
treatment could be incorporated into cognitive and functional rehabilitation programs for those
who suffer MTBI. Promising interventions include cognitive behavioral therapy or mindfulnessbased stress reduction (MBSR).
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Conclusion
For a sizeable subgroup of MTBI patients, recovery is protracted, and prediction of who
will experience protracted recovery was explored. Findings from this secondary analysis study
attempted to increase the understanding of the role of depressive mood, fatigue, and poor sleep
as a symptom cluster, on cognitive and functional recovery. This enhanced knowledge can guide
future studies that may pursue the following: (1) evaluate use of behavioral symptom clusters as
risk factors for poor cognitive/function outcomes and poor quality of life post-MTBI, and (2)
evaluate the usefulness of biomarkers (genetic variants, epigenetic modifications and proinflammatory cytokines) as predictors for the risk of more intense and enduring behavioral
symptoms in MTBI patients. Ultimately, the knowledge from this secondary analysis can be
used a starting point to build on and develop clinical strategies for earlier identification (i.e., at
discharge) of MTBI patients who are at risk of such behavioral symptoms. This crucial
knowledge can positively impact the care of MTBI patients, as it will stimulate the development
and implementation of specific symptom profiles to be used clinically to stratify risk for poor
recovery and to identify those who may require earlier and more intense intervention to promote
better quality of life.
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APPENDIX A
DATA COLLECTION TOOLS
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225

226
PTSD Checklist – Civilian Version (PCL-C)

227
Rivermead Post-Concussion Symptoms Questionnaire (RPQ)

228
Cognitive Outcomes
Mental Flexibility assessed by TMT B-A

229

230
Quality of life
Satisfaction with Life Scale

231
Functional outcome
Glasgow Outcome Scale Extended (GOSE)

232

233

APPENDIX B
TABLES
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Table 1. Study Variables

PRIMARY VARIABLES TO BE USED IN THE ANALYSIS

Biological

Psychological/Behavioral

Cognitive

Quality of life

Functional

SNPs

PTSD-PCL

Nonverbal Processing

SWLS

GOSE

rs1800497 (ANKK1)

Speed assessed by

rs1799971 (OPRM1),

WAIS-IV

rs279836 (GABRA2),

RPQ (Sleep Disturbance, Fatigue,

Verbal Learning

rs279845 (GABRA2),

Depression items)

assessed by CVLT-II

rs279871 (GABRA2),

BSI-18 (Depression, Anxiety, &

Mental Flexibility

and rs4680 (COMT)

Somatization subscales)

assessed by TMT B-A

Note: BSI-18= Brief Symptom Inventory=18, PTSD-PCL= The Post-Traumatic Stress Disorder Checklist Civilian Version, RPQ=The Rivermead Post-Concussion
Symptoms Questionnaire, SNP= single-nucleotide polymorphism, GOSE= Global outcomes Glasgow Outcome Scale-Extended score, WAIS-IV= Wechsler Adult Intelligence
Scale-IV, CVLT-II= California Verbal Learning Test-II, TMT B-A= the difference score between the Trial Making Test B and TMT A, SWLS= Satisfaction with -Life Scale
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Table 2. Tools and Data Collection Time Points
T1: 3-month

T2: six-month

Background information
Demographic Information & health assessment

X

Age & Gender

X

Biological Variables
SNPs rs1800497 (ANKK1) rs1799971 (OPRM1), rs279836 (GABRA2),
rs279845 (GABRA2), rs279871 (GABRA2), and rs4680 (COMT)

X

Psychological/Behavioral Variables
PTSD-PCL

X

RPQ (Sleep Disturbance, Fatigue, Depression items)

X

BSI-18 (Depression, Anxiety, & Somatization subscales)

X

Cognitive outcomes
Nonverbal Processing Speed assessed by WAIS-IV

X

Verbal Learning assessed by CVLT-II

X
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Table 2 (cont.)
Mental Flexibility assessed by TMT B-A

X

Quality of life
SWLS

X

Functional outcomes
GOSE

X

Note: BSI-18= Brief Symptom Inventory=18, PTSD-PCL= The Post-Traumatic Stress Disorder Checklist Civilian Version,
RPQ=The Rivermead Post-Concussion Symptoms Questionnaire, SNP= single-nucleotide polymorphism, GOSE= Global
outcomes Glasgow Outcome Scale-Extended score, WAIS-IV= Wechsler Adult Intelligence Scale-IV, CVLT-II= California
Verbal Learning Test-II, TMT B-A= the difference score between the Trial Making Test B and TMT A, SWLS= Satisfaction
with -Life Scale
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Table 3. SNPs Information
SNPs
Genoty
pe

Official Name
and type

Biological and Functional Significance

rs18004
97
(ANKK
1)

ankyrin repeat
and kinase
domain
containing 1

A frequently studied SNP, known as TaqI polymorphism Dopamine D2 receptor reduction DRD2 gene (rs1800497 allele (T))
is associated with neurobiological correlate evidenced by the decreased dopamine binding sites in the brain (Pohjalainen et al.,
1998)
There is some evidence suggesting that ANKK1 pays a role in comorbid substance use disorder (Blum et al. 1996),
diminished reaction to negative action consequences, which may explain an increased risk for addictive behaviors in A1-allele
carrier specifically (Klien et al, 2007), and risk for chronic renal disease and high blood pressure (Jiang et al., 2014). Also,
traumatic brain injury patients who are carriers of rs1800497(A) alleles recover slower as assessed by memory and attention
tests (McAllister et al., 2008)
Carriers of at least one rs1799971(G) allele are more at higher risk for alcoholism than carriers of two A alleles. (van den
Wildenberg et al., 2007; Bart et al., 2005; Bergen et al., 1997; Crowley et al., 2003; Miranda et al., 2010); however, in
alcoholics treated with naltrexone, rs1799971(G) carriers had better clinical outcome when compared to rs1799971(A: A)
carriers (Anton et al., 2008). In regards to influences of opioids consumption (i.e., heroin, codeine or morphine):
rs1799971(G) allele carriers consumed more opioids for analgesia but still reported higher pain scores and less nausea and
vomiting than rs1799971(A: A) allele carriers during the first 24-hour postoperative period (Ren et al., 2015). A118G
Polymorphism of OPRM1 Gene is Associated with Schizophrenia (Sery et al., 2010)
This SNP in the GABRA2 gene has been linked to Alcoholism (Rangaswamy and Porjesz, 2008; Lind et al, 2008), and has
been found to be associated with human cocaine addiction (Dixon et al., 2010). Some research suggests it can be used as a
marker for alcoholism (Zintzaras, 2012). Evidence are suggestive that GABRA2 might influence susceptibility to alcohol
dependence by modulating the level of neural excitations specifically in carriers of these alleles:rs279871(A) + rs279845(T) +
rs279836(A) alleles (Edenberg et al, 2004)

protein coding
rs17999
71
(OPRM
1)

opioid receptor
mu 1

rs27983
6
(GABR
A2)
rs27984
5
(GABR
A2)

gammaaminobutyric
acid type A
receptor
alpha2
protein coding

protein coding
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Table 3 (cont.)
rs4680
(COMT
)

catechol-Omethyltransfer
aseprovided
protein coding

Associated condition: panic disorder 1 and schizophrenia (Gupta et al., 2009), cocaine dependence (Lohoff at el., 2008),
breast cancer (Onay et al., 2008), venous thrombosis (Gellekink et al., 2007). Val alleles have increased COMT activity
and lower prefrontal extracellular dopamine compared with those with the Met substitution (Stein et al., 2006). Val158
alleles may be associated with an advantage in the processing of aversive stimuli (warrior strategy). Under stressful
situations that cause increased dopamine release, carriers of Val158 alleles may have improved dopaminergic
transmission and better performance. Some evidence suggests that Val158 alleles are associated with schizophrenia
(Stein et al., 2006) However, Met158 alleles may be associated with an advantage in memory and attention tasks
(worrier strategy). Under stressful situations that cause decreased dopamine release, carriers of Met158 alleles may have
less efficient neurotransmission and worse performance. Some evidence suggests Met158 alleles are associated with
anxiety (Stein et al., 2006)
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